



(51) International Patent Classification:

C07K 7/06 (2006.01)

C07K 14/31 (2006.01)

C07K 14/005 (2006.01)

(21) International Application Number:

PCT/US2021/020591

(22) International Filing Date:

03 March 2021 (03.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/985,179

04 March 2020 (04.03.2020)

US

(71) Applicant: **DUKE UNIVERSITY** [US/US]; 2812 Erwin Road, Suite 406, Durham, NC 27705 (US).

(72) Inventors: **DZURICKY, Michael**; c/o Duke University, 2812 Erwin Road, Suite 406, Durham, NC 27705 (US).
CHILKOTI, Ashutosh; 1001 Gloria Avenue, Durham, NC 27701 (US).

(74) Agent: **BROWN, Bernard, A., II.** et al.; Michael Best & Friedrich LLP, 790 N. Water Street, Suite 2500, Milwaukee, WI 53202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PROTEINS WITH PREDICTABLE LIQUID-LIQUID PHASE SEPARATION




FIG. 1A

(57) Abstract: Described herein are peptide biopolymers that exhibit controlled phase separation based on their amino acid sequence, aromatic:aliphatic ratio, hydrophobicity, temperature, molecular weight, and concentration.



**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

18 November 2021 (18.11.2021)

PROTEINS WITH PREDICTABLE LIQUID-LIQUID PHASE SEPARATION

CROSS REFERENCE TO RELATED APPLICATIONS

5 This application claims priority to U.S. Provisional Patent Application No. 62/985,179 filed on March 4, 2020, which is incorporated by reference herein in its entirety.

FEDERALLY SPONSORED RESEARCH

10 This invention was made with United States government support under National Institutes of Health grant number R35GM127042 and the National Science Foundation grant number DMR-17-29671. The United States government has certain rights in the invention.

SEQUENCE LISTING

15 This application is filed with a Computer Readable Form of a Sequence Listing in accord with 37 C.F.R. § 1.821(c). The text file submitted by EFS, "028193-9340-WO01_sequence_listing_2-MAR-2021_ST25.txt," was created on March 2, 2021, contains 317 sequences, has a file size of 527 Kbytes, and is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

20 Described herein are peptide biopolymers that exhibit controlled phase separation based on their amino acid sequence, aromatic:aliphatic ratio, hydrophobicity, temperature, molecular weight, and concentration.

BACKGROUND

25 Intrinsically disordered proteins (IDPs) are receiving significant recognition for their role in various biological (dys)functions. A subset of IDPs, termed biological condensates, physically separate themselves from the cytoplasm to control the accessibility of a variety of macromolecules. While our ability to detect protein disorder has advanced rapidly thanks to sophisticated statistical methods, the ability to predict phase separation has lagged behind. The prediction of phase separation is non-trivial, as numerous variables influence phase separation.
30 Broadly, they involve: (1) amino acid composition and amino acid patterning of the primary protein sequence; (2) heterotypic interactions with RNA or other macromolecules; and (3) solvent quality. There are many studies that note the challenge of predicting IDP phase behavior, but few studies that have directly tackled this problem. Given the recognition of its importance to cellular function, this is now an area of active research and many efforts are ongoing using computational and

experimental approaches. To date, however, most experimental methods to develop a sequence level understanding of IDP phase behavior have relied on mutational strategies of native IDPs with sweeping residue level or domain level mutations.

What is needed are peptide biopolymers comprising intrinsically disordered proteins that exhibit controlled phase separation based on their amino acid sequence, aromatic:aliphatic ratio, hydrophobicity, temperature, molecular weight, and concentration.

SUMMARY

One embodiment described herein is a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising: $(X-Z_1-X-Z_2-Z_3-X-Z_4-Z_3)_n$, where: X is proline (P) or glycine (G) and the ratio of P:G is any number; Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number; Z_2 is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number; Z_3 is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and Z_4 is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number. In one aspect, X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1. In another aspect, Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number. In another aspect, the phase separation is dependent on temperature, molecular weight, hydrophobicity, aromatic:aliphatic ratio, and concentration. In another aspect, n is 10 to 200. In another aspect, molecular weight is at least 5 kDa to 500 kDa. In another aspect, the molecular weight is about 5 kDa to about 100 kDa. In another aspect, the phase separation temperature is 0 to 100 °C. In another aspect, the phase separation temperature is 4 to 25 °C; ~25 °C; 25 to 37 °C; ~37 °C; 35 to 38 °C; or >38 °C. In another aspect, the polypeptide comprises modified amino acids, a reporter protein, or an enzyme. In another aspect, the sequence comprises: $(G-R-G-D-S-P-Y-S)_m$, where m is 20 to 80. In another aspect, the polypeptide comprises a sequence selected from one or more of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 197–279, or combinations thereof.

Another embodiment described herein is a pharmaceutically acceptable composition comprising a polypeptide with controlled reversible phase separation comprising ten or more

repeats of an amino acid sequence comprising: $(X-Z_1-X-Z_2-Z_3-X-Z_4-Z_3)_n$, where: X is proline (P) or glycine (G) and the ratio of P:G is any number; Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number; Z_2 is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number; Z_3 is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and Z_4 is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number. In one aspect, X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1. In another aspect, Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number. In another aspect, the composition further comprises an attached molecule comprising one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195). In another aspect, the composition enhances bioavailability of the attached molecule as compared to the free form of the attached molecule. In another aspect, the composition enhances expression of the attached molecule as compared to the free form of the attached molecule. In another aspect, the composition enhances the stability of the attached molecule as compared to the free form of the attached molecule. In another aspect, the composition enhances stability of the attached molecule during prokaryotic and eukaryotic expression as compared to the free form of the attached molecule. In another aspect, the enhanced stability includes resistance to denaturation during freezing, thawing, or lyophilization. In another aspect, the composition modulates enzymatic, metabolic, or physiological functions within cells or organisms. In another aspect, the modulation reduces bioavailability of the attached molecules. In another aspect, the attached molecules comprise therapeutic or cytotoxic proteins or peptides.

Another embodiment described herein is a method for enhancing the bioavailability or stability of a protein, the method comprising creating a fusion protein of one or more proteins and a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising: $(X-Z_1-X-Z_2-Z_3-X-Z_4-Z_3)_n$, where: X is proline (P) or glycine (G)

and the ratio of P:G is any number; Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number; Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number; Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and

5 Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number. In one aspect, X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1. In another aspect, Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number. In one aspect, X is proline (P) or glycine (G)

10 and the ratio of P:G is between 1:3 and 3:1. In another aspect, Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number. In another aspect, the protein comprises one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167),

15 Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding

20 peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195). In another aspect, the enhanced bioavailability of the fusion protein can be used for isolation or separation of a biologic molecule. In another aspect, the biologic molecule comprises one or more of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a viral particle. In another aspect, the nucleic acid is single stranded or double stranded DNA or RNA. In another aspect, the viral particle is an adenovirus

25 particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or herpesvirus particle. In another aspect, the protein comprises albumin, monoclonal IgG antibodies, or Fc fusion antibodies. In another aspect, the isolation or separation is accomplished via reversible phase separation.

30 BRIEF DESCRIPTION OF THE DRAWINGS

This patent or application contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1A–G shows artificial intrinsically disordered polypeptides (A-IDPs) inspired from native idps exhibit reversible UCST phase behavior. FIG 1A shows proteomic analysis of native IDPs that form biomolecular condensates reveal that they have an abundance of G/P, charged and uncharged polar residues, yet exhibit a balance of overall charge. FIG 1B shows an example of a dense, exclusionary phase formed by an UCST exhibiting A-IDP even in the complex medium of bacterial cell lysate. The coacervate shows observes almost complete separation from all other cellular proteins and debris present in the cell lysate after centrifugation, facilitating purification from the insoluble cell lysate fraction without affinity tags. FIG. 1C shows an example SDS-PAGE gel of a set of A-IDPs—[Q5,8]-20 to [Q5,8]-80—with conserved sequence but increasing MW that show the high purity of the A-IDPs that is obtained by exploiting their UCST phase behavior without need for any chromatographic purification. FIG. 1D shows a visualization of UCST phase separation of [Q5,8]-20 in water-in-oil droplets with fluorescence microscopy. Upon cooling, phase separation in a droplet is initiated at multiple sites, the puncta that grow from each site slowly coalesce with one another into a single dense phase. Upon reheating, equilibrium with the surrounding dilute phase is constantly re-established, leading to a higher concentration dilute phase and smaller volume occupied by the dense phase. $\phi = 0.0018$, scale bar = 50 μm . FIG. 1E shows a schematic UCST phase diagram for a cooling-heating cycle of a UCST polypeptide in a water-in-oil droplet. FIG. 1F shows dynamic light scattering data of [Q5,8]-20 demonstrating the change in hydrodynamic radius upon cooling. Upon reaching the cloud point, [Q5,8]-20 transitions from soluble unimeric polypeptides with a radius of hydration of 5–6 nm to micron-sized aggregates. Data collected at $\phi = 0.0043$ in 140 mM PBS, pH 7.4. FIG. 1G shows UCST cloud points are affected by polypeptide volume fraction in solution. This behavior follows a natural log dependence in the dilute regime ($R^2 = 0.98$).

FIG. 2 [WT]-20-sfGFP exhibits phase separation memory upon multiple cycles of heating and cooling. Upon multiple heating and cooling cycles, [WT]-20-sfGFP form puncta in the same location as the first cooling cycle. Given the importance of memory, it is critical to note that the observed transition temperature was below room temperature ($\sim 15^\circ\text{C}$), suggesting that these cells are naïve to phase separation as they were incubated at 37°C and processed at room temperature. Scale bar indicated 5 μm . Cooling and heating rate were set to a constant 5°C min^{-1} .

FIG. 3A–B. additional proteomic analysis. FIG. 3A shows a graph of the difference in amino acid composition between ordered and disordered regions within the same protein. A disordered region was defined as being scored with a >0.5 value using PONDR VSL2, ordered regions with a score of <0.5 . Values were calculated by subtracting the percentage of chain

composition in disordered regime from ordered regime. Bars indicate 25th–75th percentiles and whiskers indicate 10th–90th percentiles. Middle line indicates the median of the data set. N = 63, * P < 0.01 in students t-test between ordered and disordered regions of all proteins sampled. FIG. 3B shows a histogram plotting the length of the disordered regions analyzed in this study. Bars indicate 25th–75th percentiles and whiskers indicate 10th–90th percentiles.

FIG. 4. SDS-PAGE gels of purified proteins used in this study relevant to FIG. 1–5. Lane labels for each protein purified in this study are listed in Table 2 and Table 3.

FIG. 5. wide-field fluorescent microscope images of fluorescently labeled [Q5,8]-20 Inside water-in-oil compartments. [Q5,8]-20 was labeled with AlexaFluor 350 via NHS chemistry and resuspended in 140 mM PBS at pH 7.4 to a final ϕ = 0.003. Water-in-oil mixture was transferred to glass slide and cooled from 50 °C to 10 °C. Scale bar = 20 μ m.

FIG. 6. additional dynamic light scattering data. Data collected on 20 nm filtered samples at volume fractions that were predicted to exhibit liquid-liquid phase separation at 40 °C. Data collected in 140 mM PBS, pH 7.4.

FIG. 7. cyclic cooling and heating cycles exhibit minimal hysteric behavior. Optical turbidity measured at 350 nm of repeated cooling and heating curves of [Q5,8]-20 @ ϕ = 0.0025 between 40 °C and 30 °C.

FIG. 8A–F show control of UCST cloud point using main chain amino acid composition. FIG. 8A shows a schematic describing the methodology for doping repeat unit b into a homopolymer of a. The WT A-IDP with a high UCST cloud point consisting of 40 repeats of a —GRGDSPYS—is doped with increasing fractions of repeat b —GRGDQPYQ— to probe “loss of function” of UCST phase behavior of polymers of a. The doping of b into a is designed to ensure mixing of the two repeats along the polypeptide chain and minimize blocky behavior. FIG. 8B shows doping of b into a results in mutant IDPs; the UCST cloud point temperature (T_i) of each mutant IDP is a linear function of volume fraction (ϕ) of the A-IDP. FIG. 8C shows the effect of composition—degree of doping—is a linear function of the degree of substitution of b into a at constant volume fraction of 10^{-3} ($R^2=0.97$). FIG. 8D shows substitution of aromatic Y residues with aliphatic V dramatically reduces T_i . FIG. 8E shows substitution of R with K dramatically reduces T_i . A 50% substitution of K for R lowers the T_i by more than 40 °C. FIG. 8F shows the chemical composition can affect the saturation concentration by two orders of magnitude at constant molecular weight (C_{sat} @ 37 °C = 1–800 μ M). This can be visualized by normalizing to the saturation concentration of [WT]-40 which is conveniently ~1 μ M and is shown by the dashed horizontal line.

FIG. 9A–E show effects of single amino acid substitutions on UCST cloud point and new relative UCST propensity scale. FIG. 9A shows partial binodal phase boundary of well-mixed, di-block polypeptides with varied ratio of aromatic:aliphatic residues. FIG. 9B shows partial binodal phase boundary of well-mixed, di-block polypeptides with varied ratio of polar non-charged residues. FIG. 9C shows partial binodal phase boundary of well-mixed, di-block polypeptides with varied identity of positively charged and negatively residues. FIG. 9D shows partial binodal phase boundary of well-mixed, di-block polypeptides with varied amount of. Data collected under physiologic solution conditions (140 mM PBS, pH 7.4) at $\phi = 10^{-3}$. All polypeptides are 326 amino acids in length. FIG. 8E shows a relatively scale for UCST propensity based on substitutions made to the [WT] repeating motif. The transition temperatures listed are the UCST cloud point at $\phi = 10^{-3}$ if the left amino acid was replaced with the amino acid to the right of the arrow and the total number of amino acids was 326.

FIG. 10 shows analysis of secondary structure with circular dichroism (CD) spectroscopy. CD spectra of various A-IDPs lack a defined secondary structure curve shape, characteristic of other IDP and other repetitive protein polymers. Data collected at 50 °C (soluble chains) at 5 μ M in 5 mM PBS, pH 7.4. Error bars indicate standard deviation of three sequential runs.

FIG. 11A–C show control of UCST cloud point by molecular weight of A-IDP. FIG. 11A shows the molecular weight of the polypeptide affects the T_i . FIG. 11B shows the T_i directly scales with the natural log of MW. FIG. 11C shows at constant chemical composition, it is possible to modulate C_{sat} by over five orders of magnitude simply by changing the MW of the A-IDP (C_{sat} at 37 °C = 1 nM–400 μ M). [WT]-40 has a C_{sat} of ~1 μ M.

FIG. 12A–D show minor effects on UCST cloud point in protein polypeptides. FIG. 12A shows partial binodal phase diagram of sequence syntax permutations focused around the Pro residue. Mutations reveal that amino acid mutation site affects the UCST binodal, particularly at the fifth position, but do not eliminate phase behavior. Data collected under physiologic conditions (140 mM PBS, pH 7.4). FIG. 12B shows partial binodal phase boundaries of agnostically non-repetitive but compositionally identical versions of [WT]-20. FIG. 12C shows turbidity curves of [H7]-60 in different pH solutions. Decreasing the pH and protonation of the His residues increases and broadens observed UCST phase behavior. This effect centers at ~ pH 7, very close to the predicted pKa of the imidazole group in H. In contrast to, [WT]-60's UCST cloud point does not change as a function of pH (black dots, graph insert). FIG. 12D shows turbidity curves of [Q5,8]-40 in solutions with different concentrations of NaCl. In pure water, [Q5,8]-40 exhibits a broad transition at higher temperatures. Increasing the concentration of NaCl between 0–140 mM

reduces and sharpens the UCST cloud point, finally reaching a minimum at ~500 mM. From this point, the protein exhibits a salting-out effect and the transition temperature begins to rise again.

FIG. 13A–C. mapping phase diagrams using a temperature gradient device. FIG. 13A shows representative dark-field image of [Q5,8]-20 solutions on a temperature gradient device. The transition temperatures of the reference solutions (red and blue lines) and the 20 mg·mL⁻¹ [Q5,8]-20 solution (green line) are indicated by the horizontal colored lines. The dashed vertical magenta line along the 20 mg·mL⁻¹ capillary tube illustrated the region of the image used to measure the line scan. FIG. 13B shows line scan of normalized light scattering intensity versus temperature for the 20 mg·mL⁻¹ [Q5,8]-20 capillary shown in FIG. 13A. The dashed black lines represent tangent lines for the high temperature baseline and increase in light scattering at lower temperatures. These two lines intersect at T_{ph}, as indicated by the vertical green line. FIG. 13C shows final binodal phase lines of [WT]-20 and [Q5,8]-20 using multiple data points from temperature gradient device. A three-piece fit was utilized to fit three regimes that roughly correspond to the dilute, overlap, and semi-dilute regimes of the polypeptide phase diagram. The observed data and subsequent fits demonstrate that polypeptide sequence not only affects UCST cloud point in the dilute regime but over the entire concentration range measured ($\phi \leq 0.5$)

FIG. 14A–B show quantification of dextran uptake during phase separation of A-IDPs. FIG. 14A shows fluorescent microscopy images of phase separated droplets in the presence of dextran molecules of different molecular weight (10/40 kDa) labeled with Alexa488 (green) fluorophore. Inside the phase separated space (dark circles), there is very little sequestration of the dextran molecules as a function of dextran molecular weight or A-IDP sequence. Scale bar is 20 μ m. FIG. 14B shows quantification of fluorescent signal between the area inside of phase separated droplets and outside.

FIG. 15A–G show A-IDPs exhibit tunable intracellular droplet formation based on molecular weight and ratio of aromatic:aliphatic content. All scale bars are 5 μ m. FIG. 15A shows a schematic describing the use of two key parameters —ratio of aromatic:aliphatic content and molecular weight—to control intracellular droplet formation by modulating C_{sat}. FIG. 15B shows partial *in vitro* binodal of A-IDP–sfGFP fusions in the dilute regime in 140 mM PBS, pH 7.4. Similar to A-IDPs, A-IDP–GFP fusion proteins exhibit molecular weight and aromatic content dependent phase behavior. FIG. 15C shows [WT]-20–sfGFP fusion phase separates in eukaryotic cells (HEK293 cells, Day 5). Instead of forming a single droplet as seen *in vitro* in protocells (see FIG. 1C), many distinct droplets are formed indicating either diffusion-limited or arrest-limited coalescence. FIG. 15D shows confocal fluorescence images of A-IDP–sfGFP as a function of induction time and molecular weight in *E. coli*. A higher intracellular concentration is required for

[WT]-20 versus [WT]-40 to form intracellular droplets. It is noticeable that [WT]-40 has a lower ϕ' —A-IDP poor—soluble phase outside the dense droplet phase compared with [WT]-20. FIG. 15E shows reducing the aromatic content increases the C_{sat} in a dose-dependent manner. FIG. 15F shows A-IDP—sfGFP fusions exhibit a one order of magnitude shift in their C_{sat} as determined by their molecular weight and ratio of aromatic:aliphatic content. FIG. 15G shows the size of intracellular droplets (ϕ'' or dense phase) grow with induction time. As concentration of the A-IDP—sfGFP increases inside the cell, the soluble concentration outside the droplet does not change (FIG. 19) but the size of the intracellular droplets grows relative to the total cell area. Images are individual cells from [3Y7:V7]-40—sfGFP cultures at various time points. Error bars represent standard error of the mean.

FIG. 16A–C show a comparison of partial binodal phase diagrams of A-IDP and A-IDP—sfGFP fusions. FIG. 16A shows partial binodal phase boundaries of [WT]-40 and [WT]-40—sfGFP. FIG. 16B shows partial binodal phase boundaries of [3Y7:V7]-40 and [3Y7:V7]-40—sfGFP. FIG. 16C shows partial binodal phase boundaries of [WT]-20 and [WT]-20—sfGFP. The sfGFP fusion lowers the UCST binodal line for all A-IDPs. These data suggest that the larger molecular weight polypeptides are less affected by sfGFP fusion as the observed difference in [WT]-40 and [3Y7:V7]-40 is only $\sim 10^\circ\text{C}$ instead of $\sim 20^\circ\text{C}$ for [WT]-20.

FIG. 17 show confocal microscopy images of HEK293 cells with transiently transfected [WT]-20—sfGFP. Confocal fluorescence image slices throughout the cell demonstrate that phase separated droplets are formed throughout the cytoplasm without obvious colocalization with other cellular structures. Images taken 24 hours after transfection with 3 μg of pCDNA plasmid that encode [WT]-20—sfGFP. Scale bar = 5 μm .

FIG. 18 shows measurement of total cellular fluorescence as a function of time post induction. *E. coli* cultures were spun down and resuspended in 140 mM PBS, pH 7.4. The optical turbidity and fluorescence intensity of sfGFP were measured and plotted as a function of time. Data collected at 22°C .

FIG. 19 shows measurement of the cellular fluorescence at different locations within the cell. Digital partitions were made between the dense phase separated area of the cell and soluble cytoplasmic space using ImageJ. The mean of the total cell fluorescence intensity (solid line) and cytoplasmic fluorescence intensity (dotted line) are plotted as a function of time post-IPTG induction. [WT]-20—sfGFP does not exhibit intracellular droplets until the 6 hr mark. At this point the cytoplasmic fluorescence intensity remains constant but the total fluorescent increases from 6 hr onward. [WT]-40—sfGFP phase transitions prior to the 2-hr timepoint.

FIG. 20A–D show A-IDPs exhibit reversible coacervation in *E. coli* determined by their molecular weight and aromatic:aliphatic ratio. All scale bars are 5 μm . FIG. 20A shows intracellular droplets comprised of [WT]-20-sfGFP can be formed and dissolved reversibly via alternating cooling and heating cycles. This process is completely reversible over four rounds of cooling and heating. Cooling rate = 5 $^{\circ}\text{C min}^{-1}$, induction time of 4 hr. FIG. 20B shows T_i normalized to the intracellular fluorescence of sfGFP in each individual cell ($n = 30$) does not change significantly over four heating (red bars) and cooling (blue bars) cycles. Boxes indicate 25th–75th percentile. FIG. 20C shows the intracellular T_i —similar to *in vitro*—is a function of A-IDP molecular weight and aromatic content. Cooling ramp = 60 $^{\circ}\text{C} \rightarrow 10^{\circ}\text{C}$. Cooling rate = 5 $^{\circ}\text{C min}^{-1}$, A-IDP gene induction time of 8 hr. Whiskers indicate 10th–90th percentile. FIG. 20D shows intracellular binodal lines of various A-IDP–sfGFP fusions. T_i increases as a function of cellular fluorescence, a surrogate of A-IDP concentration, and aromatic content of the A-IDP. Data analyzed at 2, 4, 8 hr for [WT]-40-sfGFP and [3Y7:V7]-10 and 4, 8, 24 hr for [Y7:V7]-40 ($n = 30$). Error bars indicate standard error of the mean. FIG. 20D shows upon reconstitution of sfGFP in the dense phase, the solubility of the reconstituted GFP–A-IDP complex can be modulated with temperature. Data was collected for 36 hr post-IPTG induction and 12 hours post-arabinose induction.

FIG. 21A–C show image analysis of the number of puncta formed in each cell. 100 cells at random were tabulated for each histogram. FIG. 21A shows a number of intracellular puncta formed in each cell containing [WT]-20-sfGFP during a cooling ramp from 60 $^{\circ}\text{C} \rightarrow 10^{\circ}\text{C}$ (green) and imaged isothermally at 22 $^{\circ}\text{C}$. Isothermal analysis performed at 6 hours post induction, the first timepoint where intracellular puncta were observed. Cooling ramp performed at 4 hours post induction, where transition temperature (T_i) was between 22 $^{\circ}\text{C}$ and 37 $^{\circ}\text{C}$. FIG. 21B shows a number of intracellular puncta formed in each cell containing [3Y:V]-40-sfGFP during a cooling ramp from 60 $^{\circ}\text{C} \rightarrow 10^{\circ}\text{C}$ (green) and imaged isothermally at 22 $^{\circ}\text{C}$. Isothermal analysis performed at 4 hours post induction, the first timepoint where intracellular puncta were observed. Cooling ramp performed at 4 hours post induction, where T_i was between 22 $^{\circ}\text{C}$ and 37 $^{\circ}\text{C}$. FIG. 21C shows a number of intracellular puncta formed in each cell containing [WT]-40-sfGFP during a cooling ramp from 60 $^{\circ}\text{C} \rightarrow 10^{\circ}\text{C}$ (green) and imaged isothermally at 22 $^{\circ}\text{C}$. Isothermal analysis performed at 4 hours post induction, the first timepoint where intracellular puncta were observed. Cooling ramp performed at 4 hours post induction, but the transition observed was $>37^{\circ}\text{C}$ indicating the possibility of memory.

FIG. 22A–E show engineered intracellular droplets with programmable functions. FIG. 22A shows site specific labeling of droplets with a small molecule fluorescent dye. *E. coli* cells

containing condensates formed by a [3Y7:V7]-40 variant with azido-phenylalanine (AzF) residues that presents a biorthogonal azide which can be labeled in situ with a dibenzocyclooctyne-dye conjugate (DBCO-Alexa488). DBCO-Alexa488 mixture can diffuse into cells and into the A-IDP condensates within the cell, labeling the azide groups within 10 min of incubation with live *E. coli*.

FIG. 22B shows reconstitution of function GFP in condensates by recruitment of a partner from the cytoplasm using a split GFP system. A GFP-11-[3Y7:V7]-40 fusion protein is able to recruit GFP-1-10 from the surrounding cytoplasm into intracellular droplets. Upon formation of intracellular condensates after 24 hr of IPTG induction of GFP-11-[3Y7:V7]-40 (left panel), subsequent induction GFP-1-10 by arabinose induction enables recruitment of GFP-10 into the condensates and reconstitution of functional sfGFP within existing intracellular condensates within 12 hr of GFP-1-10 induction (right panel). FIG. 22C shows a schematic of enzyme-condensate experiment. The α -peptide (α p) of LacZ is fused to a fluorescent reporter protein (mRuby3) and expressed from an IPTG-inducible gene from a plasmid in the *E. coli* strain KRX that has a deletion mutant of the LacZ gene that produces a truncated, catalytically inactive enzyme lacking the α p. Complementation of Lac Δ M15 by a α p-A-IDP-mRuby3 fusion creates an active enzyme that converts FDG into fluorescein that is then rapidly exported from the intracellular space into the surrounding medium. FIG. 22D shows confocal microscopy images showing the fluorescent conversion of fluorescein Di- β -D-galactopyranoside (FDG). Note that the puncta-like structures of α p-mRuby3 in the top panel are due to a fraction of the fusion forming inclusion bodies in cells. When the α p is fused to [WT]-20-mRuby3 the fluorescence is first observed at the sites of intracellular phase transition in coacervate droplets, and the fluorescein then diffuses into the cytosol and then out of the cell into the extracellular space. Increasing the molecular weight of the A-IDP leads to increased FDG conversion at earlier timepoints and higher overall conversion after 20 min. Rebalanced images of α p-[WT]-40-mRuby3 and α p-[WT]-80-mRuby3 can be found in FIG. 25 for improved visualization of the colocalization of intracellular droplets and converted FDG. FIG. 22E shows intracellular concentration of fluorescein produced by catalytic conversion of FDG, normalized to the mRuby3 fluorescence of each individual cell ($n \cong 300$). The catalytic efficiency increases with A-IDP MW, as seen by the greater ratio of green fluorescence resulting from FDG conversion to fluorescein normalized to the red fluorescence of mRuby3 on a molar basis. Both α p-[WT]-40-mRuby3 and α p-[WT]-80-mRuby3 exhibit statistically significant differences from the control (α p-mRuby3). Error bars indicate standard error of the mean. FIG. 22F shows all α p-A-IDP-mRuby3 fusions exhibit a higher ratio of green fluorescence inside the cell, indicating a greater persistence of fluorescent FDG inside the

intracellular space compared to the α p-mRuby3 control. Error bars indicate standard error of the mean. All scale bars are 5 μ m.

FIG. 23A–B show confocal microscope images of split GFP recruitment into intracellular droplets. FIG. 23A shows GFP-11-[3Y7:V7]-40-mRuby3 co-expressed in the presence of GFP-1-10 creates fluorescently active GFP only in the interior of the droplet. FIG. 23B shows in the absence of GFP-1-10 induction, there is little green fluorescent inside the intracellular droplets. Data taken at 22 °C. Scale bar = 5 μ m.

FIG. 24 shows A-IDPs can modulate the solubility of an endogenously bound molecule 2. Upon recruitment of sfGFP into the dense phase, the solubility of the entire complex can be modulated with temperature. Data was collected for 36 hours post-IPTG induction and 12 hours post-arabinose induction. Scale bar = 5 μ m.

FIG. 25A–B show color balanced confocal microscopy images of α p-[WT]-40-mRuby3 and α p-[WT]-80-mRuby3. All scale bars are 5 μ m. FIG. 25A shows color re-balanced images from FIG. 22B for improved visualization of the intracellular droplets formed by α p-A-IDP-mRuby3 fusions. FIG. 25B shows split channel images of α p-[WT]-40-mRuby3 and α p-[WT]-80-mRuby3.

FIG. 26. Mander's colocalization score between converted FDG and fluorescent reporter. Data analyzed 30 min after FDG addition. Background threshold was set automatically.

FIG. 27A–B shows Lineweaver-Burk plots for determining K_m and V_{max} . Lineweaver-Burk plots created with variable starting concentrations of FDG for FIG. 27A, α p-mRuby3; FIG. 27B, α p-[WT]-20-mRuby3; FIG. 27C, α p-[WT]-40-mRuby3; and FIG. 27D, α p-[WT]-80-mRuby3. Slopes (V_o) were determined from fluorescent generation over the course of 20 minutes. Intercepts and slope were used in the calculation of K_m and V_{max} .

FIG. 28A–C show enzymatic droplets formed with variable ratios of aromatic to aliphatic residues. All scale bars are 5 μ m. FIG. 28A shows confocal microscopy images observing the fluorescent conversion of Fluorescein Di- β -D-Galactopyranoside (FDG) of α p-mRuby3, α p-[WT]-40-mRuby3, α p-[3Y7:V7]-40-mRuby3 and α p-[Y7:V7]-40-mRuby3. Decreasing the aromatic:aliphatic ratio does not increase FDG conversion over time but does change the dynamics of uptake with lower aromatic:aliphatic ratio polypeptides observing higher uptake at earlier timepoints after FDG addition. FIG. 28B shows quantified amount of converted FDG intracellularly, normalized to the amount of mRuby3 fluorescence. There is little difference between A-IDPs with different ratios of aromatic:aliphatic content. Error bars indicate standard error of the mean. FIG. 28C shows all α p-A-IDP-mRuby3 fusions exhibit a higher ratio of FDG fluorescence inside the cell, indicating a greater persistence of fluorescent FDG inside the

intracellular space compared to the α p-mRuby3 control. There is little difference between A-IDPs with different levels of aromatic content. Error bars indicate standard error of the mean.

FIG. 29A–B shows enzymatic Activity of α p-[V7]-40-mRuby3. All scale bars are 5 μ m. FIG. 29A shows confocal microscopy images showing the fluorescent conversion of fluorescein Di- β -D-galactopyranoside (FDG) attached to soluble α p-[V7]-40-mRuby3. FIG. 29B shows intracellular concentration of fluorescein produced by catalytic conversion of FDG by α p-[V7]-40-mRuby3, normalized to the mRuby3 fluorescence of each individual cell ($n \cong 300$). The soluble fusion exhibits a lower level of enzymatic activity than all puncta-forming α p-A-IDP fusions. α p-mRuby3 data from FIG. 24 redrawn to show scale. Error bars indicate standard error of the mean.

FIG. 30A–D show examples of various fusion proteins that express at low levels in prokaryotic expression systems that when fused to disordered biopolymers rescue expression levels and using the phase separation behavior of the biopolymers allow for recovery into soluble fractions. This can be performed with mAb binding proteins that have a nanobody folded structure that bind to mAb (ZD, FIG. 30A); fluorescent fusion proteins that have beta-barrel structures (sfGFP, FIG. 30B); therapeutic protein peptides (GLP-1, FIG. 30C) with strong alpha-helical tendencies, RNA binding proteins (PUMHD, FIG. 30D) that have tandem repeat structures and antimicrobial peptides that exhibit cytotoxic tendencies in *E. coli*.

FIG. 31 shows the incubation of mAb with a phase separating biopolymer fused to a domain from protein A that binds mAbs. The biopolymer is bound to the mAb and centrifuged to capture the mAb heavy (HC) and light chain (LC). The supernatant of this step is run in lanes 2 and 5. Then, the supernatant is removed, and the pellet is resuspended in an elution buffer that is a lower pH which causes dissociation between the biopolymer-ZD fusion and the mAb. The solution is spun again creating an elution supernatant (lanes 3, 6) contains pure mAb HC and LC and other protein contaminants. The elution pellet contains the biopolymer and no mAb (lanes 4, 7).

FIG. 32 shows microscopic images of fluorescently labeled mAb (red/white in grey-scale) visualized in the presence of phase separated protein ((GRGDQPYQ)₄₀, SEQ ID NO: 3 with m = 40) fused to the Z-domain of Protein A (ZD). The colocalization of the droplets with a fluorescent signal is observable in the first image. When the buffer pH is dropped at $t = 0$, there is an inversion in the fluorescent signal suggesting the mAb has completely dissociated from the phase separated protein-ZD fusion protein (white arrow) and entered the surrounding solution (red). These biopolymer-fusion proteins retain their liquid-like behavior as droplet fusion occurs between 60–240 sec (arrows).

FIG. 33 shows fusion proteins containing various AMPs were expressed fused to nothing (left side) and various biopolymer (right side). When fusion protein is not expressed (top), cell growth proceeds as normal measured by an increasing absorbance at OD₆₀₀. When the AMP alone is expressed (bottom-left), cell growth is stunted (growth curves shifted to later times).
 5 When AMP-biopolymer fusion protein is expressed, normal growth is recovered, suggesting reduced availability of the AMP.

FIG. 34 shows injection strategies for forming subcutaneous depots *in vivo*. Injection with solubilizing agent such as urea allows for injection under ambient conditions. As the solubilizing agent diffuses faster than the polypeptide, the solvent becomes a poor solvent and the
 10 polypeptide will phase separate. Alternatively, a dehydrated coacervate can be implanted in the subcutaneous space which will slowly rehydrate indirectly into a two-phase regime.

FIG. 35 shows fluorescence molecular tomography of (GRGDSPYQ)₄₀ labeled with a near infrared fluorescent dye after injection in the presence of 2 M urea + PBS. Injection concentration of 175 μM, corresponding to 1.2 mg of protein total.

15 FIG. 36 shows fluorescence molecular tomography of (GRGDSPYQ)₄₀ labeled with a near infrared fluorescent dye after injection in dehydrated state. Injection mass equal to 1.2 mg of protein total.

FIG. 37 shows binodal phase boundary of GLP-1-RIDPs of lower molecular weight. Data collected in 140 mM PBS. Dotted lines are fit lines for $y = m \cdot \ln(x) + b$.

20 FIG. 38 shows blood glucose of GLP-1-RIDP fusion proteins of ~20 kDa in size and variable C_{sat}. Data collected from C57Bl/6J mice that have been fed 60% fat diet. Error bars are standard error of the mean (n = 5).

FIG. 39: Body weight change of mice with sub-cutaneous GLP-1-RIDP depots of ~20 kDa in size and variable C_{sat}. Data collected from C57Bl/6J mice that have been fed 60% fat diet.
 25 Error bars are standard deviation of the mean (n = 5).

FIG. 40 shows binodal phase boundary of GLP-1-RIDPs of higher molecular weight. Data collected in 140 mM PBS. Dotted lines are fit lines for $y = m \cdot \ln(x) + b$.

FIG. 41 shows blood glucose of GLP-1-RIDP fusion proteins of ~35 kDa in size and variable C_{sat}. Data collected from C57Bl/6J mice that have been fed 60% fat diet. Error bars are
 30 standard error of the mean (n = 5).

FIG. 42 shows blood glucose of GLP-1-RIDP fusion proteins of different molecular weights but similar C_{sat}. Data collected from C57Bl/6J mice that have been fed 60% fat diet. Error bars are standard error of the mean (n = 5).

FIG. 43 shows body weight change of mice with sub-cutaneous GLP-1-RIDP depots of ~35 kDa in size and variable C_{sat} . Data collected from C57Bl/6J mice that have been fed 60% fat diet. Error bars are standard error of the mean ($n = 5$).

5 DETAILED DESCRIPTION

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

The terms "comprise(s)," "include(s)," "having," "has," "can," "contain(s)," and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments "comprising," "consisting of," and "consisting essentially of," the embodiments or elements presented herein, whether explicitly set forth or not.

For the specification of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6–9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0–7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

The term "about" as used herein as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term "about" refers to a range of values that fall within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

"Affinity" refers to the binding strength of a binding polypeptide to its target (i.e., binding partner).

"Agonist" refers to an entity that binds to a receptor and activates the receptor to produce a biological response. An "antagonist" blocks or inhibits the action or signaling of the agonist. An "inverse agonist" causes an action opposite to that of the agonist. The activities of agonists,

antagonists, and inverse agonists may be determined *in vitro*, *in situ*, *in vivo*, or a combination thereof.

“Amino acid” as used herein refers to naturally occurring and non-natural synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code. Amino acids can be referred to herein by either their commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids include the side chain and polypeptide backbone portions.

As used herein, the term “biomarker” refers to a naturally occurring biological molecule present in a subject at varying concentrations that is useful in identifying and/or classifying a disease or a condition. The biomarker can include genes, proteins, polynucleotides, nucleic acids, ribonucleic acids, polypeptides, or other biological molecules used as an indicator or marker for disease. In some embodiments, the biomarker comprises a disease marker. For example, the biomarker can be a gene that is upregulated or downregulated in a subject that has a disease. As another example, the biomarker can be a polypeptide whose level is increased or decreased in a subject that has a disease or risk of developing a disease. In some embodiments, the biomarker comprises a small molecule. In some embodiments, the biomarker comprises a polypeptide.

The terms “control,” “reference level,” and “reference” are used herein interchangeably. The reference level may be a predetermined value or range, which is employed as a benchmark against which to assess the measured result. “Control group” as used herein refers to a group of control subjects. The predetermined level may be a cutoff value from a control group. The predetermined level may be an average from a control group. Cutoff values (or predetermined cutoff values) may be determined by Adaptive Index Model (AIM) methodology. Cutoff values (or predetermined cutoff values) may be determined by a receiver operating curve (ROC) analysis from biological samples of the patient group. ROC analysis, as generally known in the biological arts, is a determination of the ability of a test to discriminate one condition from another, e.g., to determine the performance of each marker in identifying a patient having CRC. A description of ROC analysis is provided in P.J. Heagerty et al. (*Biometrics* 2000, 56, 337-44), the disclosure of which is hereby incorporated by reference in its entirety. Alternatively, cutoff values may be determined by a quartile analysis of biological samples of a patient group. For example, a cutoff value may be determined by selecting a value that corresponds to any value in the 25th-75th percentile range, preferably a value that corresponds to the 25th percentile, the 50th percentile or

the 75th percentile, and more preferably the 75th percentile. Such statistical analyses may be performed using any method known in the art and can be implemented through any number of commercially available software packages (e.g., from Analyse-it Software Ltd., Leeds, UK; StataCorp LP, College Station, TX; SAS Institute Inc., Cary, NC). The healthy or normal levels or ranges for a target or for a protein activity may be defined in accordance with standard practice.

The term "expression vector" indicates a plasmid, a virus, or another medium, known in the art, into which a nucleic acid sequence for encoding a desired protein can be inserted or introduced.

The term "host cell" is a cell that is susceptible to transformation, transfection, transduction, conjugation, and the like with a nucleic acid construct or expression vector. Host cells can be derived from plants, bacteria, yeast, fungi, insects, animals, etc. In some embodiments, the host cell includes *Escherichia coli*.

"Polymer" as used herein is intended to encompass a homopolymer, heteropolymer, block polymer, co-polymer, ter-polymer, etc., and blends, combinations, and mixtures thereof. Examples of polymers include, but are not limited to, functionalized polymers, such as a polymer comprising 5-vinyltetrazole monomer units and having a molecular weight distribution less than 2.0. The polymer may be or contain one or more of a star block copolymer, a linear polymer, a branched polymer, a hyperbranched polymer, a dendritic polymer, a comb polymer, a graft polymer, a brush polymer, a bottle-brush copolymer and a crosslinked structure, such as a block copolymer comprising a block of 5-vinyltetrazole monomer units. Polymers include, without limitation, polyesters, poly(meth)acrylamides, poly(meth)acrylates, polyethers, polystyrenes, polynorbornenes and monomers that have unsaturated bonds. For example, amphiphilic comb polymers are described in U.S. Patent Application Publication No. US 2007/0087114 and in U.S. Patent No. 6,207,749 to Mayes et al., the disclosure of each of which is herein incorporated by reference in its entirety. The amphiphilic comb-type polymers may be present in the form of copolymers, containing a backbone formed of a hydrophobic, water-insoluble polymer and side chains formed of short, hydrophilic non-cell binding polymers. Examples of other polymers include, but are not limited to, polyalkylenes such as polyethylene and polypropylene; polychloroprene; polyvinyl ethers; such as polyvinyl acetate); polyvinyl halides such as polyvinyl chloride); polysiloxanes; polystyrenes; polyurethanes; polyacrylates; such as poly(methyl (meth)acrylate), poly(ethyl (meth)acrylate), poly(n-butyl(meth)acrylate), poly(isobutyl (meth)acrylate), poly(tert-butyl (meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), poly(phenyl (meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate); polyacrylamides

such as poly(acrylamide), poly(methacrylamide), poly(ethyl acrylamide), poly(ethyl methacrylamide), poly(N-isopropyl acrylamide), poly(n, iso, and tert-butyl acrylamide); and copolymers and mixtures thereof. These polymers may include useful derivatives, including polymers having substitutions, additions of chemical groups, for example, alkyl groups, alkylene
5 groups, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art. The polymers may include zwitterionic polymers such as, for example, polyphosphorycholine, polycarboxybetaine, and polysulfobetaine. The polymers may have side chains of betaine, carboxybetaine, sulfobetaine, oligoethylene glycol (OEG), sarcosine, or polyethyleneglycol (PEG). For example, poly(oligoethyleneglycol methacrylate) (poly(OEGMA)) may be used.
10 Poly(OEGMA) may be hydrophilic, water-soluble, non-fouling, non-toxic and non-immunogenic due to the OEG side chains.

“Polynucleotide” as used herein can be single stranded or double stranded or can contain portions of both double stranded and single stranded sequence. The polynucleotide can be nucleic acid, natural or synthetic, DNA, genomic DNA, cDNA, RNA, or a hybrid, where the
15 polynucleotide can contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine. Polynucleotides can be obtained by chemical synthesis methods or by recombinant methods.

A “peptide” or “polypeptide” is a linked sequence of two or more amino acids linked by
20 peptide bonds. The polypeptide can be natural, synthetic, or a modification or combination of natural and synthetic. Peptides and polypeptides include proteins such as binding proteins, receptors, and antibodies. The terms “polypeptide,” “protein,” and “peptide” are used interchangeably herein. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three-dimensional structures within a
25 polypeptide. These structures are commonly known as domains, e.g., enzymatic domains, extracellular domains, transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include domains with enzymatic activity or ligand binding activity. Typical domains are made up of sections of lesser organization such as stretches
30 of beta-sheet and alpha-helices. “Tertiary structure” refers to the complete three-dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three-dimensional structure formed by the noncovalent association of independent tertiary units.

“Reporter,” “reporter group,” “label,” and “detectable label” are used interchangeably herein. The reporter is capable of generating a detectable signal. The label can produce a signal

that is detectable by visual or instrumental means. A variety of reporter groups can be used, differing in the physical nature of signal transduction (e.g., fluorescence, electrochemical, nuclear magnetic resonance (NMR), and electron paramagnetic resonance (EPR)) and in the chemical nature of the reporter group. Various reporters include signal-producing substances, such as
5 chromagens, fluorescent compounds, chemiluminescent compounds, radioactive compounds, and the like. In some embodiments, the reporter comprises a radiolabel. Reporters may include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. In some embodiments, the signal from the reporter is a fluorescent signal. The reporter may comprise a fluorophore. Examples of fluorophores include, but are not limited to,
10 acrylodan (6-acryloyl 1-2-dimethylaminonaphthalene), badan (6-bromo-acetyl-2-dimethylaminonaphthalene), rhodamine, naphthalene, dansyl aziridine, 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino]-7-nitrobenz-2-oxa-1,3-diazole ester (IANBDE), 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino-7-nitrobenz-2-oxa-1,3-diazole (IANBDA), fluorescein, dipyrrometheneboron difluoride (BODIPY), 4-nitrobenzo[c][1,2,5]oxadiazole (NBD), Alexa fluorescent dyes, and
15 derivatives thereof. Fluorescein derivatives may include, for example, 5-fluorescein, 6-carboxyfluorescein, 3'-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachlorofluorescein, 6-tetrachlorofluorescein, fluorescein, and isothiocyanate.

"Sample" or "test sample" as used herein can mean any sample in which the presence and/or level of a target is to be detected or determined. Samples may include liquids, solutions,
20 emulsions, or suspensions. Samples may include a medical sample. Samples may include any biological fluid or tissue, such as blood, whole blood, fractions of blood such as plasma and serum, muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow, cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchoalveolar lavage fluid, gastric lavage, emesis, fecal matter, lung tissue, peripheral blood mononuclear cells, total white blood cells,
25 lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluid, skin, or combinations thereof. In some embodiments, the sample comprises an aliquot. In other embodiments, the sample comprises a biological fluid. Samples can be obtained by any means known in the art. The sample can be used directly as obtained from a patient or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of
30 interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art.

The term "sensitivity" as used herein refers to the number of true positives divided by the number of true positives plus the number of false negatives, where sensitivity ("sens") may be within the range of $0 < \text{sens} < 1$. Ideally, method embodiments herein have the number of false

negatives equaling zero or close to equaling zero, so that no subject is wrongly identified as not having a disease when they indeed have the disease. Conversely, an assessment often is made of the ability of a prediction algorithm to classify negatives correctly, a complementary measurement to sensitivity.

5 The term "specificity" as used herein refers to the number of true negatives divided by the number of true negatives plus the number of false positives, where specificity ("spec") may be within the range of $0 < \text{spec} < 1$. Ideally, the methods described herein have the number of false positives equaling zero or close to equaling zero, so that no subject is wrongly identified as having a disease when they do not in fact have disease. Hence, a method that has both sensitivity and
10 specificity equaling one, or 100%, is preferred.

By "specifically binds," it is generally meant that a polypeptide binds to a target when it binds to that target more readily than it would bind to a random, unrelated target.

"Subject" as used herein can mean a mammal that wants or is in need of the herein described peptide biopolymers comprising one or more fusion proteins. The subject may be a
15 human or a non-human animal. The subject may be a mammal. The mammal may be a primate or a non-primate. The mammal can be a primate such as a human; a non-primate such as, for example, dog, cat, horse, cow, pig, mouse, rat, camel, llama, goat, rabbit, sheep, hamster, and guinea pig; or non-human primate such as, for example, monkey, chimpanzee, gorilla, orangutan, and gibbon. The subject may be of any age or stage of development, such as, for example, an
20 adult, an adolescent, or an infant.

"Transition" or "phase transition" refers to the aggregation of the thermally responsive polypeptides. Phase transition occurs sharply and reversibly at a specific temperature called the lower critical solution temperature (LCST) or the inverse transition temperature T^* . Below the transition temperature, the thermally responsive polypeptide (or a polypeptide comprising a
25 thermally responsive polypeptide) is highly soluble. Upon heating past the transition temperature, the thermally responsive polypeptides hydrophobically collapse and aggregate, forming a separate, gel-like phase. "Inverse transition cycling" refers to a protein purification method for thermally responsive polypeptides (or a polypeptide comprising a thermally responsive polypeptide). The protein purification method may involve the use of thermally responsive
30 polypeptide's reversible phase transition behavior to cycle the solution through soluble and insoluble phases, thereby removing contaminants.

"Treatment" or "treating," when referring to protection of a subject from a disease, means preventing, suppressing, repressing, ameliorating, or eliminating the disease. Preventing the disease involves administering a composition of the present invention to a subject prior to onset

of the disease. Suppressing the disease involves administering a composition of the present invention to a subject after induction of the disease but before its clinical appearance. Repressing or ameliorating the disease involves administering a composition of the present invention to a subject after clinical appearance of the disease.

5 “Substantially identical” can mean that a first and second amino acid sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 or greater number of amino acids.

10 “Valency” as used herein refers to the potential binding units or binding sites. The term “multivalent” refers to multiple potential binding units. The terms “multimeric” and “multivalent” are used interchangeably herein.

 “Variant” used herein with respect to a polynucleotide means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or
15 portion thereof; (iii) a polynucleotide that is substantially identical to a referenced polynucleotide or the complement thereof; or (iv) a polynucleotide that hybridizes under stringent conditions to the referenced polynucleotide, complement thereof, or a sequences substantially identical thereto.

 A “variant” can further be defined as a peptide or polypeptide that differs in amino acid
20 sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or polypeptide or to promote an immune response. Variant can mean a substantially identical sequence. Variant can mean a functional fragment thereof. Variant can also mean multiple copies of a polypeptide. The multiple copies can be in tandem or
25 separated by a linker. Variant can also mean a polypeptide with an amino acid sequence that is substantially identical to a referenced polypeptide with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree, and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor
30 changes can be identified, in part, by considering the hydropathic index of amino acids. See Kyte et al., *J. Mol. Biol.* 1982, 757, 105-132. The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and retain protein function. In one aspect, amino acids having hydropathic indices of ± 2 are substituted. The hydrophobicity of amino acids can also be

used to reveal substitutions that would result in polypeptides retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a polypeptide permits calculation of the greatest local average hydrophilicity of that polypeptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity, as discussed in U.S. Patent No. 4,554,101, which is incorporated herein by reference. Substitution of amino acids having similar hydrophilicity values can result in polypeptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions can be performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.

A variant can be a polynucleotide sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof. The polynucleotide sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. A variant can be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof. The amino acid sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof.

Fusion Protein

The term "fusion protein" as described herein at least one intrinsically disordered polypeptide and at least one other polypeptide. The fusion protein may optionally include at least one linker. In one aspect, the intrinsically disordered polypeptide has controlled reversible phase separation.

In some embodiments, the fusion protein includes more than one polypeptide with controlled reversible phase separation. The polypeptide with controlled reversible phase separation can include multiple repeats of a peptide motif. The fusion protein may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, and least 40, at least 60, at least 80, at least 120, at least 160, or at least 200 polypeptides with controlled reversible phase separation or repeats of a peptide motif with

controlled reversible phase separation. The fusion protein may include less than 30, less than 25, or less than 20 polypeptides with controlled reversible phase separation or repeats of a peptide motif. The fusion protein may include between 1 and 160, between 1 and 80, between 1 and 60, between 1 and 40, between 1 and 20, or between 1 and 10 polypeptides with controlled reversible phase separation or repeats of a peptide motif. In such embodiments, the polypeptides with controlled reversible phase separation may be the same or different from one another. In some embodiments, the fusion protein includes more than one polypeptide with controlled reversible phase separation positioned in tandem to one another (e.g., repeats of a peptide motif).

In some embodiments, the fusion protein includes one or more binding polypeptide. The fusion protein may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 binding polypeptides. The fusion protein may include less than 30, less than 25, less than 20, less than 10, or less than 5 binding polypeptides. The fusion protein may include between 1 and 30, between 1 and 20, or between 1 and 10 binding polypeptides. In such embodiments, the binding polypeptides may be the same or different from one another. In some embodiments, the fusion protein includes more than one binding polypeptide positioned in tandem to one another. In some embodiments, the fusion protein includes 2 to 6 binding polypeptides. In some embodiments, the fusion protein includes two binding polypeptides. In some embodiments, the fusion protein includes three binding polypeptides. In some embodiments, the fusion protein includes four binding polypeptides. In some embodiments, the fusion protein includes five binding polypeptides. In some embodiments, the fusion protein includes six binding polypeptides.

The fusion protein may be expressed recombinantly in a host cell according to one of ordinary skill in the art. The fusion protein may be purified by any means known to one of skill in the art. For example, the fusion protein may be purified using chromatography, such as liquid chromatography, size exclusion chromatography, or affinity chromatography, or a combination thereof. In some embodiments, the fusion protein is purified without chromatography. In some embodiments, the fusion protein is purified using inverse transition cycling.

Polypeptides with Controlled Reversible Phase Separation

The polypeptides with controlled reversible phase separation may comprise any polypeptide that has minimal or no secondary structure as observed by CD, being soluble at a temperature below its lower critical solution temperature (LCST) and/or at a temperature above its upper critical solution temperature (UCST), and comprising a repeated amino acid sequence.

LCST is the temperature below which the polypeptide is miscible. UCST is the temperature above which the polypeptide is miscible. In some embodiments, the polypeptide with controlled reversible phase separation has only UCST behavior. In some embodiments, the polypeptide with controlled reversible phase separation has only LCST behavior. In some embodiments, the polypeptide with controlled reversible phase separation has both UCST and LCST behavior. The polypeptide with controlled reversible phase separation may comprise a repeated sequence of amino acids. The polypeptides with controlled reversible phase separation may have a LCST between about 0 °C and about 100 °C, between about 10 °C and about 50 °C, or between about 20 °C and about 42 °C. The polypeptide with controlled reversible phase separation may have a UCST between about 0 °C and about 100 °C, between about 10 °C and about 50 °C, or between about 20 °C and about 42 °C. In some embodiments, the polypeptide with controlled reversible phase separation has a transition temperature between room temperature (about 25 °C) and body temperature (about 37 °C). In some embodiments, a fusion protein comprising one or more thermally responsive polypeptides has a transition temperature between room temperature (about 25 °C) and body temperature (about 37 °C). In some embodiments, the polypeptide with controlled reversible phase separation has no LCST or UCST behavior. The polypeptide with controlled reversible phase separation may have its LCST or UCST below body temperature or above body temperature at the concentration at which the peptide biopolymer comprising one or more fusion proteins is administered to a subject.

In some embodiments, the polypeptide with controlled reversible phase separation comprises one or more thermally responsive polypeptides. Thermally responsive polypeptides may include, for example, elastin-like polypeptides (ELP) and resilin-like protein (RLP).

In some embodiment, the polypeptide with controlled reversible phase separation comprises a plurality of polypeptides with controlled reversible phase separation. In one aspect, the polypeptide with controlled reversible phase separation a di-block of two or more polypeptides with controlled reversible phase separation. In one aspect, the polypeptides with controlled reversible phase separation comprise a di-block of a resilin-like protein (RLP) and an elastin-like polypeptide (ELP).

In one embodiment, the polypeptide with controlled reversible phase separation comprises one or more core polypeptides. In one aspect, the core polypeptide is a resilin-like polypeptide (RLP). RLPs are derived from arthropod Rec1-resilin. Rec1-resilin is environmentally responsive and exhibits a dual phase transition behavior. The thermally responsive RLPs can have LCST and UCST. Additional examples of suitable thermally responsive polypeptides are described in U.S. Patent Application Publication Nos. US 2012/0121709, and US 2015/0112022, each of


which is incorporated herein by reference. In one embodiment, the RLP polypeptide comprises the sequence (GRGDSPYS)_n (SEQ ID NO: 1). The polypeptide with controlled reversible phase separation may comprise an amino acid sequence comprising (G₁-R₂-G₃-D₄-S₅-P₆-Y₇-S₈)_n, where n is 20–200. In some embodiments, n is 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300. In some embodiments, n may be less than 500, less than 400, less than 300, less than 200, or less than 100. In some embodiments, n may be between 1 and 500, between 1 and 400, between 1 and 300, or between 1 and 200. In some embodiments, n is 20, 40, 60, 80, 100, 120, 160, 180, or 200. In one aspect, n is 20 to 200 repeats. In one aspect, n is 20 to 60 repeats.

Thermally responsive polypeptides may have a phase transition. The thermally responsive polypeptide may impart a phase transition characteristic to an unstructured polypeptide or fusion protein. “Phase transition” or “transition” may refer to the aggregation of the thermally responsive polypeptide, which occurs sharply and reversibly at a specific temperature called the lower critical solution temperature (LCST) or the inverse transition temperature (T_i). Below the transition temperature (LCST or T_i), the thermally responsive polypeptides, (or polypeptides comprising a thermally responsive polypeptide) may be highly soluble. Upon heating above the transition temperature, thermally responsive polypeptides hydrophobically may collapse and aggregate, forming a separate, gel-like phase.

The thermally responsive polypeptides can phase transition at a variety of temperatures and concentrations. Thermally responsive polypeptides, for example, may not affect the binding or potency of the binding polypeptides. Thermally responsive polypeptides may allow the fusion protein to be tuned by a user to any number of desired transition temperatures, molecular weights, and formats.

Thermally responsive polypeptides may exhibit inverse phase transition behavior and thus, the fusion protein comprising the thermally responsive polypeptide may exhibit inverse phase transition behavior. Inverse phase transition behavior may be used to form drug depots within a tissue of a subject for controlled (slow) release of the fusion protein. Inverse phase transition behavior may also enable purification of the fusion protein using inverse transition cycling, thereby eliminating the need for chromatography.

One embodiment described herein is a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

5 Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) were the ratio among N:Q:S:T
can be any number; and

Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

In one aspect, X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1. In another aspect, Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number. In another aspect, the phase separation is dependent on temperature, molecular weight, hydrophobicity, aromatic:aliphatic ratio, and concentration. In another aspect, n is 10 to 200. In another aspect, molecular weight is at least 5 kDa to 500 kDa. In another aspect, the molecular weight is about 5 kDa to about 100 kDa. In another aspect, the phase separation temperature is 0 to 100 °C. In another aspect, the phase separation temperature is 4 to 25 °C; ~25 °C; 25 to 37 °C; ~37 °C; 35 to 38 °C; or >38 °C. In another aspect, the polypeptide comprises modified amino acids, a reporter protein, or an enzyme. In another aspect, the sequence comprises: (G-R-G-D-S-P-Y-S)_m, where m is 20 to 80. In another aspect, the polypeptide comprises a sequence selected from one or more of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 197–279, or combinations thereof.

25

NAME	SEQ ID NO
SKGP-[GRGDSFY]20-GY SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GRGDSFYSGRGDSFYSGRGDSFYSGY	1,2
SKGP-[GRGDQPYQ]20-GY SKGPGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR GDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQ GRGDQPYQGRGDQPYQGRGDQPYQGY	3,4
SKGP-[GRGDTPTYI]20-GY	

[illegible]

SKGPGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGR GDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHS GRGDNPHSGRGDNPHSGRGDNPHSGY	31, 32
SKGP-(GRGDSPHN)20-GY	
SKGPGRGDSPHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGR GDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHNGRGDS PHN GRGDS PHNGRGDS PHNGRGDS PHNGY	33, 34
SKGP-(GRGDQPHN)20-GY	
SKGPGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGR GDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHN GRGDQPHNGRGDQPHNGRGDQPHNGY	35, 36
(GRGDNPHQ)20-GY	
GRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPH HQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRGDNPHQGRG NPHQGRGDNPHQGRGDNPHQGY	37, 38
GRGDSPAS	
GRGDSPASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS ASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGRGDS PASGR SPASGRGDS PASGRGDS PASGY	39, 40
GRGDSPIS	
GRGDSPISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS ISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGRGDS PISGR SPISGRGDS PISGRGDS PIS	41, 42
NR1	
GGRSDSYPGGRPSDYSSDRPSYGGGYRSGSPDSPDGYRSGRGYDGPSSRSGSPGYDSYPGSDGSRDYRPGS GSPRGDYS SSPGDSRYGGGRYDPSSPDSRGGYSPYGSRDGSSPGYGRDRSDSGGYPPDRSSGGYDGY GRSPSGSDGPRYSYGRSPGD	43, 44
NR2	
GRDSGYSPGRDGYSSYSPGDSGRSRSGPDGYSRDSYGGPSDGYPRSGGDS SPGRYGPYRDGSSGPGSRD YSRSGSYDPYPRGDSGSPYRGDSSDSSGGYSPRYDGPGRSSYSGSPDSRGRDSSGPGYSDPGYSRSGSDPG YGSRYSDPSRGSRSPDGYGS	45, 46
NR3	
GDRSPYSGGSRPGSDYGSDSRYPPGGPYRGSDSSGRSYPDGDGSGPYRSSDRPYGGSSYGGDRPGYDRSG PSGGDYS PRSGYRSPDGS GPYDGRSYGPGSRSDSDGRSGPYSDGYFSGRDPDRSGGYSRSYDGS GPYRPS DSGGPDGSRYSGRSDSGYPG	47, 48
NR4	
GPYSDRSGSDSGSYPRPRSGGDSYPGSYDGRSYSGRPDSGGSDGRYFSGRGGPYSDSRPSGYGSDDPYSGG SRGRGSPSDYDGSYRGPSPGDYSSGRGGSRYDPSDRSPSGYGPDGSGYRSSRDSGYGPGDGRPSYSDPGG SYRRSSDGPYDGSRPYGS	49, 50
NR5	
GRDSGYSPPSRGYSDGGDSYSPGRPSGRYSGDGS GPDSRYSDSGGRYFPGSYSDGRSPRSYDGSYDPGR GSPYRSGGSDPDYGSRS GGRGSSPDYGYDSPSRGRPGSDYSGGDPYSGRSSGRPDSSGYDRSSGPGYGD RPGSGSGPYRSPSRSGYGD	51, 52
NR6	
GGSPDYSRPYRGSDGSDSGGYRPSGSGDSRYPSRDYSPGGYDSPGSRGRGSDYSGPPSRSYGGDDGRPGS SYSDRSYGGPGGDSYRSPYDGGSGPPRSGGYSPGDYSGPSRGDSGYSPRRSGSGDYYPYRGDSGPDGRP SGYSYDGSRPSCSGYPGDRS	53, 54
NR7	
GGDSPGYDGYRRDSSRPDGGSYPGSRSPSSGRFPSSYGDSPRDGSSGRSPSGGGYSSSDGSYYDGRPRY GPSDPRDGGYRGSGDDPSSSPSYDYDRSRGPYPSGSSSGGRYPGDGRGGYDYGYPYRDPSSSGRDGG YSSPSRGGSPSSPSRSGGGD	55, 56
NR8	

GRSYRGDGYGSSSSYYYGGFDPSSGGPSSPPSRDGS DGRDSSGGPSSSDYPSSPSGGDYSGFDGSRDGS RRRDYPRSGGSRGYSDYGRFYGGSGGDGGPYSPPRDSSSYGPDSSSDSGRSRPSGSSYPYSDSGYPRPGG GPRRDSSGDGGYDYRSGGDS	57, 58
NR9 GDYYRGPSPRGSPGPGSSGSDSRYPGDSGDSRRYSSGGGYSRGSDRRYDSSSGGGPYPYDRDSRSGYD GPSSSGPGPSPSDSPGGRPSGSYPDDGGGRSDSSPYRGYDSRSPSGYYGGRSPYRDSPRDYGPSPDDRGSD GGRYPSGSSGGGRSGYGSYS	59, 60
NR10 GYSGSSPYRPGSSRPSDGYGPGDGGPSRDSRSYSYDDGGRGSPDPGGSRRRPGDGGYSYSSPYGSGYD GRYRDSDDPSDDGRPPRRGYDGPSYGGGRYGGSRPSDYSPSSDSSSGYSGDGGSSRDGYYYDRGSSGSPS YSDGPRSSGDPYRPRGPGSS	61, 62
NR11 GYDSSYGGDSPYPSGGSRGYRGPPDRRRGGDSSSSSPDGYRPSDGPGS DRYDSSGGSSYSRGYRSPSPGD DGYSGRGPGYDGRYYPGRSRSGSSPGSGPGSSYPSSDDGDGSPYSYDGRGSPSPSGYGPGRGDGRDYRD GGDSSSDGPGRRPYSYSGSY	63, 64
NR12 GDGSYPRSPSPSYGGGSGPSRRRDSYRGDGDGYDSSSPGDSGGRGSDDGYPSSSDSYSRSGGSSPDG YPYPGPRRYGYGPGSGYSSSSDDGSRDSPYRGGPYRGPSDGGRGSDSPGGSYSSGRGSDSYGGDRPR PGRDDYGPYSPSDSYSSRG	65, 66
NR1-eukOpt GGRSDSYPGGRPSDYSSDRPSYGGGYRSGSPDSPDGYRSGRGYDGPSSRGSPGYDSYPGSDGSRDYRPGS GSPRGDYS SSPGDSRYGGGYDPSPPSDSRGGYSPYGRDGSPPGYGRDRSDSGGYPPDRSSGGYDGY GRSPSGSDGPRYSYGRSPGD	67, 68
NR2-eukOpt GRDSGYSPPGRDGYSSSPGDSGRSRSGPDGYSRDSYGGPSDGYPRSGGDS SPGRYGPYRDGSSGPGSRD YSRSGSYDYPYRGDGS SPYRGDSSDSSGGYSPRYDGPGRSSYSGSPDSRGRDGPYSDPGYSRSGSDPG YGSRYSDPSRGGSPDGYGS	69, 70
SKGP-[GRGDSYPYSGRGDSPYSGRGDSPYSGRGDQPYQ]5-GY SKGPGRGDSYPYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSYPYSGRGDSPYSGRGDSPYSGRGDQPYQGR GDSYPYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSYPYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSYPY GRGDSYPYSGRGDSPYSGRGDQPYQGY	71, 72
SKGP-[GRGDSYPYSGRGDQPYQ]10-GY SKGPGRGDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGR GDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGRGDSYPYSGRGDQPYQGRGDSYPY GRGDQPYQGRGDSYPYSGRGDQPYQGY	73, 74
SKGP-[GRGDQPYQGRGDQPYQGRGDQPYQGRGDSPYS]5-GY SKGPGRGDQPYQGRGDQPYQGRGDQPYQGRGDSPYSGRGDQPYQGRGDQPYQGRGDQPYQGRGDSPYSGR GDQPYQGRGDQPYQGRGDQPYQGRGDSPYSGRGDQPYQGRGDQPYQGRGDQPYQGRGDSPYSGRGDQPYQ GRGDQPYQGRGDQPYQGRGDSPYSGY	75, 76
SKGP-[GRGDSYPYSGRGDSPYSGRGDSPYSGRGDSPVS]5-GY SKGPGRGDSYPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGR GDSYPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYS GRGDSYPYSGRGDSPYSGRGDSPVSGY	77, 78
SKGP-[GRGDSYPYSGRGDSPVS]10-GY SKGPGRGDSYPYSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPVSGR GDSYPYSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPYS GRGDSPVSGRGDSPYSGRGDSPVSGY	79, 80
SKGP-[GRGDSPVSGRGDSPVSGRGDSPVSGRGDSPYS]5-GY SKGPGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPYSGR GDSPVSGRGDSPVSGRGDSPVSGRGDSPYSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPYS GRGDSPVSGRGDSPVSGRGDSPYSGY	81, 82
SKGP-[GRGDSPV]20-GY	

SKGPGRGDSFVSGRGDSFVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGR GDSFVSGRGDSFVSGRGDSFVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGR GRGDSFVSGRGDSFVSGRGDSPVSGY	83, 74
SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPAS]5-GY	
SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPASGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPASGR GDSFYSGRGDSFYSGRGDSFYSGRGDSPASGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPASGRGDSFYSG RGDSFYSGRGDSFYSGRGDSPASGY	85, 86
SKGP-[GRGDSFYSGRGDSPAS]10-GY	
SKGPGRGDSFYSGRGDSPASGRGDSFYSGRGDSPASGRGDSFYSGRGDSPASGRGDSFYSGRGDSPASGR GDSFYSGRGDSPASGRGDSFYSGRGDSPASGRGDSFYSGRGDSPASGRGDSFYSGRGDSPASGRGDSFYSG RGDSPASGRGDSFYSGRGDSPASGY	87, 88
SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPIS]5-GY	
SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPISGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPISGR GDSFYSGRGDSFYSGRGDSFYSGRGDSPISGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPISGRGDSFYSG RGDSFYSGRGDSFYSGRGDSPISGY	89, 90
SKGP-[GRGDSFYSGRGDSPIS]10-GY	
SKGPGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGR GDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSG RGDSPISGRGDSFYSGRGDSPISGY	91, 92
SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPMS]5-GY	
SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSG RGDSFYSGRGDSFYSGRGDSPMSGY	93, 94
SKGP-[GRGDSFYSGRGDSPMS]10-GY	
SKGPGRGDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGR GDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSPMSGRGDSFYSG RGDSPMSGRGDSFYSGRGDSPMSGY	95, 96
SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPHS]5-GY	
SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPHSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPHSGRGDSFYSG RGDSFYSGRGDSFYSGRGDSPHSGY	97, 98
SKGP-[GRGDSFYSGRGDSPHS]10-GY	
SKGPGRGDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGR GDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSFYSG RGDSPHSGRGDSFYSGRGDSPHSGY	99, 100
SKGP-[GRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYS]5-GY	
SKGPGRGDSPHSGRGDSPHSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGR GDSPHSGRGDSPHSGRGDSPHSGRGDSFYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHS RGDSPHSGRGDSPHSGRGDSPYSGY	101, 102
SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGKGDSPYS]5-GY	
SKGPGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGR GDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSG RGDSFYSGRGDSFYSGKGDSPYSGY	103, 104
SKGP-[GRGDSFYSGKGDSPYS]10-GY	
SKGPGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGR GDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSG KGKDSFYSGRGDSFYSGKGDSPYSGY	105, 106
GRGDSFYSGRGDSFYSGRGDSFYSGRGESFYS	
GRGDSFYSGRGDSFYSGRGDSFYSGRGESFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGESFYSGRGDSP YSGRGDSFYSGRGDSFYSGRGESFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGESFYSGRGDSFYSGRGD SPYSGRGDSFYSGRGESFYS	107, 108
SKGP-[GRGDSFYSGRGESFYS]10-GY	

SKGPGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGR GDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGR GRGESFYSGRGDSFYSGRGESFYSGY	109, 110
[(GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGR)- (PRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR)-2.5 GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD YSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD SPYSGRGDSFYSGRGDSFYSGR	111, 112
GRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGR- [(GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGR)-5 GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRPD YSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRPD SPYSGRGDSFYSGRGDSFYSGR	113, 114
GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR-2.5 GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD YSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD SPYSGRGDSFYSGRGDSFYSGR	116, 116
(GRPDSPYSGRGDSFYSGR)-10 GRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD YSGRGDSFYSGRGDSFYSGRGDSFYSGRPDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGRPD SPYSGRGDSFYSGRGDSFYSGR	117, 118
SKGP[GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SGKGDSPYSGR]2GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GRGDSFYSGRGDSFYSGRGDSFYSGR	119, 120
SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR]10 -GY SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GRGDSFYSGRGDSFYSGRGDSFYSGR	121, 122
SKGP- [GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR DSPVS]2 -GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR GKGDSPYSGRGDSFYSGRGDSFYSGR	123, 124
[(GRGDSFYSGR)-3-(GRGDSPLS)]-5 GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR YSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SPYSGRGDSFYSGRGDSFYSGR	125, 126
[(GRGDSFYSGR)-(GRGDSPLS)]-10 GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR YSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SPLSGRGDSFYSGRGDSFYSGR	127, 128
R/D 19/21 GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR YSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SPYSGRGDSFYSGRGDSFYSGR	129, 130
R/D 18/22 GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR YSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR SPYSGRGDSFYSGRGDSFYSGR	131, 132
GRGRSPYSGRGDSFYSGRGDSFYSGRGDSFYSGR	

[illegible]

[illegible]

YQGRGDQPYQGRGDSFYSGRGDQPYQGRGDQPYQGRGDQPYQGRGDSFYSGRGDQPYQGRGDQPYQGRGD
QPYQGRGDSFYSGRGDQPYQGRGDQPYQGRGDQPYQGRGDSFYSGY

SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGRGDSPVS]10-GY

SKGPGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR
GDSFYSGRGDSFYSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGR
GRGDSFYSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSP 206
YSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGD
SPYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSFYSGY

SKGP-[GRGDSFYSGRGDSPVS]20-GY

SKGPGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGR
GDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGR
GRGDSFYSGRGDSPVSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSP 207
VSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSFYSGRGD
SPYSGRGDSPVSGRGDSFYSGRGDSPVSGRGDSFYSGRGDSPVSGY

SKGP-[GRGDSFVS]40-GY

SKGPGRGDSFYSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGR
GDSFYSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGR
GRGDSFYSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSP 208
VSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGD
SPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGRGDSPVSGY

SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYS]10-GY

SKGPGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGR
GDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGR
GRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSP 209
YSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGRGDSFYSGRGDSFYSGRGD
SPYSGKGDSPYSGRGDSFYSGRGDSFYSGRGDSFYSGKGDSPYSGY

SKGP-[GRGDSFYSGKGDSPYS]20-GY

SKGPGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGR
GDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGR
GKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSP 210
YSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGRGD
SPYSGKGDSPYSGRGDSFYSGKGDSPYSGRGDSFYSGKGDSPYSGY

SKGP-[GRGDQPYQ]60-GY

SKGPGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
GDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQ
GRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQ 211
YQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGD
QPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
GDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
RGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGY

SKGP-[GRGDQPYQ]80-GY

SKGPGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
GDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQ
GRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQ 212
YQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGD
QPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
GDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
RGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
YQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGD
QPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGRGDQPYQGR
GDQPYQGRGDQPYQGY

SKGP-[GRGDTPT]40-GY

SKFPGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGR
GDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTTGRGDTPTT 213

GRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDT
YTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRG
TPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGRGDTPYTGY

SKGP-[GRGDNPYN]20-GY

[illegible]

SKGP-[GRGDN PYN]40-GY

[illegible]

SKGP-[GRGDN PYN]60-GY

[illegible]

SKGP-[GRGDSPHS]20-GY

[illegible]

SKGP-[GRGDSPHS]40-GY

SKGPGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR 218
HSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGD
SPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGY

SKGP-[GRGDSPHS]60-GY

SKGPGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GRG DSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
HSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR 219
SPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
G DSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
RGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
G DSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR

SKGP-[GRGDSPHS]80-GY

SKGPGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPH
SGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSP
HSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGD
SPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPH
SGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSP
HSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGD
SPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGR
GDSPHSGRGDSPHSGY

SKGP-[GRGDSPFS]20-GY

SKGPGRGDSFFSGRGDSPFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFSGR
GDSFFSGRGDSFFSGRGDSPFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFSGRGDSFFS 221
GRGDSFFSGRGDSFFSGRGDSFFSGY

SKGP-[GRGDS]40-GY	222
SKGP-[GRGDS]20-GY	223
SKGP-[GRGDS]40-GY	224
SKGP-[GRGDS]60-GY	225
SKGP-[GRGDS]80-GY	226
SKGP-[GRGDQ]20-GY	227
SKGP-[GRGDQ]40-GY	228
SKGP-[GRGDQ]60-GY	229
SKGP-[GRGDQ]80-GY	

230

231

232

233

234

235

237

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
GDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR 245
GRGDSPYSGRGDSPYSGRGDSPYSGKGEELFTGVVPIIIVELDGDVNGHKFSVRGEGEEDATNGKLTCLKFI

CTTGKLPVFWPTLVTTTLTYGVQCFSTRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEFGD
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNIEDGVSQVLADHYQQNTF
IGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMLLEFVTAAGITHGMDELYKELHHHHHHG

SKGP-[GRGDSPYS]-40-sfGFP

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
GDSFYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
YSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
SPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGEELFTGVVPII
SVRGEEGDATNGKLTCLKFICTTGKLPVFWPTLVTTTLTYGVQCFSTRYPDHMKRHDFFKSAMPEGYVQERT
ISFKDDGNYKTRAEVKFEFGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKI
RHNIEDGVSQVLADHYQQNTFIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMLLEFVTAAGITHGMDELY
KELHHHHHHG

246

SKGP-(GRDGSPYQ)20-GY

SKGPGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGR
DGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQGRDGSPYQ
GRDGSPYQGRDGSPYQGRDGSPYQGY

247

SKGP-(GRDGQPYQ)20-GY

SKGPGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGR
DGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQGRDGQPYQ
GRDGQPYQGRDGQPYQGRDGQPYQGY

248

SKGP-(GRDGSPYN)20-GY

SKGPGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGR
DGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYNGRDGSPYN
GRDGSPYNGRDGSPYNGRDGSPYNGY

249

SKGP-(GRGDNPHN)20-GY

SKGPGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGR
GDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHNGRGDNPHN
GRGDNPHNGRGDNPHNGRGDNPHNGY

250

SKGP-(GRGDNPHS)20-GY

SKGPGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGR
GDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHSGRGDNPHS
GRGDNPHSGRGDNPHSGRGDNPHSGY

251

SKGP-(GRGDSPHN)20-GY

SKGPGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGR
GDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHNGRGDSPHN
GRGDSPHNGRGDSPHNGRGDSPHNGY

252

SKGP-(GRGDQPHN)20-GY

SKGPGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGR
GDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHNGRGDQPHN
GRGDQPHNGRGDQPHNGRGDQPHNGY

253

SKGP-[GRGDSPYSGRGDSPYSGRGDSPYSGRGDQPYQ]10-GY

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGDSPYSGRGDQPYQGR
GDSFYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSFY
GRGDSFYSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSP
YSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGDSPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGD
SPYSGRGDQPYQGRGDSFYSGRGDSPYSGRGDQPYQGY

254

SKGP-[GRGDSPYSGRGDQPYQ]20-GY

SKGPGRGDSPYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGR
GDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFY
GRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQ
PYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGR
SPYSGRGDQPYQGRGDSFYSGRGDQPYQGRGDSFYSGRGDQPYQGY

255

[illegible]

SPYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGRGDSPISGRGDSFYSGR
GDSPISGY

SKGP-[GRGDSPYSGRGDSPYSGRGDSPYSGRGDSPMS]10-GY

SKGPGRGDSFYSGRGDSFYSGRGDSPYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGR
GDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGR
GRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSP 265
YSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGRGDSFYSGRGDSFYSGRGD
SPYSGRGDSPMSGRGDSFYSGRGDSFYSGRGDSFYSGRGDSPMSGY

SKGP-[GRGDSPYSGRGDSPMS]20-GY

SKGPGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGR
GDSFPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPY
GRGDSFMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSF 266
MSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGD
SPYSGRGDSPMSGRGDSPYSGRGDSPMSGRGDSPYSGRGDSPMSGY

SKGP-[GRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHS]10-GY

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGR
GDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGR
GRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSP 267
YSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGD
SPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGR

SKGP-[GRGDSPYSGRGDSPHS]20-GY

SKGPGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGR
GDSFYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGR
GRGDSFPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGR 268
HSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPHSGR
SPYSGRGDSPHSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGD
SPYSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPYSGRGDSPHSGR

SKGP-[GRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYS]10-GY

SKGPGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGR
GDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGR
GRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGR 269
HSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGD
SPHSGRGDSPYSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPHSGRGDSPYSGY

SKGP-IGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSI10-GY

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGR
GDSPIYSGRGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGRGDSPY
GRGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSP
YSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGRGDSPYSGR
SPYSGKGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGKGDSPYSGY

SKGP-[GRGDSPYSGKGDSPYS]20-GY

SKGPGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGR
GDSFYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPY
SGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSF 271
YSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGD
SPYSGKGDSPYSGRGDSPYSGKGDSPYSGRGDSPYSGKGDSPYSGY

SKGP-[GRGDSPYSGRGESPYS]20-GY

SKGPGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGR
GDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFY
RGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESF 272
YSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGR
DSFYSGRGESFYSGRGDSFYSGRGESFYSGRGDSFYSGRGESFYSGRGESFYSGR

SKGP-IGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPWSI20-GY

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSPWSGR
GDSPYSGRGDSPYSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSPWSGRGDSPY
GRGDSPYSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSP 273

YSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGD
SPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPWSGY

SKGP-[GRGDSFYSGRGDSPWS]20-GY

SKGPGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGR
GDSFYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPY
GRGDSFYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPYSGRGDSP 274
WSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGD
SPYSGRGDSPWSGRGDSPYSGRGDSPWSGRGDSPYSGRGDSPWSGY

SKGP[GRPDSPYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR SGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGR GDSFYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR]2-GY

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGR
PDSPYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGRGDSPYSGRGDSPYSGRPDPSY
GRGDSFYSGRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSP 275
YSGRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSGRGDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGRGD
SPYSGRGDSPYSGRPDPSYSGRGDSPYSGRGDSPYSGRGDSPYSGY

SKGP-[GRPDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGR]10-GY

SKGPGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGR
PDSPYSGRGDSPYSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGRPDPSY
GRGDSFYSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSP 276
YSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGD
SPYSGRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRGDSPYSGY

SKGP-

[GRPDSPYSPRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRPDPSYSPRGDSPYSGRG DSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRPDPSYSPRGDSPYSPRGDSPY SGRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRGDSPYSGR]2-GY

SKGPGRPDPSYSGRPDPSYSGRGDSPYSPRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSPRGDSPYSGR
PDSPYSPRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRPDPSY
PRGDSFYSGRPDPSYSGRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRPDPSY 277
YSPRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRGDSPYSPRGDSPYSGRPDPSYSGRPDPSYSPRGD
SPYSGRGDSPYSGRPDPSYSPRGDSPYSGRPDPSYSGRGDSPYSGY

SKGP-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPVS]10-sfGFP

SKGPGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGR
GDSFYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPY
GRGDSFYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSP
YSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGD 278
SPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGKGEELFTGVVPIILVELDGDVNGHKF
SVRGEGEDATNGKLTLLKFICTTGKLPVWPPTLVTTLTGYVQCFSRYPDHMKRHDFFKSAMPEGYVQERT
ISFKDDGNYKTRAEVKFEGDTLVNRIELKIDFKEDGNILGHKLEYNYNHNVYITADKQKNGIKANFKI
RHNIEDGSVQLADHYQONTPIGDGPVLLFDNHYLSTQSVLSKDPNEKRDMVLLLEFVTAAGITHGMDELY
KELHHHHHHG

AzF-[GRGDSFYSGRGDSPYSGRGDSPYSGRGDSPVS]-5-AzF)2

XGRGDSFYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGD
PYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGR
DSPYSGRGDSPYSGRGDSPVSXGRGDSFYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPY 279
GRGDSFYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGD
YSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPYSGRGDSPVSGRGDSPYSGRGDSPYSGRGDSPVSX

X: AzF

Binding Polypeptide

The binding polypeptide (or “targeting polypeptide”) may comprise any polypeptide that is capable of binding at least one target. The binding polypeptide may bind at least one target.

“Target” may be an entity capable of being bound by the binding polypeptide. Targets may include, for example, another polypeptide, a cell surface receptor, a carbohydrate, an antibody, a small molecule, or a combination thereof. The target may be a biomarker. The target may be activated through agonism or blocked through antagonism. The binding polypeptide may specifically bind the target. By binding target, the binding polypeptide may act as a targeting moiety, an agonist, an antagonist, or a combination thereof. In some embodiments, the binding polypeptide domain binds

The binding polypeptide may be a monomer that binds to a target. The monomer may bind one or more targets. The binding polypeptide may form an oligomer. The binding polypeptide may form an oligomer with the same or different binding polypeptides. The oligomer may bind to a target. The oligomer may bind one or more targets. One or more monomers within an oligomer may bind one or more targets. In some embodiments, the fusion protein is multivalent. In some embodiments, the fusion protein binds multiple targets. In some embodiments, the activity of the binding polypeptide alone is the same as the activity of the binding protein when part of a fusion protein.

In one aspect, the wherein the binding polypeptide comprises one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195).

Linker

In some embodiments, the fusion protein further includes at least one linker. In some embodiments, the fusion protein includes more than one linker. In such embodiments, the linkers may be the same or different from one another. The fusion protein may include, none, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at

least 95, or at least 100 linkers. The fusion protein may include less than 500, less than 400, less than 300, or less than 200 linkers. The fusion protein may include between 1 and 1000, between 10 and 900, between 10 and 800, or between 5 and 500 linkers.

The linker may be positioned in between a binding polypeptide and a polypeptide with controlled reversible phase separation, in between binding polypeptides, in between polypeptides with controlled reversible phase separation, or a combination thereof. Multiple linkers may be positioned adjacent to one another. Multiple linkers may be positioned adjacent to one another and in between the binding polypeptide and the polypeptide with controlled reversible phase separation.

The linker may be a polypeptide of any amino acid sequence and length. The linker may act as a spacer peptide. The linker may occur between polypeptide domains. The linker may sufficiently separate the binding domains of the binding polypeptide while preserving the activity of the binding domains. In some embodiments, the linker comprises charged amino acids. In some embodiments, the linker is flexible. In some embodiments, the linker comprises at least one glycine and at least one serine. In some embodiments, the linker comprises at least one proline.

Polynucleotides

Further provided are polynucleotides encoding the fusion proteins detailed herein. A vector may include the polynucleotide encoding the fusion proteins detailed herein. To obtain expression of a polypeptide, one typically subclones the polynucleotide encoding the polypeptide into an expression vector that contains a promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. An example of a vector is pET24. Suitable bacterial promoters are well known in the art. Further provided is a host cell transformed or transfected with an expression vector comprising a polynucleotide encoding a fusion protein as detailed herein. Bacterial expression systems for expressing the protein are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Paiva et al., *Gene* 1983, 22, 229-235; Mosbach et al., *Nature* 1983, 302, 543-545). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are commercially available. Retroviral expression systems can be used in the present invention. In some embodiments, the fusion protein comprises repeats or single sequences of one or more of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109,

111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 197–279. In some embodiments, the fusion protein comprises repeats or single sequences of one or more of a polypeptide encoded by a polynucleotide sequence of any one of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, or 158. In some embodiments, the fusion protein comprises a polypeptide comprising an amino acid sequence of any one of SEQ ID NO: 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, or 316.

Administration

The peptide biopolymers comprising one or more fusion proteins as detailed herein can be formulated in accordance with standard techniques well known to those skilled in the pharmaceutical art to form a therapeutic agent or targeted delivery agent. Such compositions comprising peptide biopolymers comprising one or more fusion proteins can be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the age, sex, weight, and condition of the particular subject, and the route of administration.

The peptide biopolymers comprising one or more fusion proteins can be administered prophylactically or therapeutically. In prophylactic administration, the peptide biopolymer can be administered in an amount sufficient to induce a response. In therapeutic applications, the peptide biopolymers are administered to a subject in need thereof in an amount sufficient to elicit a therapeutic effect. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the particular composition of the peptide biopolymer regimen administered, the manner of administration, the stage, and severity of the disease, the general state of health of the patient, and the judgment of the prescribing physician.

The peptide biopolymer can be administered by methods well known in the art as described in Donnelly et al. *Ann. Rev. Immunol.* 1997, 75, 617-648; Feigner et al., U.S. Patent No. 5,580,859; Feigner, U.S. Patent No. 5,703,055; and Carson et al., U.S. Patent No. 5,679,647, the contents of each of which are incorporated herein by reference in their entirety. The peptide biopolymer can be complexed to particles or beads that can be administered to an individual, for example, using a vaccine gun. One skilled in the art would know that the choice of a

pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration.

The peptide biopolymers can be delivered via a variety of routes. Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular, or subcutaneous delivery. Other routes include oral administration, intranasal, intravaginal, transdermal, intravenous, intraarterial, intratumoral, intraperitoneal, and epidermal routes. In some embodiments, the peptide biopolymer is administered intravenously, intraarterially, or intraperitoneally to the subject.

The peptide biopolymer can be a liquid preparation such as a suspension, syrup, or elixir. The peptide biopolymer can be incorporated into liposomes, microspheres, or other polymer matrices (such as by a method described in Feigner et al., U.S. Patent No. 5,703,055; Gregoriadis, *Liposome Technology*, Vols. I to III (2nd ed. 1993), the contents of which are incorporated herein by reference in their entirety). Liposomes can consist of phospholipids or other lipids, and can be nontoxic, physiologically acceptable, and metabolizable carriers that are relatively simple to make and administer.

In some embodiments, the peptide biopolymer is administered in a controlled release formulation. In some embodiments, the peptide biopolymer comprises one or more thermally responsive polypeptides, the thermally responsive polypeptide having a transition temperature such that the peptide biopolymer remains soluble prior to administration and such that the peptide biopolymer transitions upon administration to a gel-like depot in the subject. In some embodiments, the peptide biopolymer comprises one or more fusion proteins comprising one or more thermally responsive polypeptides, the thermally responsive polypeptide having a transition temperature such that the fusion protein remains soluble at room temperature and such that the fusion protein transitions upon administration to a gel-like depot in the subject. For example, in some embodiments, the fusion protein comprises one or more thermally responsive polypeptides, the thermally responsive polypeptide having a transition temperature between room temperature (about 25 °C) and body temperature (about 37 °C), whereby the fusion protein can be administered to form a depot. As used herein, "depot" refers to a gel-like composition comprising a fusion protein that releases the fusion protein over time. In some embodiments, the peptide biopolymer can be injected subcutaneously or intratumorally to form a depot (coacervate). The depot may provide controlled (slow) release of the peptide biopolymer. The depot may provide slow release of the peptide biopolymer into the circulation or the tumor, for example. In some embodiments, the peptide biopolymer may be released from the depot over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 1 week, at least about 1.5 weeks,

at least about 2 weeks, at least about 2.5 weeks, at least about 3.5 weeks, at least about 4 weeks, or at least about 1 month.

Detection

5 As used herein, the term “detect” or “determine the presence of” refers to the qualitative measurement of undetectable, low, normal, or high concentrations of one or more peptide biopolymers, targets, or peptide biopolymers bound to target. Detection may include *in vitro*, *ex vivo*, or *in vivo* detection. Detection may include detecting the presence of one or more peptide biopolymers comprising one or more peptide biopolymers or targets versus the absence of the
10 one or more peptide biopolymer or targets. Detection may also include quantification of the level of one or more peptide biopolymers or targets. The terms “quantify,” or “quantification” may be used interchangeably, and may refer to a process of determining the quantity or abundance of a substance (e.g., peptide biopolymer or target), whether relative or absolute. Any suitable method of detection falls within the general scope of the present disclosure. In some embodiments, the
15 peptide biopolymer comprises a reporter attached thereto for detection. In some embodiments, the peptide biopolymer is labeled with a reporter. In some embodiments, detection of a peptide biopolymer bound to a target may be determined by methods including but not limited to, band intensity on a Western blot, flow cytometry, radiolabel imaging, cell binding assays, activity assays, SPR, immunoassay, or by various other methods known in the art.

20 In some embodiments, including those wherein the peptide biopolymer is an antibody mimic for binding and/or detecting a target, any immunoassay may be utilized. The immunoassay may be an enzyme-linked immunoassay (ELISA), radioimmunoassay (RIA), a competitive inhibition assay, such as forward or reverse competitive inhibition assays, a fluorescence polarization assay, or a competitive binding assay, for example. The ELISA may be a sandwich
25 ELISA. Specific immunological binding of the peptide biopolymer to the target can be detected via direct labels, attached to the peptide biopolymer or via indirect labels, such as alkaline phosphatase or horseradish peroxidase. The use of an immobilized peptide biopolymer may be incorporated into the immunoassay. The peptide biopolymers may be immobilized onto a variety of supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate
30 (such as microtiter wells), pieces of a solid substrate material, and the like. An assay strip can be prepared by coating the peptide biopolymer or plurality of peptide biopolymers in an array on a solid support. This strip can then be dipped into the test biological sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot.

Methods of Treating a Disease

The present invention is directed to a method of treating a disease in a subject in need thereof. The method may comprise administering to the subject an effective amount of the peptide
5 biopolymer comprising one or more peptide biopolymers as described herein. The disease may be selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorders. In some embodiments, the disease is a disease associated with a target of the at least one binding polypeptide.

Metabolic disease may occur when abnormal chemical reactions in the body alter the
10 normal metabolic process. Metabolic diseases may include, for example, insulin resistance, non-alcoholic fatty liver diseases, type 2 diabetes, insulin resistance diseases, cardiovascular diseases, arteriosclerosis, lipid-related metabolic disorders, hyperglycemia, hyperinsulinemia, hyperlipidemia, and glucose metabolic disorders.

Autoimmune diseases arise from an abnormal immune response of the body against
15 substances and tissues normally present in the body. Autoimmune diseases may include, but are not limited to, lupus, rheumatoid arthritis, multiple sclerosis, insulin dependent diabetes mellitus, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, polyarteritis nodosa, myocarditis, psoriasis, Celiac
20 disease, Crohn's disease, ulcerative colitis, and fibromyalgia.

Cardiovascular disease is a class of diseases that involve the heart or blood vessels. Cardiovascular diseases may include, for example, coronary artery diseases (CAD) such as angina and myocardial infarction (heart attack), stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart
25 disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

Orthopedic disorders or musculoskeletal disorders are injuries or pain in the body's joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck, and back. Orthopedic disorders may include degenerative diseases and inflammatory conditions that cause pain and impair normal activities. Orthopedic disorders may include, for example, carpal tunnel
30 syndrome, epicondylitis, and tendinitis. Cancers may include, but are not limited to, breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcomas, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphoid cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, renal cancer, bladder cancer, thyroid cancer,

bone cancers, carcinomas, sarcomas, and soft tissue cancers. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is colorectal adenocarcinoma.

One application of protein therapeutics is cancer treatment. In specific embodiments, the present invention provides a method for using scaffold proteins in developing antibody mimetics for oncological targets of interest. With the emergence of scaffold protein engineering come the possibilities for designing potent protein drugs that are unhindered by steric and architectural limitations. Although potent protein drugs can be invaluable for diagnostics or treatments, successful delivery to the target region can pose a great challenge.

10 **Methods of Diagnosing a Disease**

Provided herein are methods of diagnosing a disease. The methods may include administering to the subject a peptide biopolymer comprising one or more fusion proteins as described herein and detecting binding of the peptide biopolymer to a target to determine presence of the target in the subject. The presence of the target may indicate the disease in the subject. In other embodiments, the methods may include contacting a sample from the subject with a peptide biopolymer as described herein, determining the level of a target in the sample, and comparing the level of the target in the sample to a control level of the target, wherein a level of the target different from the control level indicates disease in the subject. In some embodiments, the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorders, as detailed above. In some embodiments, the target comprises a disease marker or biomarker. In some embodiments, the fusion protein may act as an antibody mimic for binding or detecting a target.

Methods of Determining the Presences of a Target

Provided herein are methods of determining the presence of a target in a sample. The methods may include contacting the sample with a peptide biopolymer comprising one or more fusion proteins as described herein under conditions to allow a complex to form between the peptide biopolymer and the target in the sample and detecting the presence of the complex. Presence of the complex may be indicative of the target in the sample. In some embodiments, the peptide biopolymer is labeled with a reporter for detection.

In some embodiments, the sample is obtained from a subject and the method further includes diagnosing, prognosticating, or assessing the efficacy of a treatment of the subject. When the method includes assessing the efficacy of a treatment of the subject, then the method may further include modifying the treatment of the subject as needed to improve efficacy.

Methods of Determining the Effectiveness of a Treatment

Provided herein are methods of determining the effectiveness of a treatment for a disease in a subject in need thereof. The methods may include contacting a sample from the subject with a peptide biopolymer comprising a fusion protein as detailed herein under conditions to allow a complex to form between the peptide biopolymer and a target in the sample, determining the level of the complex in the sample, wherein the level of the complex is indicative of the level of the target in the sample, and comparing the level of the target in the sample to a control level of the target, wherein if the level of the target is different from the control level, then the treatment is determined to be effective or ineffective in treating the disease.

Time points may include prior to onset of disease, prior to administration of a therapy, various time points during administration of a therapy, and after a therapy has concluded, or a combination thereof. Upon administration of the peptide biopolymer comprising one or more fusion proteins to the subject, the peptide biopolymer may bind a target, wherein the presence of the target indicates the presence of the disease in the subject at the various time points. In some embodiments, the target comprises a disease marker or biomarker. In some embodiments, the peptide biopolymer may act as an antibody mimic for binding and/or detecting a target. Comparison of the binding of the peptide biopolymer to the target at various time points may indicate whether the disease has progressed, whether the diseased has advanced, whether a therapy is working to treat or prevent the disease, or a combination thereof.


In some embodiments, the control level corresponds to the level in the subject at a time point before or during the period when the subject has begun treatment, and the sample is taken from the subject at a later time point. In some embodiments, the sample is taken from the subject at a time point during the period when the subject is undergoing treatment, and the control level corresponds to a disease-free level or to the level at a time point before the period when the subject has begun treatment. In some embodiments, the method further includes modifying the treatment or administering a different treatment to the subject when the treatment is determined to be ineffective in treating the disease.

It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the compositions,

formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere
 5 herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or
 10 phrases in this disclosure are controlling. Furthermore, the foregoing discussion discloses and describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.

Various embodiments and aspects of the inventions described herein are summarized by the following clauses:

15 Clause 1. A polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

20 Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z_2 is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

25 Z_3 is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and

Z_4 is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

30 Clause 2. The polypeptide of clause 1, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.

Clause 3. The polypeptide of clause 1 or 2, wherein Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.

Clause 4. The polypeptide of any one of clauses 1–3, wherein the phase separation is dependent on temperature, molecular weight, hydrophobicity, aromatic:aliphatic ratio, and concentration.

Clause 5. The polypeptide of any one of clauses 1–4, wherein n is 10 to 200.

5 Clause 6. The polypeptide of any one of clauses 1–5, wherein the molecular weight is at least 5 kDa to 500 kDa.

Clause 7. The polypeptide of any one of clauses 1–6, wherein the molecular weight is about 5 kDa to about 100 kDa.

10 Clause 8. The polypeptide of any one of clauses 1–7, wherein the phase separation temperature is 0 to 100 °C.

Clause 9. The polypeptide of any one of clauses 1–8, wherein the phase separation temperature is 4 to 25 °C; ~25 °C; 25 to 37 °C; ~37 °C; 35 to 38 °C; or >38 °C.

Clause 10. The polypeptide of any one of clauses 1–9, wherein the polypeptide comprises modified amino acids, a reporter protein, or an enzyme.


15 Clause 11. The polypeptide of any one of clauses 1–10, wherein the sequence comprises:



where m is 20 to 80.

20 Clause 12. The polypeptide of any one of clauses 1–11, wherein the polypeptide comprises a sequence selected from one or more of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 197–279, or combinations thereof.

25 Clause 13. A pharmaceutically acceptable composition comprising a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

30 Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

Z_3 is asparagine (N), glutamine (Q), serine (S), or threonine (T) were the ratio among N:Q:S:T can be any number; and

Z_4 is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

Clause 14. The composition of clause 13, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.

Clause 15. The composition of clause 13 or 14, wherein Z_1 is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.

Clause 16. The composition of any one of clauses 13–15, further comprising an attached molecule comprising one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195).

Clause 17. The composition of any one of clauses 13–16, wherein the composition enhances bioavailability of the attached molecule as compared to the free form of the attached molecule.

Clause 18. The composition of any one of clauses 13–17, wherein the composition enhances expression of the attached molecule as compared to the free form of the attached molecule.

Clause 19. The composition of any one of clauses 13–18, wherein the composition enhances the stability of the attached molecule as compared to the free form of the attached molecule.

Clause 20. The composition of clause 19, wherein the composition enhances stability of the attached molecule during prokaryotic and eukaryotic expression as compared to the free form of the attached molecule.


Clause 21. The composition of clause 19 or 20, wherein the enhanced stability includes resistance to denaturation during freezing, thawing, or lyophilization.

Clause 22. The composition of any one of clauses clause 13–21, wherein the composition modulates enzymatic, metabolic, or physiological functions within cells or organisms.

5 Clause 23. The composition of clause 22, wherein the modulation reduces bioavailability of the attached molecules.

Clause 24. The composition of clause 23, wherein the attached molecules comprise therapeutic or cytotoxic proteins or peptides.

10 Clause 25. A method for enhancing the bioavailability or stability of a protein, the method comprising creating a fusion protein of one or more proteins and a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

15 X is proline (P) or glycine (G) and the ratio of P:G is any number;

Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

20 Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) were the ratio among N:Q:S:T can be any number; and

Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

25 Clause 26. The method of clause 25, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.

Clause 27. The method of clause 25 or 26, wherein Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.

30 Clause 28. The method of any one of clauses 25–27, wherein the protein comprises one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO:

177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195).

5 Clause 29. The method of any one of clauses 25–28, where the enhanced bioavailability of the fusion protein can be used for isolation or separation of a biologic molecule.

Clause 30. The method of any one of clauses 25–26, wherein the biologic molecule comprises one or more of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a viral particle.

10 Clause 31. The method of clause 30, wherein the nucleic acid is single stranded or double stranded DNA or RNA.

Clause 32. The method of clause 30, wherein the viral particle is an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or herpesvirus particle.

15 Clause 33. The method of clause 30, wherein the protein comprises albumin, monoclonal IgG antibodies, or Fc fusion antibodies.

Clause 34. The method of clause 29, wherein the isolation or separation is accomplished via reversible phase separation.

EXAMPLES

20 Example 1

De Novo Engineering of Intracellular Condensates using Artificial Disordered Proteins

We have taken a different and complementary approach to understand how phase behavior is encoded in polypeptides. Analogous to—and inspired by—synthetic polymers that exhibit lower and upper critical solution temperature (LCST/UCST) phase behavior, we began by systematically scanning the sequence space of native IDPs to identify minimal peptide motifs that will confer LCST or UCST phase behavior when polymerized into a macromolecule that consists of many repeats of the peptide motif. With the greatly reduced sequence complexity of these repetitive polypeptides—compared to native IDPs that exhibit LCST/UCST phase behavior—we then made rational changes in the amino acid repeat motif that systematically propagate along the sequence. These repetitive polypeptides can be rationally designed to exhibit both LCST and UCST phase behavior, and their phase behavior can be systematically modulated by amino acid mutations of the repeat motif. These artificial polypeptides also exhibit the same basic principles of phase separation inside cells as native IDPs.

Informed by a heuristic knowledge of factors that drive phase separation in repetitive polypeptides from these studies as well as the natural composition of membrane-less organelle IDPs, we set out to create artificial IDPs (A-IDPs) that exhibit phase separation in living cells to impart new functionality to the cell. Our design began with (G₁-R₂-G₃-D₄-S₅-P₆-Y₇-S₈)_{xx} (where
 5 xx is the number of repeats between 20 and 80) a sequence inspired by *Drosophila melanogaster* Rec-1 Resilin, known to exhibit UCST phase behavior, that is chemically similar to IDPs that are critical constituents of membrane-less organelles (FIG. 1A). We chose this sequence precisely because it exhibits UCST phase behavior, which appears to be far more common among native IDPs than LCST phase behavior. Thus, we created a set of 63 A-IDPs consisting of repeats of
 10 the parent (G₁-R₂-G₃-D₄-S₅-P₆-Y₇-S₈)_{xx} motif and variants with rational amino acid mutations of this motif. We characterized the UCST phase behavior for this set of 63 IDPs from which we were able to quantify the effect of various amino acid mutations and modifications to the chain architecture on homotypic liquid-liquid phase separation.

We then used a subset of A-IDPs from this library to engineer intracellular condensates in
 15 living cells. The behavior of intracellular condensates for these A-IDPs proved to be surprisingly predictable and tunable, and enabled dynamic control over their cytoplasmic solubility and their interaction with the surrounding environment. Capitalizing on these observations, we created intracellular droplets capable of sequestering an enzyme whose catalytic efficiency within the engineered condensates can be genetically encoded by modulating the MW of the A-IDP.

Materials and Methods

pET24+ vectors were purchased from Novagen (Madison, WI). gBlock fragments encoding repetitive IDP (A-IDP) sequences of interest, superfolder GFP (sfGFP), mRuby3 and primers for pcDNA5 vector were purchased from Integrated DNA Technologies (Coralville, IA).
 25 Ligation enzymes, restriction enzymes, DNA ladders were purchased from New England Biolabs (Ipswich, MA). BL21(DE3) chemically competent *Escherichia coli* (*E. coli*) cells were purchased from Biotline (Taunton, MA). All *E. coli* cultures were grown in Terrific Broth media purchased from VWR International (Radnor, PA). Kanamycin sulfate was purchased from EMD Millipore (Billerica, MA). Protein expression was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) from Gold Biotechnology (St. Louis, MO). All salts, 10/40 kDa fluorescein labeled dextran molecules, L-(+)-Arabinose, L-Rhamnose and Fluorescein di(β-D-galactopyranoside) were purchased from Sigma-Aldrich (St. Louis, MO). 1× phosphate buffered saline (PBS) tablets (10 mM phosphate buffer, 140 mM NaCl, 3 mM KCl, pH 7.4 at 25 °C) were purchased from EMD Millipore (Billerica, MA). KRX *E. coli* cell line that endogenously expresses mutated LacZ were
 30

purchased from Promega (Madison, WI). NHS Ester reactive fluorophores (NHS-Alexa Fluor® 350 and NHS-Alexa Fluor® 647) were purchased from Life Technologies (Grand Island, NY). DNA extraction kits, DNA gel purification kits were purchased from Qiagen Inc. (Germantown, MD). Expi293 Eukaryotic Expression System for HEK293 expression was purchased from Thermo Fischer Scientific (Waltham, MA). Whatman Anotop sterile syringe filters (0.02 µm) were purchased from GE Healthcare Life Sciences (Pittsburgh, PA). ABIL® EM 90 and TEGOSOFT® DEC surfactants were purchased from Evonik Industries (Essen, Germany). A single emulsion droplet-generating chip was purchased from Dolomite Microfluidics (Royston, United Kingdom). Syringe pumps were acquired from Chemyx Inc. (Stafford, TX).

Proteomic Analysis

A search of the literature provided an excellent list of intrinsically disordered proteins or protein regions are present in genes known to form membrane-less organelles. Each gene was divided into disordered regions and ordered regions according to the Predictor of Natural Disordered Regions (PONDR) VSL2 algorithm which is a meta-predictor of protein disorder of various lengths. Amino acid quantity was normalized to total protein length.

Gene Synthesis

Each octapeptide amino acid motif inspired by our proteomic analysis was propagated twenty times in silico. This repetitive amino acid sequence was fed into an algorithm that creates an optimally non-repetitive DNA template from a repetitive protein gene. This 20-mer repeat gene was then ordered from IDT with Gibson assembly overhangs for easy insertion into modified pET24+ vector. To increase the number of total repeats of the gene, we performed iterative cloning steps of Recursive Directional Ligation by Plasmid Reconstruction adding an additional twenty repeats during each step. Transformations were performed into the desired *E. coli* cell line – BL21(DE3) for recombinant expression and single plasmid confocal experiments and a modified BL21(DE3) cell line termed KRX by Promega that contains a mutated LacZ gene for enzymatic experimentation.

In experiments with dual expression, genes were inserted into the pBAD33.1 vector by cutting custom pET24+ vector and pBAD33.1 cut with *Hind* III and *Xba* I. Gel purification was used to isolate the gene of interest from the housing pET24+ vector, which was then ligated into the similarly cut pBAD33.1 vector. Co-transformation was performed with ~1 ng final concentration of each plasmid on kanamycin/chloramphenicol dual selection plates.

Protein Expression, Purification and Characterization

Individual liquid cultures of BL21 *E. coli* strains each harboring our gene of interest from Table 2 or Table 3 were inoculated into 5 mL of Terrific Broth (TB) medium from frozen glycerol stocks and grown to confluence overnight (16-18 hours). Cultures were then inoculated at a 1:200 dilution in 1 L TB media supplemented with 45 $\mu\text{g mL}^{-1}$ kanamycin. Cells were grown at 37 °C in a shaking incubator (~200 RPM) for 9 h, at which time protein expression was induced by the addition of 500 μM IPTG (final concentration). Cells were then incubated at 37 °C (shaking at ~200 RPM.) for an additional 18 h. Protein was then purified from the insoluble cell suspension fraction. In brief, cell pellets were isolated by centrifuging cultures at 3500 RCF and resuspending in 20 mL of milli-Q water. Cells were then lysed by sonicating the cell solutions for 2 minutes, with 10 seconds of pulsing followed by 40 seconds of rest on ice (Misonix; Farmingdale, NY).

Centrifuging each lysate suspension at 20,000 RCF for 20 minutes results in a soluble and insoluble fraction. The supernatant was discarded with the insoluble fraction resuspended in an approximately equal volume of 8 M urea + 150 mM PBS (~6–8 mL). For proteins with a fluorescent fusion tag, the insoluble fraction was resuspended in 3× insoluble volume at a final concentration of urea of ~2 M to prevent protein misfolding. This suspension was heated for 10 min in a 37 °C water bath and then centrifuged at 20,000 RCF for 20 minutes. The supernatant was collected from this suspension and dialyzed in a 10 kDa membrane (SnakeSkin™, Thermo Fischer Scientific) against a 1:200 milli-Q water solution at 4 °C. The dialysis water was changed twice over a 48-hour period. From inside the dialysis bag, both insoluble and soluble components were collected and centrifuged at 3500 RCF for 10 minutes and 4 °C. The supernatant was removed and the remaining insoluble pellet containing the protein of interest was lyophilized for a minimum of three days to remove all water from the pellet.

Protein purity was characterized by 4–20% gradient tris-HCl (Biorad, Hercules, CA) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and staining with either 0.5 M copper chloride or SimplyBlue™ SafeStain (Thermo Fischer Scientific). Protein yield was determined by weight after lyophilization.

Creation of Water in Oil Droplets with Chip Microfluidics

To create water-in-oil emulsion droplets, two liquid phases – a dispersed, aqueous phase containing protein of interest in 150 mM PBS and an organic, continuous phase comprised of 75%/5%/20% vol/vol TEGOSOFT® DEC/ABIL® EM 90/mineral oil – were injected into the microfluidic droplet generators at constant flow rates using precision syringe pumps. The flow rates of the dispersed and continuous fluids were tuned to ensure droplet formation in the dripping

regime; in these experiments, the dripping regime was achieved using a constant flow rate of 500 $\mu\text{L hr}^{-1}$ for the organic continuous phase and 50–75 $\mu\text{L hr}^{-1}$ for the aqueous, dispersed phase. The production of droplets within the microfluidic device was monitored using a 5 $\times$ objective on an inverted microscope (Leica) equipped with a digital microscopy camera (Lumenera Infinity 3-1 CCD).

Circular Dichroism Spectroscopy

Circular Dichroism (CD) spectroscopy was performed using an Aviv Model 202 instrument and a 1 mm quartz sample cell (Hellma). A-IDPs were prepared by dissolving the purified lyophilized product in 5 mM PBS, pH 7.4 at a final concentration of 10 μM . The CD spectra were obtained at 50 $^{\circ}\text{C}$ from 260 nm to 180 nm in 1 nm steps at a 0.5 second average time. Data points with a dynode voltage above 500 V were ignored in the analysis. The CD spectra were corrected for the 5 mM PBS buffer signal at 50 $^{\circ}\text{C}$. This data collection was repeated in triplicate, and the average of the three measurements was represented as molar ellipticity.

Light Scattering

Dynamic light scattering (DLS) measurements were performed over a temperature range of 10–80 $^{\circ}\text{C}$ using a Wyatt DynaPro temperature-controlled microsamplers (Wyatt Technology, Santa Barbara, CA). Samples for the DLS system were prepared in 1 $\times$ PBS and filtered through 0.02 μm Whatman Anotop sterile syringe filters (GE Healthcare Life Sciences, Pittsburgh, PA) into a 12 μL quartz crystal cuvette (Wyatt Technology, Santa Barbara, CA). 5 acquisitions were taken at each temperature for a 5 second duration, and the results presented represent the mean R_h of the sample at each temperature.

Temperature-controlled UV-Vis Spectrophotometry

Cloud point transition temperatures (T_c) were determined via temperature-controlled spectrophotometry using a Cary 300 (Agilent Technologies). Samples containing various concentrations of protein in 150 mM PBS were cooled at 1 $^{\circ}\text{C}/\text{min}$ while the absorbance at $\lambda = 350$ nm was recorded every 1 $^{\circ}\text{C}$. Absorbance was normalized to the absorbance at the highest temperature point collected, corresponding to the more soluble point during a given experiment. The cloud point was determined as the maximum in the first derivative of the absorbance as a function of temperature. Transition temperature was calculated by the point of minimum slope. Saturation concentration was defined by the natural logarithm fit line created from a minimum of

three volume fractions. Error bars are standard error of the mean from three repeats of a minimum of three transition temperatures.

Dextran Uptake Experiments

5 The uptake of dextran molecules into the phase separated space of [WT]-20 and [Q_{5,8}]-20 was performed to quantify the isolation of A-IDPs from their surroundings. Fluorescein isothiocyanate labeled dextrans (10 kDa, 40 kDa, Sigma-Aldrich, St. Louis, MO) were added to 4 mg mL⁻¹ solutions of unlabelled [WT]-20 and [Q_{5,8}]-20 at final concentrations of 4 mg mL⁻¹ and 1 mg mL⁻¹, respectively at 60 °C. Soluble samples were then transferred to room temperature glass
10 slides and mounted with #1.5 cover slip. Samples were imaged on an upright Zeiss Axio Imager D2 microscope with a 20× objective and the appropriate filter set (ex 470/40, em 525/50) after 1-hour incubation below the transition temperature. Fluorescent intensity was calculated from background corrected fluorescent intensities inside/outside droplets in ImageJ portioned using bright field images of the phase separated space.

Sample Preparation for Temperature Gradient Experiments

High concentration A-IDP stock solutions (60 wt%) were prepared by resuspending a mass of lyophilized A-IDP pellets with an appropriate volume of phosphate buffer saline solution (PBS) at a solution pH of 7.0. The concentration was converted to mg mL⁻¹ by assuming that the
20 density of the A-IDP was 1 g mL⁻¹. The RLP stock solution was heated in a water bath at 85 °C for 60 minutes and mixed periodically along with sonication to ensure homogeneity. Lower concentration samples were made by mixing the initial stock solution volumetrically with PBS at a pH of 7. To prepare for temperature gradient microfluidics (TGM) measurements, the solutions were loaded into 12 mm × 1 mm × 0.1 mm rectangular borosilicate glass capillary tubes
25 (VitroCom, Inc.), by capillary action, and sealed with wax to avoid sample evaporation and convection. The capillary tubes were held in contact with a hot plate at 85 °C housed within an incubator at 65 °C during the loading process. The high temperature environment ensured that the RLP solutions were held above the critical phase transition temperature (~85 °C for [WT]-20). Capillary arrays were prepared by taping several capillaries together. The arrays were stored at
30 85 °C in an oven for 10 minutes prior to subjecting them to the temperature gradient experimentation.

Measuring Phase Transition Temperatures on a Temperature Gradient Device

The temperature gradient device imposed a linear temperature gradient across the A-IDP solutions. This was accomplished by placing the glass capillary array into thermal contact with a heat source on one side and a cold sink on the other. The sample was then bathed in white light. This light was scattered by phase separated A-IDP droplets at cold temperature and was imaged via dark-field microscopy. The temperature gradient was calibrated for each experiment using two reference solutions placed alongside the A-IDP samples of interest. The cold temperature calibration reference contained 10 mg mL⁻¹ poly(N-isopropyl acrylamide) (PNIPAM) with MW = 1.868 × 10⁵ g mol⁻¹ in H₂O (Polymer Source, Inc.). The hot temperature calibration reference contained 10 mg mL⁻¹ poly(ethylene oxide) (PEO) with MW = 9 × 10⁵ g mol⁻¹ in a 1 M NaCl aqueous solution (Sigma-Aldrich). The LCST of each reference solution was obtained with a melting point apparatus that measured the light scattering intensity as the temperature was increased at a rate of 0.5 K min⁻¹. When placed onto the temperature gradient device, the reference solutions became cloudy at temperatures above the LCST. The pixel position of the LCST was obtained by the onset of light scattering intensity relative to the low intensity baseline on the cold side of the capillary. The temperature gradient was calculated using the pixel positions and the LCSTs of the two samples, assuming a linear relationship between position and temperature.

Fitting of Phase Diagram Binodal

Fits for the roughly dilute, overlap and semi-dilute regions of our obtained phase diagrams were calculated using fitting methods for lower critical solution transition polypeptides adopted for upper critical solution transition polypeptides as described previously.

Briefly, for low volume fractions ($\phi < 0.1$), A-IDPs exhibit roughly a log-normal dependence on UCST cloud point with respect to volume fraction as seen with other repeat polypeptides. For the high density regime ($\phi > \sim 0.4$) using surface tension scaling methods previously described for elastin-like polypeptides, we determined the coefficients of proportionality (A) and estimated theta temperature (θ) of [WT]-20 and [Q_{5.8}]-20 to be A = -0.00092, $\theta = 389$ K and A = -0.00092, $\theta = 392$ K respectively. In a poor solvent, the surface tension of a dilute phase globule γ can be written in the form $\gamma \approx C k T b^2 \phi^2$ where b is the polypeptide Kuhn length (b = 2.2 nm as measured by Fluegel and co-workers for other repetitive polypeptides) and C an adjustable coefficient. Replacing the surface tension γ by $k T \phi^2 A^* (T - \theta)$ we obtain an equation for the temperature dependence of the coacervate volume fraction

$$\phi_2 = \left[\frac{A}{C} b^2 (T - \theta) \right]^{\frac{3}{4}}$$

Using a least-squares fit in Igor (WaveMetrics Inc. Portland, OR), we adjust the coefficient C for this temperature dependence to match the measured [WT]-20 binodal and the [Q_{5,8}]-20 binodal points to determine C = 0.62 and 1.05, respectively.

Closer to the critical point in the so-called Ginzburg zone one needs to use the critical Ising model to describe the phase behavior of polymer solutions. The phase boundary in the critical zone varies more gradually than predicted by mean field theory:

$$\phi_2 - \phi_1 = C_c \left(\frac{T}{T_c} - 1 \right)^{0.3}$$

where $T_c = 351.5$ K for [WT]-20 and $T_c = 332.3$ K for [Q_{5,8}]-20, 0.3 is the critical Ising exponent (Flory-Huggins mean field value is 0.5) for both [WT]-20 and [Q_{5,8}]-20, and C_c is the fitting coefficient. We calculated fitting coefficients in Igor (WaveMetrics Inc. Portland, OR) equal to 1.29 and 1.27 for [WT]-20 and [Q_{5,8}]-20 respectively. Note that we calculated ϕ_1 explicitly using data collected with UV-Vis spectrophotometry and according to natural logarithm fits described in Table 1.

Whole Cell Fluorescent Intensity Measurements

Cells were grown overnight in 5 mL of TB media from glycerol stocks. In conjunction to fluorescent or confocal imaging, cells were analyzed for total sfGFP fluorescence and OD₆₀₀. Briefly, 50 ul of cell culture at various time points was resuspended in 1 mL of 150 mM PBS. Using a combination of a UV-Vis spectrophotometry signal from a NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA) and fluorescent spectra from a NanoDrop 3300 (Thermo Fisher Scientific, Waltham, MA), we calculated the relative ratio of sfGFP fluorescence normalized to cell density. Using this information in conjunction with imaging analysis, we were able to determine the intracellular saturation concentration normalized to cell density.

Temperature Controlled Fluorescent Microscopy of Protocell Droplets and *E. coli* Bacteria

Water-in-oil droplets were collected on a glass microscope slide and cooled using a precision Peltier heating and cooling stage (Linkam LTS120) equipped with a temperature control unit (Linkam PE95). The spatial distribution of Alexa Fluor 350-labeled (25% molar fraction N-terminal labeled) [Q_{5,8}]-20 and Alexa Fluor 594-labeled +4 Net was characterized via fluorescence microscopy using an upright Zeiss Axio Imager D2 microscope with a 20× objective and the appropriate filter set. Similarly, intracellular patterning of A-IDP-superfolder GFP over time was characterized via fluorescence microscopy using an upright Zeiss Axio Imager D2 microscope with a 20× objective and the appropriate filter set (ex 470/40, em 525/50). Cell fluorescent was

calculated using ImageJ software. Temperature ramps began at various temperatures but always were set to a constant speed of 5 °C/min.

Transient Transfection of [WT]-20-sfGFP in HEK293 Cells

5 [WT]-20-sfGFP was extracted from the pET24(+) vector using polymerase chain reaction (PCR). Briefly, the forward and reverse primers were resuspended with 1 ng of pET24(+) plasmid containing [WT]-20-sfGFP gene fusion. Using a PCR cycle of [98 °C, 1 min; 65 °C, 30 sec; 72 °C, 2 min] × 30 cycles, followed by gel purification, the gene was finally constructed with Gibson assembly. pcDNA5 vector containing [WT]-20-sfGFP was transfected into HEK293 cells
10 according to manufacturer instructions (Expi293 Expression System, Thermo Fischer Scientific, Waltham, MA). Cells were spun down at 500 RCF for 10 min at room temperature on day 5 of transient transfection and resuspended in 150 mM PBS for imaging.

Confocal Imaging of A-IDP-sfGFP Fusions for Puncta Formation and Colocalization

15 Cells were prepared as follows. A tube containing 5 mL of TB media was inoculated overnight with protein of choice from bacterial glycerol stock. After 16 hr of growth, induction with 1 mM IPTG and 2% L-rhamnose (Sigma-Aldrich, St. Louis, MO) was added each flask of interest. Samples were collected at the indicated time points and prepared for imaging as follows: 50 µL of cell suspension was pelleted under 20,000 RCF for 1 min at room temperature. Cells were
20 resuspended to OD₆₀₀ = 0.15 at 1 cm path length. 50 µL of resuspended bacterial cells were transferred to a 384-well plated with #1.5 glass bottom (Cellvis). There was a 10 min equilibration period to the incubation chamber prior to each time point data collection.

Images were collected at different time points with a 63X oil-immersion objective on a Zeiss 710 inverted confocal with temperature-controlled incubation (Car Zeiss AG, Oberkochen,
25 Germany). sfGFP fluorescent was detected with a 488 nm excitation laser and 488/594 emission filter. Data was primarily taken at 25 °C unless otherwise noted. All fluorescent quantification and cell portioning analysis was performed in ImageJ.

In colocalization experiments, cells were grown overnight from glycerol stock in dual antibiotic media containing 45 µg/mL kanamycin and 25 µg/mL chloramphenicol (final
30 concentration). After 16–18 hours, pET24(+) expression was induced with 1 mM concentration of IPTG (final concentration). After 24 hours of IPTG induction, media was replaced with 5 mL of TB supplemented with 1 mM IPTG and 2% arabinose (final concentration) (Sigma Aldrich, St. Louis, MO). After 9 hours of induction with both, cells were prepared for confocal imaging by spinning down 50 µL of culture at room temperature and resuspended in 150 mM PBS to OD₆₀₀

= 0.15 at 1 cm path length. All imaging details remain the same except that mNeonGreen/sfGFP detection was performed with 488 nm excitation laser and 488/594 emission filter and mRuby3 detection with 561 nm excitation laser and 488/561 emission filter.

5 Spinning Disc Confocal Imaging of Lac Z alpha-peptide-A-IDP Gene Fusions for Localization and Quantification of Enzymatic Activity

Cells were prepared as follows. A tube containing 5 mL of TB media was inoculated overnight with protein of choice from bacterial glycerol stock. After 16 hr of growth, induction with 1 mM IPTG and 2% L-rhamnose (Sigma-Aldrich, St. Louis, MO) was added each flask of interest. ~24 hours later, 50 μ L of cell suspension was pelleted under 20,000 RCF for 1 min at room temperature. Cells were resuspended in 150 mM PBS to OD_{600} = 0.15 at 1 cm path length. Fifty microliters of sample were added to Culture-Insert 4 Well (1.5 coverslip, Ibidi, Madison, WI) petri dishes and allowed to incubate at room temperature for 10 minutes. After incubation, 2 μ L of 1 mg mL⁻¹ FDG resuspended in 98% water, 1% DMSO and 1% EtOH was added. Imaging began immediately (within 20 seconds) and images were captured every minute for 30 minutes total. Imaging was performed on an Andor Dragonfly Spinning Disk 500 series confocal on a LeicaDMi8 microscope stand (Oxford Instruments, Abingdon, UK) with a 63 $\times$ water immersion objective and equipped with a Zyla 4.2 series camera. Converted FDG was detected with a 488 nm excitation laser and 525/50 nm emission filter and mRuby3 fluorescence with a 561 nm excitation laser and 600/50 nm emission filter.

Fluorescent Spectroscopy for Determining K_m , V_{max} and k_{cat}

Liquid cultures of KRX *E. coli* containing plasmid of interest were grown from glycerol stocks overnight (16–18 hours). Cells were then induced with 1 mM IPTG and 2% L-rhamnose (Sigma-Aldrich, St. Louis, MO) for 24 hours. Cells were pelleted and resuspended at OD_{600} = ~0.15 in 140 mM PBS. Various concentrations of FDG were added while monitoring fluorescent intensity at 520 nm using NanoDrop 3300 (Thermo Fisher Scientific, Waltham, MA). The same instrument was used to also calculate the fluorescent intensity of mRuby3 as a relativistic measure of expression level of the various alpha peptide fusions. Plotting the observed fluorescent intensity at different times provides a surrogate measure of the rate of hydrolysis at various concentrations of the substrate (V_0). These rates were then converted into typical Lineweaver-Burk conventions to determine V_{max} and K_m . For consistency in units, [FDG] was converted into fluorescent intensity using a fluorescein standard curve of $y = 185919 \times [\text{FDG in mg}]$

+ 1045. This conversion assumes that converted FDG into fluorescein has similar fluorescent intensity profile to free fluorescein dye.

Image Quantification and Statistical Analysis

For experiments performed with regard to determining the intracellular fluorescent intensity of A-IDP-sfGFP at various points post-IPTG induction the following statistical analysis was performed. For determining the saturation concentration intracellular, whole cell fluorescence normalized to cellular density (OD₆₀₀) on three independent samples was calculated while imaging of their intracellular architecture. Upon first observation of phase separation in *E. coli* in more than 50% of cells within a microscopic field of view, this normalized cell density was recorded as the saturation concentration. Data is normalized to data collected for [WT]-40 as a reference point. Error bars represent propagated standard error of the mean of three separate samples from the same original cell suspension.

With the microscope images collected with confocal microscopy at various time points, we isolated the soluble and puncta fractions within the cells at various points in time via analysis in ImageJ. Puncta consistently create pixels dense enough to saturate the detector while simultaneously observing the rest of the cell. Thus, by thresholding around the upper 2% of total pixel intensities, one can easily partition this section from the remaining cell cytoplasm. Using this constant thresholding between timepoints in each experimental group, we were able to track the total size of these puncta over time with regard to the total size of the cell (puncta + soluble fraction). Error bars of these data are standard errors of the mean of normalized puncta (two-phase) area of three images of different fields of view of the sample overall cell samples. These two channels are combined and split differently in FIG. 2 but have the same thresholding process applied to each image.

Given the lack of automated tools for the detection of intracellular phase separation between two images, we calculated the intracellular transition temperatures manually. Similar to the detection of phase separation with UV-Vis spectrophotometry, the intracellular transition temperature was determined as the midpoint between a frame that was certainly homogenous and a second frame that was certainly two phases. All transition temperatures were determined in this way, going from a point of solubility to insolubility whether the solution was being heated or cooled. Due to the level of subjectivity of this assessment, sample identifiers were blinded to the analyst and a high number of cells were analyzed in each experiment (n = 30). Data was normalized to the initial mean fluorescence of the homogeneous cells at a consistent temperature (often 60 °C unless otherwise noted). Error bars indicate standard error of the mean.

The error bars of dextran fluorescence indicate the standard error of the mean fluorescence inside and outside of the phase separated space from three separate fields of view.

For quantification of Fluorescein Di- β -D-Galactopyranoside (FDG) relative to the different expression levels of alpha peptide, channels were split between fluorescence from FDG and mRuby3 respectively. Using the particle analysis tool from ImageJ, areas of green fluorescence were isolated from the background. If the mean fluorescence of this area was 5% greater than the background fluorescence (mean fluorescent of the area excluded by the previous particle mask), then this particular particle's background subtracted green fluorescence was included in the analysis. Particles were excluded if their area was below 0.1 μm^2 . Using the same particle mask, the background subtracted mean fluorescence of mRuby3 was calculated on the other fluorescent channel. We report the ratio of these two channels as a surrogate for enzymatic efficiency. Error bars are standard errors of the mean at each timepoint.

For quantification of Fluorescein Di- β -D-Galactopyranoside (FDG) inside the cellular space versus outside the cellular space, channels were first split between fluorescence from FDG and mRuby3 respectively. Using the same particle analysis tool from ImageJ, areas of green fluorescence were isolated from the background. If the mean fluorescence of this area was 5% greater than the background fluorescence (mean fluorescent of the area excluded by the previous particle mask), then this particular particle's background subtracted green fluorescence was included in the analysis. Particles were excluded if their area was below 0.1 μm^2 . Ratio of fluorescent intensity inside of cells versus the extracellular space is the background corrected mean fluorescence of FDG divided by the background fluorescence. Error bars are standard errors of the mean at each timepoint.

To quantify the amount of colocalization we used the Coloc2 plug-in available through ImageJ software. Using automated thresholding, we report the Mander's colocalization coefficient which accounts for the intensity to the two channels of interest as described previously.

Identification of a minimal IDP repeat from proteomic analysis and sequence heuristics

We conducted a proteomic analysis of 63 IDPs that form membrane-less organelles to investigate their sequence composition. We were particularly interested in categories of amino acids suspected to drive phase behavior *via* intrachain interactions, such as charge-charge, cation- π and hydrogen bonding *via* non-charged polar residues (FIG. 1A). The composition of these 63 proteins is remarkably similar to previously identified repetitive protein polypeptides that exhibit UCST phase behavior and their side-chains groups are chemically similar to synthetic UCST polymers. Using a combination of our previously developed sequence heuristics and

insights from this proteomic analysis, we designed an octa-peptide motif that we expected would exhibit robust phase behavior when polymerized into a macromolecule, under physiologically relevant solution conditions.

In order to manage the vast sequence space of all possible mutations of the octapeptide repeat, we classify each amino acid into categories of intrachain interactions that could contribute to UCST phase behavior. N, Q, S, T are classified as polar, uncharged amino acids. R-K and D-E are pairs of positively charged and negatively charged amino acids. G and P are placed into a separate category given their unusual structure and importance in promoting a disordered polypeptide backbone (FIG. 3A). The remaining amino acids are classified as “hydrophobic.” To ensure that we modulate the UCST phase behavior via mutagenesis of the WT repeat, but do not abolish it completely, we only make mutations wherein the mutant maintains the type of interactions and simply modulates the strength of that interaction. For example, R and K are both positively charged under normal physiological pH. Thus, by substituting K for R we maintain the charge neutral state of the polymeric backbone—a parameter known to dramatically affect the observed phase behavior. Similarly, N, Q, S and T are all capable of creating hydrogen bonds with water and one another more readily than an aliphatic amino acid such as V. Thus, substituting these four amino acids for one another maintains an equal number of residues per chain capable for forming this particular type of bond.

The wild-type (WT) repeat unit is $(G_1-R_2-G_3-D_4-S_5-P_6-Y_7-S_8)_{40}$ where 40 refers to the number of repeats. The MW of the A-IDPs was varied between ~15 and ~70 kDa—by varying the number of repeat motifs from 20 to 80—to account for observed differences in MW in the intrinsically disordered regions (IDRs) of naturally occurring IDPs (FIG. 3B). The parent sequence is referred to as WT in this paper, and we use a short-hand notation to refer to sequences throughout the text where the bracketed letter refers to a specific point—substitution—mutant. For example, a mutant with a complete substitution of Y_7 in the WT repeat unit with V would result in a notation of “[V₇]-XX”. When a residue is only partially substituted in the A-IDP, we use the notation “[B_{Y_o}:Z_{V_o}]” where the B to Z ratio represents the ratio of Y to V ratio in the variant and the subscript o is the position of that residue along the repeat unit. For example, [Y₇:V₇]-40 would hence represent 50% of all Y replaced with V, whereas [3Y₇:V₇]-40 would represent a 25% substitution of V for Y. A double mutant, such as 100% substitution of residues at the 5th and 8th position in the octapeptide repeat with Q, would be denoted as [Q_{5,8}]-XX with and fractional substitution at these positions with S and Q would be denoted as [BS_{5,8}:ZQ_{5,8}]-XX where B and Z represent the ratio of S to Q. Full sequence descriptions of common sequences used throughout

the paper can be found in Table 1. A full description of all architectures of A-IDPs wherein mutant and WT repeats are mixed along the A-IDP chain can be found in Table 2 and Table 3.

Table 1. Amino Acid Sequences of A-IDPs

Protein Name	Full Amino Acid Sequence	Aa (N)	Mol. Wt. (Da)	SEQ ID NO:
[WT]-20	SKGP-[GRGDSFYYS] ₂₀ -GY	166	17004	197
[WT]-40	SKGP-[GRGDSFYYS] ₄₀ -GY	326	33400	198
[WT]-60	SKGP-[GRGDSFYYS] ₆₀ -GY	486	49797	199
[WT]-80	SKGP-[GRGDSFYYS] ₈₀ -GY	646	66193	200
[Q _{5,8}]-20	SKGP-[GRGDQPYQ] ₂₀ -GY	166	18646	201
[Q _{5,8}]-40	SKGP-[GRGDQPYQ] ₄₀ -GY	326	36685	202
[3S _{5,8} :Q _{5,8}]-40	SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGRGDQPYQ] ₁₀ -GY	326	34221	203
[S _{5,8} :Q _{5,8}]-40	SKGP-[GRGDSFYSGRGDQPYQ] ₂₀ -GY	326	35042	204
[S _{5,8} :3Q _{5,8}]-40	SKGP-[GRGDQPYQGRGDQPYQGRGDQPYQGRGDSFYYS] ₁₀ -GY	326	35863	205
[3Y ₇ :V ₇]-40	SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGRGDSFVS] ₁₀ -GY	326	32760	206
[Y ₇ :V ₇]-40	SKGP-[GRGDSFYSGRGDSFVS] ₂₀ -GY	326	32119	207
[V ₇]-40	SKGP-[GRGDSFVS] ₄₀ -GY	326	30839	208
[3R ₂ :K ₂]-40	SKGP-[GRGDSFYSGRGDSFYSGRGDSFYSGKGDSFYYS] ₁₀ -GY	326	33120	209
[R ₂ :K ₂]-40	SKGP-[GRGDSFYSGKGDSFYYS] ₂₀ -GY	326	32840	210

Table 2. Amino Acid Sequence of A-IDPs with a Single Repeat Motif

Protein Name	Full Amino Acid Sequence	AA No.	Mol. Wt. (Da)	μM, 37 °C	Image Index	SEQ ID NO:
[WT]-20	SKGP-[GRGDSFYYS] ₂₀ -GY	166	17004	44.18	1	197
[WT]-40	SKGP-[GRGDSFYYS] ₄₀ -GY	326	33400	0.755	2	198
[WT]-60	SKGP-[GRGDSFYYS] ₆₀ -GY	486	49797	0.044	3	199
[WT]-80	SKGP-[GRGDSFYYS] ₈₀ -GY	646	66193	0.0002	4	200
[Q _{5,8}]-20	SKGP-[GRGDQPYQ] ₂₀ -GY	166	18646	247.9	8	201
[Q _{5,8}]-40	SKGP-[GRGDQPYQ] ₄₀ -GY	326	36685	6.593	9	202
[Q _{5,8}]-60	SKGP-[GRGDQPYQ] ₆₀ -GY	486	54723	1.034	10	211
[Q _{5,8}]-80	SKGP-[GRGDQPYQ] ₈₀ -GY	646	72762	0.241	11	212
[T _{5,8}]-40	SKGP-[GRGDTPTYT] ₄₀ -GY	326	34522	0.856	60	213
[N _{5,8}]-20	SKGP-[GRGDNFYN] ₂₀ -GY	166	18085	337.2	12	214
[N _{5,8}]-40	SKGP-[GRGDNFYN] ₄₀ -GY	326	35562	39.18	13	215
[N _{5,8}]-60	SKGP-[GRGDNFYN] ₆₀ -GY	486	53040	4.827	14	216
[H ₇]-20	SKGP-[GRGDSFHS] ₂₀ -GY	166				217
[H ₇]-40	SKGP-[GRGDSFHS] ₄₀ -GY	326	32359	8376.0	61	218

[H7]-60	SKGP-[GRGDSPHS] ₆₀ -GY	486	48235	286.8	24	219
[H7]-80	SKGP-[GRGDSPHS] ₈₀ -GY	646	64111	327.0	25	220
[F7]-20	SKGP-[GRGDSPFS] ₂₀ -GY	166				221
[F7]-40	SKGP-[GRGDSPFS] ₄₀ -GY	326	32760	1.923	62	222
[Q8]-20	SKGP-[GRGDSPYQ] ₂₀ -GY	166	17825	0.029	38	223
[Q8]-40	SKGP-[GRGDSPYQ] ₄₀ -GY	326	35042	0.135	39	224
[Q8]-60	SKGP-[GRGDSPYQ] ₆₀ -GY	486	52260	3.179	40	225
[Q8]-80	SKGP-[GRGDSPYQ] ₈₀ -GY	646	69478	15.72	41	226
[Q5]-20	SKGP-[GRGDQPYQ] ₂₀ -GY	166	17825	149.0	29	227
[Q5]-40	SKGP-[GRGDQPYQ] ₄₀ -GY	326	35042	7.941	30	228
[Q5]-60	SKGP-[GRGDQPYQ] ₆₀ -GY	486	52260	0.723	31	229
[Q5]-80	SKGP-[GRGDQPYQ] ₈₀ -GY	646	69478	0.086	32	230
[N5]-20	SKGP-[GRGDNPYQ] ₂₀ -GY	166				231
[N5]-40	SKGP-[GRGDNPYQ] ₄₀ -GY	326	34481	0.670	21	232
[N5]-60	SKGP-[GRGDNPYQ] ₆₀ -GY	486	51418	0.028	22	233
[N5]-80	SKGP-[GRGDNPYQ] ₈₀ -GY	646	68356	0.004	23	234
[N8]-20	SKGP-[GRGDSPYN] ₂₀ -GY	166	17544	484.1	18	235
[N8]-40	SKGP-[GRGDSPYN] ₄₀ -GY	326	34481	16.17	19	236
[N8]-60	SKGP-[GRGDSPYN] ₆₀ -GY	486	51418	3.748	20	237
[N5,Q8]-20	SKGP-[GRGDNPYQ] ₂₀ -GY	166				238
[N5,Q8]-40	SKGP-[GRGDNPYQ] ₄₀ -GY	326	36123	2.449	5	239
[N5,Q8]-60	SKGP-[GRGDNPYQ] ₆₀ -GY	486	53882	0.176	6	240
[N5,Q8]-80	SKGP-[GRGDNPYQ] ₈₀ -GY	646	71640	0.108	7	241
[Q5,N8]-20	SKGP-[GRGDQPYN] ₂₀ -GY	166	18365	637.5	15	242
[Q5,N8]-40	SKGP-[GRGDQPYN] ₄₀ -GY	326	36123	52.62	16	243
[Q5,N8]-60	SKGP-[GRGDQPYN] ₆₀ -GY	486	53882	13.47	17	244
[WT]-20-sfGFP	SKGP-[GRGDSPYS]-20-sfGFP	410	44551	216.1	26	245
[WT]-40-sfGFP	SKGP-[GRGDSPYS]-40-sfGFP	570	60947	3.448	27	246

Table 3. Amino Acid Sequence of A-IDPs with Multiple Repeat Motifs

Protein Name	Full Amino Acid Sequence	AA No.	Mol. Wt. (Da)	μ M, 37 °C	Image Index	SEQ ID NO:
[3S _{5,8} :Q _{5,8}]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDQPYQ] ₁₀ -GY	326	34221	1.600	33	254
[S _{5,8} :Q _{5,8}]-40	SKGP-[GRGDSPYSGRGDQPYQ] ₂₀ -GY	326	35042	1.907	34	255
[S _{5,8} :3Q _{5,8}]-40	SKGP-[GRGDQPYQGRGDQPYQGRGDQPYQ GRGDSPYS] ₁₀ -GY	326	35863	5.062	35	256
[3Y ₇ :V ₇]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPVS] ₁₀ -GY	326	32760	24.54	36	257
[Y ₇ :V ₇]-40	SKGP-[GRGDSPYSGRGDSPVS] ₂₀ -GY	326	32119	815.5	37	258
[Y ₇ :3V ₇]-40	SKGP-[GRGDSPVSGRGDSPVSGRGDSPVS GRGDSPYS] ₁₀ -GY	326	31479	Unk	N/A	259

[V7]-40	SKGP-[GRGDSPVS] ₄₀ -GY	326	30839	Unk	N/A	260
[3Y7:A7]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPAS] ₁₀ -GY	326	32479	28.46	45	261
[Y7:A7]-40	SKGP-[GRGDSPYSGRGDSPAS] ₂₀ - GY	326	31558	1816	46	262
[3Y7:I7]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPIS] ₁₀ -GY	326	32900	12.88	47	263
[Y7:I7]-40	SKGP-[GRGDSPYSGRGDSPIS] ₂₀ - GY	326	32400	214.8 506	48	264
[3Y7:M7]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPMS] ₁₀ -GY	326	33080	7.914	49	265
[Y7:M7]-40	SKGP-[GRGDSPYSGRGDSPMS] ₂₀ - GY	326	32761	110.5	50	266
[3Y7:H7]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPHS] ₁₀ -GY	326	33140	7.125	42	267
[Y7:H7]-40	SKGP-[GRGDSPYSGRGDSPHS] ₂₀ - GY	326	32880	70.86	43	268
[Y7:3H7]-40	SKGP-[GRGDSPHSRGGDSPHSRGGDSPHS GRGDSPYS] ₁₀ -GY	326	32619	508.5	44	269
[3R2:K2]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GKGDSPYS] ₁₀ -GY	326	33120	8.537	51	270
[R2:K2]-40	SKGP-[GRGDSPYSGKGDSPYS] ₂₀ - GY	326	32840	79.88	52	271
[D4:E4]-40	SKGP-[GRGDSPYSGRGESPYS] ₂₀ - GY	326	33681	1.779	53	272
[3Y7:W7]-40	SKGP-[GRGDSPYSGRGDSPYSGRGDSPYS GRGDSPWS] ₂₀ -GY	326	33671	0.066		273
[Y7:W7]-40	SKGP-[GRGDSPYSGRGDSPWS] ₂₀ - GY	326	33901	0.023		274
[5G:7P]-40	SKGP[GRPDSPYSGRGDSPYSGRGD SPYSGRGDSPYSPRGDSPYSGRGDS PYSGRGDSPYSGRGDSPYSGRPDSP YSGRGDSPYSGRGDSPYSGRGDSPY SPRGDSPYSGRGDSPYSGRGDSPYS GRGDSPYS GRPDSPYSGRGDSPYSGRGDSPYSG RGDSPYS] ₂ -GY	326	33801	0.742	54	275
[G:P]-40	SKGP-[GRPDSPYSGRGDSPYSPRGDSPYS GRGDSPYS] ₁₀ -GY	326	34202	0.728	55	276
[7G:5P]-40	SKGP-[GRPDSPYSPRGDSPYSGRPDSPYS GRGDSPYSPRGDSPYSGRPDSPYSP RGDSPYSGRGDSPYSGRPDSPYSPR GDSYSGRPDSPYSGRGDSPYSPRG DSYSGRPDSPYSPRGDSFYSGRGD SPYSGRPDSPYSPRGDSPYSGRPDS PYSGRGDSPYS] ₂ -GY	326	34602	0.910	56	277

[3Y7:V7]-40-sfGFP	SKGP-- [GRGDSPPYSGRGDSPYSGRGDSPYS GRGDSPPVS]10-sfGFP	570	60307	42.46	28	278
[3Y7:V7]-40-UAA	AzF-- ([GRGDSPPYSGRGDSPYSGRGDSPY SGRGDSPPVS]-5-AzF)2	323	32660	Unk	N/A	279

Table 4. Amino Acid Sequence of Fluorescent Protein Reporters

Protein	Full Amino Acid Sequence	AA No.	Mol. Wt. (Da)	SEQ ID NO: (AA, DNA)
sfGFP	GKGEELFTGVVPIILVELDGDVNGHKFSVRGEGEGDATNGKL TLKFICTTGKLPVWPPTLVTTLTLYGVQCFSRYPDHMKRHDF FKSAMPEGYVQERTISFKDDGNYKTRAEVKFEQDTLVNRIE LKGI DFKEDGNILGHKLEYNNSHNVIITADKQKNGIKANF KIRHNIEDGSGVQLADHYQONTPIGDGPVLLPDNHYLSTQSV LSKDPNEKRDHMLLEFVTAAGITHGMDELYKELHHHHHHG GVSKGEELIKENMRMKVVMESVNGHQFKCTGEGERPYEG VQTMRIKVIIEGGPLPFAFDILATSFMYGSRTFIKYPADIPD FFKQSFPEGETWERTVTRYEDGGVVTVTQDTSLEDGELVYNV KVRGVNFPSPNGPVMQKKTGWEPNTEMMYPADGGLRGYTDI ALKVDGGGHLHCNFTTYRSKKTGVGNIKMPGVHAVDHRLER IEESDNETYVVQREVAVAKYSNLGGGMDELYK	246	27785	280, 281
mRuby3		237	26486	282, 283

Table 5. Primers for pcDNA5 Cloning of [WT]-20-sfGFP

pcDNA5-Fwd-[WT]-20-sfGFP	CTCACTATAGGGAGACCCAAAGCTGGCTAGCATGAGCAAAGGG CCGGGACGCGGCGATAGT	SEQ ID NO: 282
pcDNA5-Rev-[WT]-20-sfGFP	TTAGCCGTGATGGTGATGGTGATGGAGCTCGTTGATTGTCTGA GGGCCCTCTAGACTCGAG	SEQ ID NO: 283

A-IDPs Exhibit Robust and Reversible UCST Phase Behavior in an Aqueous Environment

One advantage of A-IDPs is their minimal interaction with other proteins or biomolecules stemming from their repetitive nature. This feature of A-IDPs combined with their reversible aqueous two-phase separation enables simple column-free purification by UCST phase transition cycling between the one- and two-phase regime of the phase diagram. An example of this purification process is shown in FIG. 1B, where the highly expressing A-IDP, [Q_{5,8}]-20, completely phase separates from the soluble fraction of the cell lysate and can be isolated by centrifugation. Subsequent removal of the protein-poor supernatant, dissolution of the protein-rich pellet with urea, and dialysis of the soluble fraction in milli-Q water results in 95-99% pure protein as observed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (FIG. 1C and FIG. 4). The yield of purified A-IDP ranges from 25-300 mg per liter of culture media in shaker flask culture.

A-IDPs [WT]-20 and [Q_{5,8}]-20 exhibit UCST phase behavior *in vitro*. To characterize their phase transition behavior, we employed three different techniques. First, we utilized droplet

microfluidics, where monodisperse water droplets are formed in oil containing the A-IDP of interest (FIG. 1D). Phase separation can be directly visualized in the spatially limited compartment of water-in-oil microdroplets to observe the types of structures formed as one cools the surrounding medium. These A-IDPs exhibit classic liquid-liquid phase separation where, upon crossing the phase boundary upon cooling from 50 °C to 10 °C, multiple nucleation sites of coacervate condensates are observed (FIG. 1D Panel 2). These nucleation sites wet one another and quickly coalesce into a single, spherical A-IDP–dense phase that is in equilibrium with the surrounding A-IDP–poor phase (FIG. 1D panel 3 and 3-1/3-2). Upon reheating to 50 °C, the A-IDP–rich phase shrinks in size, as the A-IDP re-solubilizes, re-establishing equilibrium rapidly (FIG. 1D Panel 4-1/4-2). A wider field of view of this transition can be found in FIG. 5. These data clearly show that these A-IDPs exhibit *reversible* UCST phase separation via coalescence and growth kinetics (FIG. 1E).

Second, we employed temperature dependent dynamic light scattering (DLS) to observe the two-phase separation in bulk. A solution of [Q_{5,8}]-20 is heated to 80 °C and DLS data was collected as the solution is cooled to 10 °C. We observe a transition from soluble A-IDP molecules with a hydrodynamic radius (R_h) of 4 nm to aggregates larger than 1 μm as a function of temperature (FIG. 1F and FIG. 6). This transition is quite sharp, as it occurs within a 2 °C window at ~38 °C.

Third, we employed temperature-dependent turbidity measurements at a fixed wavelength of 350 nm to characterize the UCST phase separation while heating and cooling a solution of an A-IDP at a rate of 1 °C min⁻¹ (FIG. 1G). Using this technique, we can capture partial phase diagrams of each A-IDP of interest as a function of many different sequence and solution parameters. At dilute volume fractions of [Q_{5,8}]-40 we observed different UCST cloud points that increase as a function of the natural logarithm of A-IDP concentration ($T_i = m \cdot \ln([A-IDP]) + b$). We also confirmed the complete reversibility of the UCST phase behavior of these A-IDPs, with a <1 °C difference in UCST T_i after ten successive heating and cooling ramps (FIG. 7).

Arginine Composition, Aromatic to Aliphatic Ratio, Charge Balance and Molecular Weight Define UCST Cloud Point

To understand the effects of a particular residue substitution in the octapeptide repeat on the phase separation for the A-IDP, we created a set of “mutant” A-IDPs ranging from 100% of *a* to 100% of *b* where *a* is the WT repeat unit. The doping scheme wherein the mutant repeat unit *b* is periodically inserted into the WT sequence is visually illustrated by the color-coded schematic in FIG. 8A. The mutant repeat is well mixed—distributed along the WT sequence to reduce

“blockiness” of the co-polypeptide, which has been shown in LCST polypeptides to lead to nanoscale self-assembly instead of the desired liquid-liquid coacervation. Measuring the UCST phase behavior of these copolymers is analogous to a loss-of-function or gain-of-function screen for UCST cloud point upon substitution of motif *b* for *a* (FIG. 8A). Due to experimental limitations, loss of function—phase separation that cannot be detected—is operationally defined as a $T_i < 4^\circ\text{C}$ at volume fractions less than or equal to 0.1 in a 140 mM salinity aqueous buffer. A total length of 40 repeats was chosen for these A-IDPs to approximate the median length (~320 amino acids) of IDRs found in the proteomic analysis of naturally occurring IDPs.

The T_i of the WT and each A-IDP is a linear function of its volume fraction (ϕ) (FIG. 8B and C). At a specified ϕ , the T_i is a function of composition ($R^2 = 0.97$), which demonstrates that the behavior of the mutant A-IDPs—block co-polypeptides of *a* and *b*—can be linearly interpolated between that of pure polypeptides of *a* and *b*. The linear behavior of the T_i of these mutant A-IDPs also allows extrapolation of the UCST phase behavior for homopolymers that exhibit a UCST cloud point beyond the experimentally observable range of detection thus putting each point mutation on a single relative scale (FIG. 9).

We next tested the effect of fifteen different site-specific substitution mutations of the reference—WT—repeat motif on the saturation concentration (C_{sat})—defined as is the concentration at which the T_i is 37°C —of the A-IDPs. We found that single residue changes in the octapeptide repeat are capable of changing the C_{sat} —normalized to the degree of substitution defined by the percent change in amino acid composition—of the repeat polypeptide by over by two orders of magnitude at constant molecular weight that ranged from 1-800 μM (FIG. 8D, E and F). This can be visualized by normalizing to the saturation concentration of [WT]-40 which is conveniently $\sim 1\ \mu\text{M}$ and is shown by the dashed horizontal line in FIG. 8F. We do not believe that changes in chain conformation as a result of these mutations is responsible for these effects on the T_i and C_{sat} . Indeed, circular dichroism spectrophotometry shows that the mutant A-IDPs are structurally disordered, consistent with their G- and P-rich composition (FIG. 10).

These substitutions present quantitative evidence for the importance of interactions between R and aromatic residues in the repeat motif of the A-IDP. When Y_7 is substituted, we observe dramatic shifts in the UCST cloud point at $\phi = 10^{-3}$, from 66°C to 123°C , 59°C and $\sim 2^\circ\text{C}$ for W, F or H respectively (FIG. 9A). These data indicate that interactions between the cationic side-chain of R and the aromatic side-chain of W, F, Y and H are important driving forces for phase separation, although the strength of these interactions is side-group dependent with $W \gg Y > F \gg H$. Likewise, replacing R for K lowers the UCST cloud point temperature and hence the phase boundary (FIG. 8E) and increases the C_{sat} (FIG. 8F).

We next looked at the effect of A-IDP MW on phase behavior; we chose A-IDPs with MWs between ~17kDa and ~70kDa, as this MW range covers 75% of the IDRs in our proteomic analysis of native IDPs (FIG. 8B). Our results indicate that MW exhibits at least as large an effect on UCST cloud point as amino acid substitution (FIG. 11A). We observed that the effect of MW on T_i —in the ~17–70 kDa range that we studied—can be approximated with a linear fit to the natural logarithm of MW (FIG. 11B). By simply doubling the MW of [WT]-40, we were able to create A-IDPs with predicted C_{sat} in the nanomolar regime (FIG. 11C), similar to the C_{sat} exhibited by some native IDPs. Notably, by varying both the MW and composition we can vary the C_{sat} of A-IDPs by over seven orders of magnitude, ranging from 10^{-4} to $10^2 \mu\text{M}$.

In addition to composition, concentration (ϕ) and MW on T_i , there are several other parameters that have a measurable effect on UCST phase behavior but that do not eliminate UCST phase behavior under physiologically relevant conditions. Uncharged polar substitutions, the ratio of G/P, the syntax of the repeating polypeptide, solution salt content, pH (in the absence of H) and identity of the negatively charged amino acid (E vs. D) all result in smaller changes to the UCST binodal phase boundary than MW, volume fraction, aromatic:aliphatic amino acid ratio and R content (FIG. 9B–C). The residue N-terminal to P_6 appears to have a unique impact on the UCST binodal boundary where compositionally identical A-IDPs shifted the UCST binodal lines depending on which polar non-charged residue is located at position 5 of the octapeptide repeat (FIG. 12A). We also produced and tested non-repetitive, but compositionally identical versions of [WT]-20 and observed minimal effects of scrambling the amino acid sequence on the UCST binodal (FIG. 12B). Collectively, these results indicate that three parameters—the aromatic:aliphatic ratio, the volume fraction (ϕ), and the MW are the most important for controlling UCST phase boundaries or C_{sat} *in vitro*.

A-IDPs create dense phase separated condensates at saturation concentrations mediated by amino acid composition

Having observed that C_{sat} and the binodal phase boundary in the dilute regime of the UCST phase diagram of A-IDPs can be modified drastically by amino acid substitution, we were interested in the factors that modulate the high concentration regime of the phase diagram of A-IDPs. Polypeptides [WT]-20 and [Q_{5,8}]-20 express extraordinarily well for recombinant proteins, with yields of ~500 mg L⁻¹ in shaker flask culture, which made it easy to purify over one gram of material to measure the UCST cloud point behavior at high-volume fractions of these A-IDPs directly (> 0.1). To minimize the amount of material required, these experiments were performed in a multiplexed linear temperature gradient microfluidic device mounted on an upright light

microscope, wherein the T_1 could be quantified by the temperature at which phase separation occurs by a visible increase in light scattering intensity. These experiments produce binodal phase boundaries similar to optical turbidity measurements that are typically carried out in a UV-vis spectrophotometer (FIG. 13) and demonstrate that a $\sim 25^\circ\text{C}$ difference between the two binodal lines of [WT]-20 and [Q_{5,8}]-20 is maintained over the entire range of volume fractions tested. This corresponds to an increase in A-IDP volume fraction in the dense phase (ϕ_2) from $\phi_2 = 0.4$ for [Q_{5,8}]-20 to $\phi_2 = 0.55$ for [WT]-20 at an isotherm of 37°C . In addition to these phase diagram descriptions, phase separation in the presence of low (10kDa) and high (40kDa) MW fluorescently labeled dextran indicate that both [WT]-20 and [Q_{5,8}]-20 droplets are highly exclusionary, as we observed no fluorescence partitioning of dextran into the dense phase (FIG. 14A–B). These data in combination with our ability to easily purify A-IDPs from bacterial cell lysate with phase separation indicate that A-IDPs form highly exclusionary droplets *in vitro* at physiological solution, temperature, and pH conditions ($\phi_2 > 0.4$).

15 A-IDPs have controlled C_{sat} in eukaryotic and prokaryotic cell lines

With a set of A-IDPs that exhibit a range of T_1 as a function of concentration, and C_{sat} that vary over seven orders of magnitude we sought to understand: (1) the dynamics of droplet assembly in living cells, and (2) to elucidate if it proceeds *in vivo* similarly to *in vitro*. To explore these two issues, we chose a set of IDPs that have a range of C_{sat} from 1 to 815 μM with MWs of either ~ 17 kDa or ~ 32 kDa. To visualize localization of the A-IDPs within bacterial cells, each A-IDP was genetically fused to a super folder version of green fluorescent protein (sfGFP) (FIG. 15A).

Fusion of sfGFP to A-IDPs to [WT]-20, [WT]-40, [3Y₇:V₇]-40, [Y₇:V₇]-40 did not eliminate the phase behavior but shifted the phase diagram (FIG. 15B and FIG. 16). Despite this shift, using confocal fluorescence microscopy, we were able to observe the formation of intracellular droplets of [WT]-20-sfGFP in both transfected human embryonic kidney (HEK) cells and *E. coli* (FIG. 15C and FIG. 15D, respectively). Interestingly, in the *in vitro* environment of an aqueous droplet in oil, we observed that nucleation occurs at multiple points in the aqueous compartment, but with time all the individual coacervate puncta coalesce into a single, large coacervate puncta. This indicated a lack of any significant energetic barriers to diffusion or coalescence. In HEK cells nucleation of coacervate puncta also occurred at multiple locations throughout the cell. However, unlike the *in vitro* situation, these puncta never coalesced into a single coacervate droplet so that individual coacervate puncta in the 2–4 μm diameter range remained dispersed throughout the cytosol of the HEK cell (FIG. 17).

In contrast, phase separation in *E. coli* is significantly different from eukaryotic cells. The initiation of the UCST phase transition in *E. coli* is similar to HEK cells—and *in vitro*—where small densely fluorescent puncta form after the A-IDP concentration in the cell exceeds C_{sat} , that then grow in size over time (FIG. 15G). The growth in the size of these puncta, as more A-IDP is expressed with time, is consistent with measurements of sfGFP fluorescence from the bulk *E. coli* population normalized to the absorbance at 600 nm (OD_{600}). The increase in fluorescence with time indicates that the intracellular concentration of the A-IDP-sfGFP fusion increases with increased protein induction time (FIG. 18). Unlike HEK cells however, but similar to *in vitro* experiments, these puncta in *E. coli* coalesce to form a single coacervate droplet per cell (Table 6). This result suggests differences in the diffusivity of the A-IDP between the prokaryotic and eukaryotic cytoplasm and suggest that the barriers to diffusion and coalescence of coacervate droplets in *E. coli* are far lower than in HEK cells. Simultaneously, the residual dilute regime remains at a relatively constant concentration (FIG. 19). Together, these results suggest that as the global concentration of the A-IDP within the cell increases with time, the cytoplasmic concentration of the protein is buffered—remains constant—but that the volume of the coacervate increases relative to the size of the cell.

Table 6. Number of phase-separated domains per *E. coli* as a function of induction time (n = 3 images)

Time Post-Induction (hr)	[WT]-20-sfGFP	[WT]-40-sfGFP
2	N/A	1.01 ± 0.02
6	1.03 ± 0.01	1.03 ± 0.03
10	1.13 ± 0.01	1.10 ± 0.09

Similar to *in vitro*, the MW and aromatic:aliphatic content affect droplet formation in *E. coli*. Doubling the MW of [WT]-20-sfGFP to [WT]-40-sfGFP decreases C_{sat} enough to cause droplet formation even prior to A-IDP induction, presumably because of leaky transcriptional regulation (FIG. 15D). Similarly, increasing the aliphatic content with V at the expense of Y increases the C_{sat} to a concentration that is not measurable in the time course of these experiments (FIG. 15E). Although differences in C_{sat} *in vivo* are not as dramatic as predicted by *in vitro* experiments with A-IDP-sfGFP fusions (FIG. 22F), perhaps because of the effect of intramolecular crowding within the cell, we can modulate the intracellular C_{sat} by at least an order of magnitude using both MW and aromatic:aliphatic ratio of the A-IDP.

A-IDPs exhibit reversible UCST droplet formation in *E. coli*

Just as one can cross a binodal line into the two-phase regime under isothermal conditions by increasing polypeptide volume fraction, this line may be crossed under constant volume fractions by decreasing solvent quality or the chi parameter (χ). Experimentally this is most easily accomplished by reducing the temperature of the bulk solution. Similar to the UCST phase behavior of A-IDPs *in vitro*, A-IDPs exhibit reversible UCST phase separation inside cells that is reversible by repeated four cooling and heating cycles (FIG. 20A). The phase separation exhibits minimal hysteresis as the difference in the transition temperature of cooling (T_{LC}) and the transition temperature of heating (T_{LH}) varies by less than 2 °C (FIG. 20B).

Interestingly, upon multiple heating and cooling cycles, we observed that *E. coli* exhibit spatial phase separation memory, with puncta forming in the same location as the first cycle (FIG. 2). Additionally, we observed cooling-triggered phase separation results in a higher number of puncta per cell (FIG. 21). The greater number of puncta observed with higher MW species indicates that the number of puncta formed per cell is a function of their diffusion coefficient, consistent with prior studies.

Increasing the MW of the A-IDP increases the observed T_L in *E. coli* (FIG. 20C). By manipulating the aromatic:aliphatic ratio while keeping MW constant and observing the formation of puncta within individual bacterium at various times post-induction (varying intracellular concentration), we were able to create partial intracellular phase diagrams as a function of T_L and intracellular fluorescence (FIG. 20D). This result is important because it ties the observed behavior upon cooling to a specific concentration for a given construct, essentially normalizing the observed cloud point for differing overall levels of protein expression throughout the cell population. Again, with increasing concentration we see an increase in UCST cloud point, although the rate of increase upon increasing concentration does not appear to follow a log-normal dependence.

De Novo Design of Functional A-IDP Droplets in Cells

In order to understand the potential of using spatially confined intracellular coacervate droplets to carry out new functions, we asked the following questions: (1) Can coacervate droplets in cells recruit other molecules, and if so, what, if any, are the size limitations of such molecules? (2) Can these molecules interact with the A-IDP to impart a new function to the droplet?

To answer these questions, we first examined whether a small molecule could diffuse into and react with the A-IDP in a coacervate droplet located within an *E. coli* cell. We designed and expressed an A-IDP—[3Y₇:V₇]-40-UAA—that carries three copies of a unique biorthogonal

reactive group—an azide; its primary amino acid sequence is listed in Table 3. After reaching intracellular concentrations greater than the C_{sat} of [3Y₇:V₇]-40-UAA, we incubated live *E. coli* with 1 mg mL⁻¹ dibenzocyclooctyne-dye (DBCO-Alexa488) for 10 min (FIG. 22A). After a single wash step to remove excess dye, we observed fluorescent condensates in the cells. These experiments also demonstrate that the ϕ_1 fraction is also labeled in addition to the condensates. These data clearly show that a small molecule can diffuse from the extracellular environment into preformed condensates created by A-IDP phase separation and react with the A-IDP.

Next, we asked if larger molecules such as proteins are also capable of interacting with an A-IDP puncta. To answer this question, we designed a droplet capture experiment based on split green fluorescent protein (GFP). We first verified if the two components of a split GFP can interact with each other to create a functional GFP molecule if one of the components is fused to an A-IDP. GFP-11-[3Y₇:V₇]-40-mRuby3 was co-expressed in the presence of GFP-1-10; because the IDP is fused to mRuby3, the A-IDP condensates fluoresce red and can be visualized by fluorescence microscopy within the cell. We see fluorescently active GFP only in the interior of the condensates as seen by the co-localization of green fluorescence with the red fluorescence from the A-IDP condensates, indicating that the fragments GFP bind to each other to create an intact and functional GFP molecules that fluoresces green (FIG. 237A). In contrast, in the absence of GFP-1-10 induction, there is minimal green fluorescent inside the red fluorescent condensates (FIG. 237B).

These results show that two protein fragments of GFP can find and bind to each other in the cell despite the steric hindrance imposed by an A-IDP and a fluorescent reporter fused to one fragment of the protein. It does not however, prove that a protein can be recruited after an A-IDP condensate has formed, as the protein partners in the previous experiment are co-expressed and could bind in the cytoplasm prior to phase separation that occurs once the intracellular concentration of GFP-11-[3Y₇:V₇]-40-mRuby3 exceeds its C_{sat} . To directly answer this question, we co-transformed *E. coli* with two plasmids—a Lac operon regulated plasmid that encodes one fragment of GFP (GFP-11) that is fused to [3Y₇:V₇]-40 and a second plasmid regulated by araBAD operon that encodes the other fragment of GFP (GFP-1-10). Once expression of GFP-11-[3Y₇:V₇]-40 at 37 °C proceeds long enough that its intracellular concentrations is greater than its C_{sat} , we removed the IPTG induction media, and replaced it with arabinose containing media that induce the expression of the larger GFP fragment (GFP-1-10). We observed that subsequent to arabinose induction, both the ϕ_1 and ϕ_2 fractions of the *E. coli* contained fluorescently active GFP (FIG. 22B). This result suggested that the large GFP fragment is capable of penetrating the preformed condensate in the cell, find its binding partner and form a fully functional molecule,

despite the fusion to the A-IDP. Once a fully functional GFP molecule is recruited into the intracellular droplets, it is then possible to dynamically modify the intracellular solubility of the reconstituted GFP–A-IDP by changing the temperature of the bulk (FIG. 24).

These experiments clearly show that small molecules and proteins can be recruited into intracellular coacervate droplets in *E. coli* and that a protein can be reconstituted within a coacervate droplet. These results suggested a path for the *de novo* design of intracellular coacervate droplets with new enzymatic function. We chose biocatalysis as the function of interest, because one of the proposed reasons for the evolutionary development of biomolecular condensates is to modulate the kinetics of various biological functions, including enzymatic reactions. However, there is little experimental evidence demonstrating how the function of enzymes is modulated by phase separation.

To investigate this, we created an A-IDP fusion that can recruit an enzyme into intracellular droplets to modulate its catalytic activity. We chose β -galactosidase for two reasons: (1) it has a range of small molecule substrates, one of which, Fluorescein Di β -Galactopyranoside (FDG), is colorless but when cleaved by β -galactosidase, will fluoresce green. Thus, using a combination of a red fluorescent protein tagged to our enzyme-A-IDP fusion and fluorescein fluorescence we can track the colocalization of enzymatic reactions with A-IDPs in real time. (2) We had concerns that a large enzyme fused to a large A-IDP would not express at high enough concentrations in *E. coli* and thus not phase separate *in vivo*. To alleviate this concern, we took advantage of the widely used β -galactosidase (LacZ) blue-white screening system, where the alpha peptide (α p) complements the mutated enzyme LacZ Δ M15 to create a functional β -galactosidase enzyme. In our system, the α p is fused to a A-IDP-mRuby3 construct, such that enzyme activity is physically linked to the A-IDP which in turn is physically linked to red fluorescence.

Our studies with the DBCO-Alexa488 and split GFP provided the basis for this more complicated experiment. The DBCO-Alexa488 experiment suggested that a small molecule such as an enzyme substrate can penetrate puncta, even if delivered extracellularly (FIG. 22A). The split GFP experiment suggested that relatively large proteins can be recruited to A-IDP condensates to form functional proteins, suggesting that the same should be possible with the split β -galactosidase system (FIG. 22B). This peptide binding system also represents a more ubiquitous, engineered puncta platform as there are a number of split enzyme systems or small protein motifs that have been engineered to bind various intracellular targets.

Thus, we genetically fused the α -peptide (α p) from LacZ β -galactosidase to a A-IDP-mRuby3 construct. Our hypothesis is that the α p-A-IDP-mRuby3 protein can bind and recruit the other fragment of the enzyme—LacZ Δ M15 that has an α -peptide deletion—that is expressed

endogenously in genetically modified *E. coli* (KRX, Promega) into intracellular droplets. After protein induction and resulting condensate formation, we deliver the substrate Fluorescein Di β -Galactopyranoside (FDG) to the cell medium where it is trafficked intracellularly, hydrolyzed into fluorescein at the sites of active β -galactosidase, and eventually exported outside the cell (FIG. 22C). By tracking the onset of the green fluorescence of fluorescein with confocal microscopy we can specifically observe where and when enzymatic activity is occurring within the cell and quantitatively track enzyme activity.

In our control experiment— α p-mRuby3—we observe limited persistence of fluorescence within the cells. It is important to note that the α -peptide itself is known to form inclusion bodies, and therefore, even in this control experiment, we observe some puncta inside the bacterial cells. However, upon fusion with [WT]-20, we observe that the fluorescence localizes long enough with the A-IDP condensates to be observed with confocal microscopy (FIG. 22D). Despite this increased colocalization, the total fluorescent production over time is not statistically significant from the α p-mRuby3 control (FIG. 22E).

When we increase the MW of the A-IDP, and thus decrease C_{sat} , we observe a dose-response effect in the total FDG fluorescence intensity as well as colocalization with the α p-A-IDP-mRuby3 fusion (FIG. 22D). α p-[WT]-40-mRuby3 and α p-[WT]-80-mRuby3 have 2.5X and 7.5X greater FDG converted at 20 minutes compared with the α p-mRuby3 control (FIG. 22D and FIG. 25). Quantification of the colocalization of green and red fluorescence with Mander's overlap coefficient indicates increased colocalization when the α -peptide is fused to A-IDPs compared to the fluorescent reporter alone (FIG. 26). To quantify the observed colocalization, we analyzed individual cells within the image frame with green fluorescence that were above the background threshold at each timepoint. Higher MW A-IDPs exhibit higher fluorescence inside the cell normalized to the background at each point in time (FIG. 22F). This dose-response effect of MW emphasizes a mechanism of increased persistence of the substrate molecule inside the droplets leading to more efficient green fluorescence conversion.

Quantification of fluorescence production at various substrate concentrations *in vitro* suggests that the mechanism of this effect is a statistically significant increase in the catalytic constant (K_{cat}) of the enzyme with increasing MW. This constant can be interpreted as the "turnover efficiency" of the enzyme or the number of catalytic events that occur per unit time. We observed 1.4X, 1.6X and 4.2X increase in the K_{cat} for α p-[WT]-20-mRuby3, α p-[WT]-40-mRuby3, α p-[WT]-80-mRuby3 compared to the α p-mRuby3 control (FIG. 27 and Table 7). Considering our previous observation of increased colocalization of product (fluorescein) and the labeled A-IDP as a function of MW, we propose that the observed increase in fluorescence is caused by

increased colocalization of the enzyme and substrate in the condensates, leading to a higher measured K_{cat} . We observed non-significant changes to the Michaelis-Menten constant (K_m) which describes the affinity of the enzyme for the substrate, suggesting that fusion of the A-IDP does not change the binding constant of the enzyme-substrate complex. Using K_{cat} and K_m , we can define a catalytic efficiency which also supports our hypothesis of an increase in the enzymes' efficiency within condensates with increasing MW of the A-IDP. This enhancement in enzymatic efficiency is on the order of magnitude of change observed by various protein engineering techniques used primarily to improve K_{cat} .

Table 7. Michaelis-Menten enzyme kinetic parameters (standard error of the mean, $n = 3$)

Protein	V_{max} (FI _{FDG} *min ⁻¹)	K_m (FI _{FDG})	k_{cat} (min ⁻¹)	k_{cat}/K_m (FI _{FDG} ⁻¹ *min ⁻¹)
ap-mRuby3	3708 ± 183.2	4972 ± 636.3	3.56 ± 0.10	7.43E-04 ± 1.02 × 10 ⁻⁴
ap-[WT]-20-mRuby3	2165 ± 35.02	5896 ± 380.5	5.10 ± 0.43	8.79E-04 ± 1.16 × 10 ⁻⁴
ap-[WT]-40-mRuby3	1549 ± 34.75	5988 ± 475.1	5.75 ± 0.13	9.81E-04 ± 9.96 × 10 ⁻⁵
ap-[WT]-80-mRuby3	2922 ± 174.9	4504 ± 439.7	15.2 ± 0.68	3.45E-03 ± 4.58 × 10 ⁻⁴

We also fused the LacZ alpha peptide to A-IDPs with differing levels of aromatic content at a constant MW (FIG. 28A). We hypothesized that differing levels of aromatic content would affect FDG uptake into the droplets and therefore affect overall enzymatic activity. Surprisingly, we observed similar overall levels of fluorescence between ap-[WT]-40-mRuby3, ap-[3Y₇:V₇]-40-mRuby3 and ap-[Y₇:V₇]-40-mRuby3. However, the dynamics of enzymatic activity are different, with A-IDPs of greater aliphatic content allowing for faster uptake into the condensates (FIG. 28B). The differences between the ratio of FDG fluorescence inside the cell and outside the cell between ap-A-IDP-mRuby3 fusions with different aliphatic content were insignificant, indicating that MW is the primary driving force for fluorescein and/or FDG persistence inside intracellular droplets (FIG. 28C). Completely deleting the aromatic residues from the repeat unit of the A-IDP results in apparently soluble enzymes that do not form intracellular condensates, and whose activity is lower than the enzyme formed by complementation of LacZΔM15 with the ap-mRuby3 fusion that has no A-IDP tag (FIG. 29A–B).

We show herein A-IDPs that consist of repeats of an octapeptide motif inspired by native IDP exhibit reversible UCST phase separation in aqueous solution. Despite the simplicity of their sequence, they recapitulate many of the features seen in more complex, native IDPs. The formation and dynamics of their phase separation into coacervate droplets are controlled by two simple design parameters that are genetically encodable at the sequence level—MW of the A-IDP and the ratio of aromatic:aliphatic residues in the octapeptide repeat. Using these two parameters—aromatic:aliphatic ratio and MW—we were able to produce A-IDPs with C_{sat} s ranging

from nanomolar to millimolar concentrations. This work supports the growing evidence of R-aromatic interactions that drive phase behavior and also adds additional evidence of the molecular hierarchy that exists between the aromatic groups W, Y, F and H in modulating UCST phase behavior. Although the IDP literature often ignores the importance of MW, our results suggest that MW may be more critical than composition for defining the UCST binodal. We anticipate that these results will inform and dramatically shift the strategy for mutating native IDPs and designing *de novo* IDPs.

These design parameters faithfully translate from *in vitro* to intracellular environments. The A-IDPs phase separate inside cells by the same principles that drive their UCST phase separation *in vitro* indicating that the same thermodynamic driving forces embedded in the sequence and molecular weight also modulate droplet formation dynamics in isolation. Due to the simplicity of their design, A-IDPs behave *in vivo* as their phase diagrams *in vitro* suggest—as their intracellular concentration increases to a C_{sat} , small phase separating droplets form at individual points in space that continue to grow in size with increasing overall A-IDP concentration inside the cell. This predictable observation has been theorized by previous studies but has not been conclusively demonstrated until now.

Finally, these proteins can be used for the *de novo* design of functional intracellular droplets. We rationally designed intracellular puncta capable of binding and recruiting a β -galactosidase deletion mutant, which could modify the catalytic efficiency of the enzyme-substrate complex—a complex which has not evolved to form intracellular condensates. The catalytic efficiency of the reconstituted enzyme in phase separated coacervate droplets is MW dependent and increases with the MW of the A-IDP. Higher MW A-IDPs more efficiently sequester the substrate in the enzymatically active, intracellular phase separated puncta, which results in a higher catalytic efficiency as measured by K_{cat} . These proof-of-concept experiments demonstrate that intracellular droplets can be engineered to have non-canonical functions in live cells and provide a new platform for intracellular material manipulation. In summary, with over 60 IDPs synthesized for this study that span a range of C_{sat} , and proof of concept experiments recruiting proteins into coacervate droplets within a cell and thereby modulating protein function, these studies lay the groundwork for the *de novo* design of functional intracellular condensates. We expect that these A-IDPs will be useful as building blocks from which new biological condensates with emergent behaviors can be built within living cells to better study the functional significance of phase separation in living cells and to encode new functions for droplets within cells. We also anticipate that these IDPs will prove useful in other biomedical applications beyond the design of intracellular droplets that can profit from their tunable UCST phase behavior. This marriage

of soft material science with biophysical characterization of subcellular materials will continue to be an exciting space for to engineer cells with new or improved function and new biomaterials.

Example 2

FIG. 30A–D shows examples of various fusion proteins that express at low levels in prokaryotic expression systems that when fused to disordered biopolymers rescue expression levels and using the phase separation behavior of the biopolymers allow for recovery into soluble fractions. This can be performed with mAb binding proteins that have a nanobody folded structure that bind to mAb (ZD), fluorescent fusion proteins that have beta-barrel structures (sfGFP), therapeutic protein peptides (GLP-1) with strong alpha-helical tendencies, RNA binding proteins (PUMHD) that have tandem repeat structures and antimicrobial peptides that exhibit cytotoxic tendencies in *E. coli*.

Table 8 shows the expression levels of various fusion proteins.

Table 8. Expression levels of various fusion proteins

Sequence	Protein Function	Titer	SEQ ID NO: (AA, DNA)
SKGP-(GRGDQPYQ) ₄₀ -ZD	mAb binding	~300 mg/L	284, 285
SKGP-(GRGDQPYQ) ₂₀ -ZD	mAb binding	~150 mg/L	286, 287
SKGP-(GRGDSPYS) ₄₀ -PKD2	AAV binding	~100 mg/L	288, 289
SKGP-(GRGDSPYS) ₄₀ -sfGFP	Fluorescent reporter	~50 mg/L	290, 291
GLP-1-(GRGDSP[3Y:V]S) ₂₀	Therapeutic	~200 mg/L	292, 293
GLP-1-(GRGDSP[Y:V]S) ₂₀	Therapeutic	~50 mg/L	294, 295
GLP-1-(GRGDSP[3V:Y]S) ₂₀	Therapeutic	~25 mg/L	296, 297
GLP-1-(GRGDSPYS) ₄₀	Therapeutic	~50 mg/L	298, 299
GLP-1-(GRGDSPYS) ₂₀	Therapeutic	~100 mg/L	300, 301
GLP-1-(GRGDSP[3Y:V]S) ₄₀	Therapeutic	~150 mg/L	302, 303
GLP-1-(GRGDSP[Y:V]S) ₄₀	Therapeutic	~50 mg/L	304, 305
GLP-1-(GRGDSP[3V:Y]S) ₂₀	Therapeutic	~50 mg/L	306, 307
AMP 1	Therapeutic	~25 mg/L	308, 309
AMP 2	Therapeutic	~20 mg/L	310, 311
AMP 3	Therapeutic	~50 mg/L	312, 313
SKGP-(GRGDSP[3Y:V]S) ₄₀ -PUMHD	RNA binding	~25 mg/L	314, 315
SKGP-(GRGDQPYQ) ₄₀ -PUMHD	RNA binding	~20 mg/L	316, 317

FIG. 31 shows the in incubating mAb with a phase separating biopolymer fused to a domain from protein A that binds mAbs. First, the biopolymer is bound to the mAb and centrifuged to capture the mAb heavy (HC) and light chain (LC). Then, the supernatant was removed, and the pellet was resuspended in an elution buffer that is a lower pH which causes dissociation between the biopolymer-ZD fusion and the mAb. The solution was spun again creating an elution

supernatant which contains pure mAb HC and LC that had few other protein contaminants. The elution pellet contained the biopolymer and no mAb.

FIG. 32 shows microscopic images of fluorescently labeled mAb (red/white in grey-scale) is visualized in the presence of phase separated protein ((GRGDQPYQ)₄₀, SEQ ID NO: 3 with m = 40) fused to the Z-domain of Protein A (ZD). The first frame shows colocalization of the droplets with a fluorescent signal. When the buffer pH is dropped at t = 0, there is an inversion in the fluorescent signal suggesting the mAb has completely dissociated from the phase separated protein-ZD fusion protein (white arrow) and entered the surrounding solution (red). These biopolymer-fusion proteins retain their liquid-like behavior as droplet fusion occurs between 60–240 sec.

FIG. 33 shows fusion proteins containing various AMPs fused to biopolymers. When the fusion protein is not expressed cell growth proceeds as normal measured by an increasing absorbance at OD₆₀₀. When the AMP alone is expressed, cell growth is stunted (. When AMP-biopolymer fusion protein is expressed, normal growth is recovered, suggesting reduced availability of the AMP.

Example 3

Effect of repetitive polypeptide design on *in vivo* release of glucagon like peptide 1 (GLP-1) from sub-cutaneous depots

We utilized the phase behavior of the repeat polypeptide, chemically inspired from naturally occurring IDPs, to control the bio-availability of resources when confined by a lipid bi-layer in bacteria and to control the assembly of micelles when sterically confined by a relatively hydrophilic ELP or RLP molecule exerting a surfactant like effect. We were motivated to test the efficacy of controlling bio-availability in a system where the dilute phase is attached to an infinite sink – where the dilute phase is in equilibrium with a biological system capable of protein clearance. The Chilkoti lab has extensive experience with subcutaneous delivery of peptide molecules in vertebrae animals in this exact set up, the primary focus on delivering therapeutic molecules for diabetes and various cancers, albeit exclusively with LCST polypeptides.

The delivery of peptides remains an outstanding challenge for drug delivery. Despite protein engineering improvements focused on improving half-life, their effective window lasts from minutes to a few hours rendering them unsuitable for therapeutic use. Interestingly, nature utilizes peptides in various biological applications, but regulation of their activity is often tightly controlled by a cellular population that can react to a phenotype change. Thus, man-made peptide drugs

require a delivery solution, one that can improve the pharmacokinetics of these valuable macromolecules.

The most common approaches to improve a peptide's half-life include protein engineering and changing the formulation to prolong release and/or reducing renal clearance. Sequence engineering—such as the incorporation of D-amino acids or other chemically esoteric amino acid derivatives—can limit proteolytic degradation of the protein, but severely limit manufacturing choices. Encapsulation methods produce inconsistent effects on bioavailability or require harsh production conditions that limit the type of peptide drug that can be delivered via these methods. Strategies to decrease renal clearance revolve around increasing the size of the molecule and reducing opsonization including attachment to synthetic or biological polymers that extend half-life, fusion to a large protein, and conjugating chemical moieties that allow the peptide to piggyback on endogenous biomolecules with slow turnover rates like albumin or antibody fragments. These strategies are not without limitations as they dramatically reduce potency and rely on a patient population to express these piggybacking biomarkers consistently between individuals.

These engineered polypeptides offer an elegant solution—through their primary amino acid sequence and molecular weight they control the dense and local dilute phase of the bioactive molecule effectively controlling the bioavailability of the drug. Unless proteases possess the unique ability to diffuse into the dense phase of the polypeptide-peptide drug depot, the availability of peptide drug is mediated exclusively by the primary amino acid sequence of the polypeptide. This local dilute phase can then diffuse from the subcutaneous space into circulation and exert a therapeutic effect. Using the principles of polypeptide design described herein we can rationally design drug release depots that can prolong the half-life of the peptide drug *in vivo*.

For this study, the relevant peptide drug is GLP-1, which is a 31 amino acid peptide produced in the L cells of the intestines, capable of exerting blood glucose control over a large therapeutic window. Previous experience with GLP-1-polypeptide depots revealed much about the design of sub-cutaneous depots for drug release. (1) Fusion of a macromolecule such as the polypeptide ELPs reduce potency of the GLP-1 molecule by about ~30 fold but this does not preclude *in vivo* activity. (2) Zero order release can be achieved for up to 10 days in mice and 17 days in monkeys under optimal conditions. (3) Optimal conditions are an injectable transition temperature 5–7 °C below the body temperature of the animal and a molecular weight of 35 kDa or greater to avoid renal clearance. This optimal 5–7 °C below body temperature corresponds to a dilute phase concentration of approximately 1–100 μM where non-optimal depots exhibited C_{sat} s an order of magnitude above and below this optimal range.

The peptide drug of choice for these experiments is GLP-1 for several reasons. (1) GLP-1 can rapidly exert a therapeutic effect *in vivo*. (2) GLP-1 is a prime candidate for improved pharmacokinetics with a half-life of ~5 min *in vivo*. (3) GLP-1 can be easily studied in established mice models of diet induced obesity where a high fat diet increases the blood glucose. 4) GLP-1 is a stable peptide drug which will eliminate confounding variables associated with genetic fusion to various polypeptide partners and myriad delivery strategies.

Previous studies suggested that transition temperature at injection concentration is the important parameter for determining efficacy. However, this misjudges the important isotherm on the phase diagram to be room temperature instead of the operating temperature of the depot which is defined by the animals resting body temperature. In subcutaneous mice models, this temperature is approximately 35 °C. Thus, we are looking proteins with variable dilute phase concentrations, at an isotherm of 35 °C (similar to a saturation concentration at 35 °C) and different molecular weights to test to observe how these two variables affect the bioavailability of GLP-1.

A potentially confounding effect of this study is the method of delivery. With polypeptides that exhibit a UCST, to achieve C_{sat} that are equivalent to the range of C_{sat} previously tested with LCST polypeptides, the solution cloud point of the polypeptide will often be dramatically higher than the body temperature of the animal. Thus, one of our first tests will be establishing depots using either solubilizing small molecules (urea) that can diffuse from the injection site more rapidly than the polymer, thus enabling the polypeptide to be injected in a soluble solvent that rapidly exchanges with the environment to become a poor solvent, forming a depot (FIG. 34). Secondly, we physically implanted a desiccated depot of a prescribed shape, size and dose that will rehydrate and begin to release active polypeptide after an initial delay (FIG. 34). We searched for consistent dosing that rapidly produces depots of similar size in the sub-cutaneous space.

Next, we designed polypeptides of similar molecular weight that exhibit different C_{sat} . We will achieve this feat by utilizing the same parameter as before, the aromatic:aliphatic ratio to rationally tune the binodal of the GLP-1-polypeptide fusion. This allowed us to observe the effect to C_{sat} on the therapeutic efficacy of the fusion. However, C_{sat} is just one parameter that affects bioavailability. The overall size of the molecule is also critical to the diffusion/convection in the subcutaneous space. Thus, using similar ranges of C_{sat} we will test depots for delivery as we increase the molecular weight of the molecule overall. Previous studies by previous lab members have demonstrated that there diminishing returns of molecular weight beyond ~35 kDa.

Gene synthesis

Each octapeptide amino acid motif with the desired saturation concentration were genetically fused to the C terminus of GLP-1. To increase the number of total repeats of the gene, we performed iterative cloning steps of Recursive Directional Ligation by Plasmid Reconstruction adding an addition twenty repeats during each step. Transformations were performed into the
5 desired *E. coli* cell line – BL21 (DE3) for recombinant expression.

Protein purification

Individual liquid cultures of BL21 *E. coli* strains each harboring our gene of interest were inoculated into 5 mL of Terrific Broth (TB) medium from frozen glycerol stocks and grown to
10 confluence overnight (16-18 hours). Cultures were then inoculated at a 1:200 dilution in 1L TB media supplemented with 45 $\mu\text{g mL}^{-1}$ kanamycin. Cells were grown at 37 °C in a shaking incubator (~200 RPM) for 9 hr, at which time protein expression was induced by the addition of 500 μM Isopropyl- β -D-thiogalactoside (IPTG). Cells were then incubated at 37 °C (shaking at ~200 RPM) for an additional 18 hr. Protein was then purified from the insoluble cell suspension
15 fraction. In brief, cell pellets were isolated by centrifuging cultures at 3500 RCF and resuspending in 20 mL of milli-Q water. Cells were then lysed by sonicating the cell solutions for 2 minutes, with 10 seconds of pulsing followed by 40 seconds of rest on ice (Misonix; Farmingdale, NY)

Centrifuging each lysate suspension at 20,000 RCF for 20 minutes results in a soluble and insoluble fraction. The supernatant was discarded with the insoluble fraction resuspended in
20 an approximately equal volume of 8 M urea + 140 mM PBS (~6–8 mL). This suspension was heated for 10 min in a 37 °C water bath and then centrifuged at 20,000 RCF for 20 minutes. The supernatant was collected from this suspension and dialyzed in a 10 kDa membrane (SnakeSkin™, Thermo Fischer Scientific) against a 1:200 milli-Q water solution at 4 °C. The dialysis water was changed twice over a 48-hour period. From inside the dialysis bag, both
25 insoluble and soluble components were collected and centrifuged at 3500 RCF for 10 minutes and 4 °C. The supernatant was removed and the remaining insoluble pellet containing the protein of interest was lyophilized for a minimum of three days to remove all water from the pellet.

Protein purity was characterized by 4–20% gradient tris-HCl (Biorad, Hercules, CA) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and staining with either
30 0.5 M copper chloride or SimplyBlue™ SafeStain (Thermo Fischer Scientific). Protein yield was determined by weight after lyophilization.

Temperature dependent UV-vis spectrophotometry

Turbidity profiles were obtained for each of the constructs by recording the optical density as a function of temperature ($1\text{ }^{\circ}\text{C min}^{-1}$ ramp) on a temperature-controlled UV-vis spectrophotometer (Cary 300 Bio; Varian Instruments; Palo Alto, CA). The transition temperature (T_i) was defined as the inflection point of the turbidity profile. Samples were measured in PBS at 10 μM .

Animal husbandry

All experimental procedures were conducted under protocol A053-15-02 approved by the Duke Institutional Animal Care and Use Committee (IACUC). 6-week old, male C57Bl/6J mice were purchased from Jackson Labs (strain 000664) and group housed in a room with a controlled photoperiod (12 hr light/12 hr dark cycle) and allowed at least 1 week to acclimate to the facilities prior to that start of procedures. Animals had unlimited access to water and food and were observed daily for signs and symptoms of distress. The diet-induced obese (DIO) phenotype was achieved by maintaining the mice on a high-fat (60 kcal% fat) diet upon arrival to the facility.

Endotoxin removal

Constructs were endotoxin purified prior to injection by passing the solution through a sterile 0.22 μm Acrodisc filter comprised of a positively charged and hydrophilic Mustang® E membrane (Pall Corporation). Constructs were filtered in 2 M urea + 140 mM PBS at $37\text{ }^{\circ}\text{C}$ and then dialyzed against milli-Q H_2O at $4\text{ }^{\circ}\text{C}$, changing the water three separate times over the course of 72 hours. Aggregated material was removed from the dialysis bag and pelleted with centrifugation ($4\text{ }^{\circ}\text{C}$, 3500 rpm). Samples were frozen and lyophilized for a minimum of 48 hrs.

Method of establishing GLP-1 releasing sub-cutaneous depots

In one method, the polypeptide is resuspended at 175 μM in 2 M urea + 140 mM PBS. A total volume of 200 μL is injected into the right hind flank after shaving and removing all hair with chemical dissolution at the site of injection. Mice were weighed to determine injection volume required for ~2100 nmole of GLP-1 per kg of animal weight. Injection volume did not exceed 200 μL . In a second method, a small incision is made on the right hind flank with surgical scissors after animals were anesthetized with isoflurane. Incision site was pre-sterilized according to Duke husbandry guidelines. Pre-weighed, dehydrated polypeptide pellets are then inserted under the skin. The pellets rapidly rehydrate and become adherent to the skin tissue and thus for sealing the incision site, only a small amount of surgical glue was used to secure the skin flap.

Blood glucose measurement and weight measurements

Mice were put into a clear restraining tube. Their tails were wiped with 50% ethanol in sterile water and then dried. A small incision was made adjacent to the tail vein using a small lancet. The first drop of blood was blotted away. Blood glucose was quantified by applying the second drop of blood to the test strip of an AlphaTRAK 2 blood glucose meter (Abbott Laboratories). Weight was measured on a scale zeroed with a container into which the mice were briefly placed.

Statistical analysis

Experimental numbers for both *in vitro* and *in vivo* studies were selected based on knowledge gleaned from previous experiments or other published data. Because of the small sample size ($n \leq 6$), normality of groups was not tested. Variance across groups was similar except in untreated versus treated *in vivo* groups, which is not unexpected given the lack of glucose control in the mouse models tested. Blood glucose and percent change in weight studies were analyzed using repeated measures ANOVA, followed by lower order ANOVAs and Dunnett's Test for multiple comparisons. For comparing two groups, two-tailed Student's t-tests were used. No blinding was performed. Analysis and data processing were performed using Igor and R software.

Results

We envisioned two strategies with the potential to establish depots subcutaneously for the UCST polypeptides which have transition temperatures far above safe biological temperature ranges, precluding a soluble to insoluble transition upon cooling to body temperature. The two strategies are to 1) employ urea to lower the solution cloud point for injection and 2) injection of a concentrated, dehydrated GLP-1-IDP fusion that will rehydrate, releasing peptide fusion. We decided to directly visualize this effect via fluorescent tomography. We chose a model IDP, (Gly-Arg-Gly-Asp-Ser-Pro-Tyr-Gln)-40 which has a predicted transition temperature of $>70^\circ\text{C}$ at the injection concentration necessary ($175\ \mu\text{M}$ or $1.2\ \text{mg}$ which corresponds to equivalent doses of GLP-1-ELP fusions used in previous studies, $1000\ \text{nmole kg}^{-1}$). Using a near infrared fluorescent tag (CW800) attached via NHS-ester chemistry at free amines, we visualized the localization of the polypeptide in the hind flank.

We know that inclusion of $1\ \text{M}$ urea in solution with the polypeptide will reduce is observed cloud by point by $\sim 25^\circ\text{C}$. Thus, by resuspending the model polypeptide in $2\ \text{M}$ urea + PBS at $175\ \mu\text{M}$ we can inject in a soluble state under ambient conditions. We hypothesize that

considering the two order of magnitude difference in molecular weight between urea and the model polypeptide, urea will rapidly diffuse out of the sub-cutaneous space, leaving the remaining polypeptide in a poor solvent and thus will transition *in situ*.

Upon injection we observe something akin to a “burst” release of the polypeptide (FIG. 35). This is characterized by a large area of fluorescence with a center of mass along the axis of the injection path of the needle. Over the first 8 hours this center of mass reduces in intensity, slowly reaching an equilibrium shape over the first two days. This center of mass disappeared by day 14.

We also injected a dehydrated coacervate that had the same total protein content as the urea experiments. Here we observe a completely different behavior. Although our initial intention was to use convective flow from the syringe to push the dehydrated depot from the needle point into the subcutaneous space, upon contact with water, the dehydrated depot becomes extremely adhesive to the hydrophobic needle (FIG. 36). Thus, we implanted the material with forceps, placing the dehydrated pellet underneath the skin through a small incision. Upon implantation, we observe an extremely small area of fluorescent that slowly expands over the first 90 minutes. The center of mass of the implant does not move noticeably over the course of two weeks. However, the mass of the depot is decreasing over this time, slowly releasing material surrounding the depot primarily during the first three days of implantation. Comparing these two injection strategies, we decided to move forward with the dehydrated depot strategy due to the lack of burst release and the increased persistence of the depot.

Fusion of GLP-1 to the N terminus of polypeptides was generally well tolerated. We observed minimal loss in yield from recombinant expression with most constructs expressing between 25–50 mg L⁻¹. As mentioned previously, we wanted to design peptide-polypeptide fusions that have C_{sat} in the general ranges of ~0.1, 10, >100 μ M corresponding to slow release, optimal release and near soluble release from the depot. This roughly corresponds to the C_{sat} s predicted for [3Y:V]-20, [Y:V]-20 and [3V:Y]-20. [3V:Y]-20 was not expected to exhibit phase behavior under physiologic conditions and thus six His residues were fused to the C terminus of the polypeptide and purified from the soluble fraction with chromatography.

The phase behavior of these polypeptide fusions was measured as before with temperature dependent UV-vis spectrophotometry. In determining the UCST binodal line, we identify these two proteins indeed have the desired phase behavior with GLP-1-[3Y:V]-20 exhibiting a C_{sat} of ~30 μ M and GLP-1-[Y:V]-20 exhibiting a C_{sat} of ~500 μ M (FIG. 37). These roughly correspond to the values predicted by the RIDP of choice alone. As predicted GLP-1-[3V:Y]-20-His6X did not exhibit any phase behavior under physiologic conditions.

After endotoxin purification, 1.2 mg of GLP-1-[3Y:V]-20, GLP-1-[Y:V]-20 and GLP-1-[3V:Y]-20-His6X were weighed and implanted in the hind flank of C57Bl/6J mice that have been fed 60% fat diet. In addition to these 3 groups, there is an additional group that received a saline injection. Over the course of the study, we measured blood glucose via tail vein blood draws at 0, 1, 2, 4, 8, 24 hrs and then each day thereafter for a total of 8 days.

The blood glucose data can be visualized in FIG. 38. Overall, our strategy of implanting dehydrated depots was successful at controlling blood glucose. It is also positive that we are observing an effect of aromatic:aliphatic ratio, even in non-optimal molecular weight polypeptides. First, it is notable that in the early time points blood glucose drops at approximately same speed suggesting that even in the soluble control, there are limitations regarding the minimal time to observe an effect on blood glucose. Second, each experimental group exhibits elements of burst release, with the largest change observed for those constructs that form subcutaneous depots. This result suggests that upon solubilization there is a larger bolus dose that reaches the blood stream, which is reduced upon reaching an equilibrium state between depot release and protein clearance. Third, our depot forming formulations (GLP-1-[3Y:V]-20 and GLP-1-[Y:V]-20) each control blood glucose at least one additional day compared to the soluble RIDP control.

Measurements of the body weight of the mice provide supplementary information on the efficacy of our sub-cutaneous depots (FIG. 39). Again, we observe that our depot-forming proteins exhibit the greatest level of a burst release effect, resulting in the largest change in body weight in the first 2 days. This effect appears to be somewhat depot-dose dependent where the lower C_{sat} construct exhibits the largest depression in appetite. As expected, the saline injection does not affect body weight.

Body weight measurements also differentiate our two depot forming fusions from one another.

The high C_{sat} construct body weight measurements suggest that their efficacy has waned by day 5 whereas the low C_{sat} appears to be exerting a phenotypic effect until the end of the study (day 8).

These experiments mirror similar results of optimization experiments with GLP-1-ELP depots. There were diminishing returns of polypeptides with molecular weights exceeding 35 kDa but improvements to glucose control between 20–35 kDa. Thus, we explored creating higher molecular weight variants of GLP-1-RIDP fusions.

Increasing the molecular weight of polypeptide fusions produced a series that have C_{sat} s of 0.5, 7, and 60 μ M by progressively reducing the aromatic content with aliphatic substitutions. (FIG. 40). Another GLP-1 protein fusion was also made with 75% aliphatic content that did not exhibit UCST phase behavior under physiologic conditions. I also synthesized a molecular weight

control (GLP-1-[S]-20) that has similar C_{sat} to GLP-1-[3Y:V]-40 (7 μ M compared to 12 μ M) but is half the molecular weight.

The blood glucose measurements of mice with 2.0 mg depots implanted in their subcutaneous space can be visualized in FIG. 41. These proteins that exhibit variable C_{sat} also exhibit variable release from the depot in the subcutaneous space. The most hydrophobic depot, GLP-1-S-[40], appears to release the least amount of material suggesting that the depot biophysical properties is retarding a phenotypic effect of the peptide drug. The middle hydrophobic depots, GLP-1-[3Y:V]-40 and GLP-1-[Y:V]-40, with C_{sat} between 7 and 60 μ M, exert similar levels of glucose control that is nearly a full 24 hr improvement over the low molecular weight versions. The most hydrophilic "depot," predicted to be soluble can only manage glucose control over the first 24 hr. This is still an improvement from the soluble control at a lower molecular weight. These experiments support previous conclusions of optimal depot design, identifying that optimal release kinetics can be achieved with polypeptides that exhibit a C_{sat} between 7 and 60 μ M.

The effect of molecular weight, independent of C_{sat} , on blood glucose can be visualized in FIG. 42. Increasing the molecular weight but retaining a C_{sat} that is within an optimal release range can prolong glucose control by an additional two days. This effect is likely a result of delayed diffusion into the blood stream and prolonged drug half-life from delayed renal clearance.


Tracking the body weight of the mice supports the conclusions inferred from the blood glucose measurements (FIG. 43). Here the parabolic effect of depot hydrophobicity is clear—at the extremes of hydrophobicity and hydrophilicity there is a lesser burst release and shorter duration of weight control. The "optimal" constructs, GLP-1-[3Y:V]-40 and GLP-1-[Y:V]-40, are still exhibiting weight control at 7 days suggesting that there must be small amounts of material releasing from the depot even at 144 hours after implantation. The molecular weight control, GLP-1-[S]-20, exhibits lesser burst released and shorter duration of efficacy than its larger molecular weight analogue, GLP-1-[3Y:V]-40, again supporting the conclusion of delayed entry and prolonged persistence in the blood stream from higher molecular weight depots.

In summary, we designed mimetic fusions with the GLP-1-ELP system. We also discovered multiple new routes of establishing sub-cutaneous depots with unfavorable working transition temperatures. Using these two innovations we were able to create depots that performed with similar efficacy to previous GLP-1-ELP depots, controlling blood glucose for up to 5 days *in vivo* in a DIO mice model.

CLAIMS

What is claimed:

1. A polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;


Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and

Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

2. The polypeptide of claim 1, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.
3. The polypeptide of claim 1, wherein Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.
4. The polypeptide of claim 1, wherein the phase separation is dependent on temperature, molecular weight, hydrophobicity, aromatic:aliphatic ratio, and concentration.
5. The polypeptide of claim 1, wherein n is 10 to 200.
6. The polypeptide of claim 1, wherein the molecular weight is at least 5 kDa to 500 kDa.
7. The polypeptide of claim 1, wherein the molecular weight is about 5 kDa to about 100 kDa.
8. The polypeptide of claim 1, wherein the phase separation temperature is 0 to 100 °C.

9. The polypeptide of claim 1, wherein the phase separation temperature is 4 to 25 °C; ~25 °C; 25 to 37 °C; ~37 °C; 35 to 38 °C; or >38 °C.
10. The polypeptide of claim 1, wherein the polypeptide comprises modified amino acids, a reporter protein, or an enzyme.
11. The polypeptide of claim 10, wherein the sequence comprises:

$$(G-R-G-D-S-P-Y-S)_m,$$
 where m is 20 to 80.
12. The polypeptide of claim 1, wherein the polypeptide comprises a sequence selected from one or more of SEQ ID NO: 1–1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 197–279, or combinations thereof.
13. A pharmaceutically acceptable composition comprising a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;


Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and

Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

14. The composition of claim 13, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.
15. The composition of claim 13, wherein Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.
16. The composition of claim 13, further comprising an attached molecule comprising one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO: 159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195)..
17. The composition of claim 13, wherein the composition enhances bioavailability of the attached molecule as compared to the free form of the attached molecule.
18. The composition of claim 13, wherein the composition enhances recombinant expression of the attached molecule as compared to the free form of the attached molecule.
19. The composition of claim 13, wherein the composition enhances the stability of the attached molecule as compared to the free form of the attached molecule.
20. The composition of claim 19, wherein the composition enhances stability of the attached molecule during prokaryotic or eukaryotic expression as compared to the free form of the attached molecule.
21. The composition of claim 19, wherein the enhanced stability includes resistance to denaturation during freezing, thawing, lyophilization or prolonged storage at temperatures greater than 4 °C.

22. The composition of claim 13, wherein the composition modulates enzymatic, metabolic, or physiological functions within cells or organisms.
23. The composition of claim 22, wherein the modulation reduces bioavailability of the attached molecules.
24. The composition of claim 23, wherein the attached molecules comprise therapeutic or cytotoxic proteins or peptides.
25. A method for enhancing the bioavailability or stability of a protein, the method comprising creating a fusion protein of one or more proteins and a polypeptide with controlled reversible phase separation comprising ten or more repeats of an amino acid sequence comprising:



where:

X is proline (P) or glycine (G) and the ratio of P:G is any number;

Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D is any number and the ratio of K:R can be any number;

Z₂ is Asp (D), Arg (R), Glu (E), where the ratio of R:D can be any number and D:E can be any number;

Z₃ is asparagine (N), glutamine (Q), serine (S), or threonine (T) where the ratio among N:Q:S:T can be any number; and

Z₄ is tyrosine (Y), histidine (H), tryptophan (W), phenylalanine (F), methionine (M), valine (V), isoleucine (I), alanine (A), or leucine (L) and the ratio among Y:H:W:F:M:V:I:A:L can be any number.

26. The method of claim 25, wherein X is proline (P) or glycine (G) and the ratio of P:G is between 1:3 and 3:1.
27. The method of claim 25, wherein Z₁ is arginine (R), aspartic acid (D), or lysine (K) and the ratio of R:D does not exceed 1:5 and the ratio of K:R can be any number.
28. The method of claim 25, wherein the protein comprises one or more of an antibody binding domain derived from *Staphylococcus* protein A (ZD) (SEQ ID NO:159), an antimicrobial peptide selected from LL37 (SEQ ID NO: 161), Ib-M1 (SEQ ID NO: 163), Ib-M2 (SEQ ID

NO: 165), Ib-M5 (SEQ ID NO: 167), Cathelicidin-1 (SEQ ID NO: 169), A(A1R, A8R, I17K) (SEQ ID NO: 171), H5 (SEQ ID NO: 173), H5-61-90 (SEQ ID NO: 175); RGD peptide (RGDSPAS, SEQ ID NO: 39); protein drugs, GLP-1 (SEQ ID NO: 177); fluorescent reporters (sfGFP (SEQ ID NO: 179), mRuby3 (SEQ ID NO: 181); RNA binding proteins (PUM-HD (SEQ ID NO: 183), eIF4E (SEQ ID NO: 185), PABP (SEQ ID NO: 187), Tis11D (SEQ ID NO: 189)); KH domains (Yifan or FMRP (SEQ ID NO: 191)); or AAV binding peptides PKD1 (SEQ ID NO: 193) or PKD2 (SEQ ID NO: 195).

29. The method of claim 25, where the enhanced bioavailability of the fusion protein can be used for isolation or separation of a biologic molecule.
30. The method of claim 25, wherein the biologic molecule comprises one or more of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a viral particle.
31. The method of claim 30, wherein the nucleic acid is single stranded or double stranded DNA or RNA.
32. The method of claim 30, wherein the viral particle is an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or herpesvirus particle.
33. The method of claim 30, wherein the protein comprises albumin, monoclonal IgG antibodies, or Fc fusion proteins.
34. The method of claim 30, wherein the isolation or separation is accomplished via reversible phase separation.




FIG. 1B




FIG. 1C




FIG. 1A




FIG. 1D




FIG. 1E




FIG. 1F





FIG. 1G






FIG. 2




FIG. 3A




FIG. 3B

4/39







FIG. 4

5/39

**FIG. 5**

**FIG. 6****FIG. 7**




FIG. 8C




FIG. 8D




FIG. 8E





FIG. 8F






FIG. 9A




FIG. 9C




FIG. 9B




FIG. 9D

Tt @ $\Phi = 10^{-3}$

Y -> W	123
G -> P	90
D -> E	69
S/Y/R/D	66
S -> T	60
Y -> F	59
P -> G	54
S -> Q	45
Q -> N	34
Y -> H	2.3
R -> K	-8.9
Y -> M	-19
Y -> I	-47
Y -> V	-62
Y -> A	-65

FIG. 9E







FIG. 10

10/39

**FIG. 11A****FIG. 11B****FIG. 11C**




FIG. 12B

FIG. 12A




FIG. 12D







FIG. 12C

13/39

**FIG. 13A****FIG. 13B****FIG. 13C**




FIG. 14B







FIG. 14A

15/39


**FIG. 15A****FIG. 15C****FIG. 15B**



Higher Molecular Weight
Lower Csat
[WT]-20- sfGFP

[WT]-40- sfGFP

FIG. 15D





Higher Aliphatic: Aromatic Ratio
Higher Csat
[3Y7:V7]-40- sfGFP

[Y7:V7]-40- sfGFP

[Y7:3V7]-40- sfGFP

FIG. 15E

17/39

**FIG. 15F****FIG. 15G**




FIG. 16B

FIG. 16A






FIG. 16C

19/39

**FIG. 17****FIG. 18**




FIG. 19




FIG. 20A








FIG. 20C

FIG. 20D

22/39

**FIG. 21A****FIG. 21B****FIG. 21C**




FIG. 22B

FIG. 22A




FIG. 22C




FIG. 22E




FIG. 22F









FIG. 22D


25/39

**FIG. 23A****FIG. 23B****FIG. 24**





26/39

**FIG. 25A****FIG. 25B**

27/39

**FIG. 26**

28/39

**FIG. 27A****FIG. 27B****FIG. 27C****FIG. 27D**




FIG. 28B




FIG. 28C




FIG. 28A




FIG. 29A






FIG. 29B

31/39


(GRGDQPYQ)40-ZD

**FIG. 30A**


(GRGDQPYQ)20-sfGFP

**FIG. 30B**



GLP-1-(GRGDSP[3Y:V]S)20
GLP-1-(GRGDSP[Y:V]S)20
GLP-1-(GRGDSP[3V:Y]S)20

**FIG. 30C**

SKGP-(GRGDQPYQ)40-PUMHD
SKGP-(GRGDSP[3V:Y]S)40-PUMHD

**FIG. 30D**

32/39

**FIG. 31****FIG. 32**




FIG. 33

34/39




FIG. 34




FIG. 35








FIG. 36



36/39

**FIG. 37****FIG. 38**


37/39

**FIG. 39****FIG. 40**

38/39

**FIG. 41****FIG. 42**

39/39

**FIG. 43**

SEQUENCE LISTING

<110> DUKE UNIVERSITY
Dzuricky, Michael
Chilkoti, Ashutosh

<120> PROTEINS WITH PREDICTABLE LIQUID-LIQUID PHASE SEPARATION

<130> 028193-9340-W001

<150> US 62/985,179

<151> 2020-03-04

<160> 317

<170> PatentIn version 3.5

<210> 1

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 1

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		50				55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65					70					75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
				85					90					95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 2
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 2
ggacgcggcg atagtccata ttcaggtcgg ggagatagtc cctactcagg taggggagac 60
agcccatata gcgggcgtgg cgactctcca tatagtggga gaggggactc tccgtactct 120
gggcgcggtg attcaccata ttctggtcga ggtgactcac cttattctgg caggggtgat 180
agtccgtatt caggccgtgg tgattcccc tatagtggaa ggggagattc accgtatagt 240
ggtagaggcg acagtcctta ttcgggacga ggtgattctc cttatagtgg ccgaggggat 300
tcaccctatt ctggaagagg tgatagccct tattcagga ggggcgattc tccctattca 360
ggacgggggtg actctcctta ctccggtcgc ggagattctc catactcggg tcgtggagac 420
tccccatatt ccggcagagg tgacagtcca tacagtggac gtggggatag tccttacagt 480

<210> 3
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 3

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln

20

25

30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 145 150 155 160

<210> 4

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 4

gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 60

cagccttatc aaggtcgcgg tgatcaaccg tatcaaggta gaggggacca accatatcag 120

ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 180

caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 240

ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 300

cagccataacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa	360
ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcgat	420
caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag	480

<210> 5
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 5

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
1				5				10						15	

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
			20					25					30		

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
		35					40					45			

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
	50					55					60				

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
65					70					75				80	

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
			85					90						95	

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
			100					105					110		

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
		115					120					125			

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr
	130					135					140				

Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr	Gly	Arg	Gly	Asp	Thr	Pro	Tyr	Thr

145

150

155

160

<210> 6

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 6

ggacgtggtg acacccccta tacgggacgt ggagatacac cttacactgg acgcggtgat 60

acgccttaca ccggacgtgg cgatacacca tatactggta gaggtgatac accctataca 120

ggccgtggag acactccata cactggtcgg ggagacacgc catatacagg acgaggtgac 180

acaccttata ctggaagagg ggacacacca tacacaggtc gcggcgatac gccgtatact 240

gggagaggcg acactcctta tacagggcgc ggagataccc cgtacactgg gcgtggggat 300

actccgtata ccggtcgagg ggatacaccg tatacaggta ggggtgacac tccctatact 360

ggcaggggag atactcccta cactggccgg ggtgatactc cttacacggg tcgtggtgat 420

accccttaca caggaagggg cgatactcca tatacgggcc gaggcgatac cccatatacc 480

<210> 7

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 7

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
1 5 10 15Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
20 25 30Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
35 40 45Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
50 55 60

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
65 70 75 80

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
85 90 95

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
100 105 110

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
115 120 125

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
130 135 140

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
145 150 155 160

<210> 8
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 8
ggtcgaggcg ataaccgta taatggaagg ggagataacc cttataatgg tagaggggat 60
aaccatata atgggcgtgg cgacaaccg tacaatggca ggggcgataa tccctataat 120
ggacgaggtg ataacccta caacggacgc ggtgataatc catacaacgg gaggggtgac 180
aaccataca atgggagagg ggacaatcct tataatggcc gtggtgataa tccctacaat 240
ggtcgtgggg ataatccata taacggtcgc ggagataatc cttataacgg ccggggtgat 300
aatccgtata acggaagagg tgacaatccc tataacgggc gcggggacaa cccctataat 360
ggtaggggag acaaccctta caacggcaga ggcgacaatc catataatgg tcggggagat 420
aatccgtaca acggtagagg tgataatcct tacaatggac gtggagacaa tccgtataat 480

<210> 9
<211> 160
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 9

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
20 25 30

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
35 40 45

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
50 55 60

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
85 90 95

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
100 105 110

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
115 120 125

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
130 135 140

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
145 150 155 160

<210> 10

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 10
 gggcgtggag actctccaca tagcgaaga ggggacagtc ctcattcagg tcgggggtgat 60
 tccccctcatt cgggtcgagg tgattctcca cactcgggac ggggagattc tccccattct 120
 gggcgcggtg atagcccgc ttcaggacgc ggggactcgc cacatagtgg gagaggtgat 180
 agtccacaca gtggaagggg agatagtccc catagtggcc gaggggattc accacattcc 240
 ggtaggggag acagccctca tagtggacgt ggtgattcgc cgcatagtgg tagaggcgat 300
 agtcctcact caggaggagg cgattcaccc cactccggca ggggtgactc acctcacagc 360
 ggtcgtggag atagcccaca ttcaggccgt ggggatagtc cgcactctgg cagaggtgac 420
 agtccacatt ctggtcgcgg agattcacct cattctggac gaggcgactc cccccacagt 480

<210> 11
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 11

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 20 25 30

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 50 55 60

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 65 70 75 80

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 85 90 95

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser

100

105

110

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser
 145 150 155 160

<210> 12

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 12

ggccgcggcg attctccatt ttctggcaga ggtgacagcc ctttttccgg tcggggtgac 60

tctccgttct cgggacgtgg cgacagtcct tttagtggac gaggtgactc cccctttagt 120

ggccgtgggg attcaccgtt ttctgggaga ggggactctc cattcagcgg gcgtggtgat 180

tctccctttt caggccgagg ggatagtccc ttctccggca ggggtgattc acctttttca 240

ggacggggag atagtccttt ctccaggagg ggcgatagtc cgtttagtgg taggggagac 300

tctcctttca gtggaagggg agattcccca tttagtgggc gcggagattc tcctttttct 360

ggtcgaggtg atagcccatt ctctggaaga ggtgattcgc ctttttcggg tcgtggagat 420

tcaccatttt caggtcgcgg tgatagtcca tttagcggta gaggcgactc accctttagt 480

<210> 13

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 13

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
 1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser
145 150 155 160

<210> 14
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 14
ggacgaggtg atcagccgta ttcgggtcga ggggatcagc catattcagg tcgcggggat 60
caaccatact caggtagagg ggaccaaccg tattccgggtc gtggtgacca accatatagc 120
ggcaggggtg atcaaccgta tagtggtcgg ggtgaccaac cctattctgg taggggagat 180
cagccctatt caggacgcgg agatcaacct tactctggga gaggtgacca gccttacagt 240

ggaagggg	cg accagccata	tagtggccga	ggcgatcaac	cgtactcggg	acggggagat	300
caaccctata	gtggg	cgcggtgatca	accc tactccgggc	gtggcgatca	gccatacagc	360
ggacgtgg	tg atcaaccata	ttctggcaga	ggtgatcaac	cttatagtg	g acgtggagat	420
cagccttatt	ctggaagagg	cgaccaac	ct tattcaggcc	gtggggacca	gccctacagt	480

<210> 15
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 15

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			35					40					45		

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			50				55					60			

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
65						70				75				80	

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
				85				90						95	

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			115				120					125			

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
			130				135					140			

Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Ser
145					150					155					160

<210> 16
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 16	
ggacggggtg ataatccgta ttcgggacga ggtgataatc cctacagcgg cagaggtgac	60
aaccctact cagggagggg cgataatcct tacagtggaa ggggagacaa cccttactcc	120
ggtcgaggcg acaaccata tagcggacgt ggcgacaatc cgtatagtgg gagaggcgat	180
aacccttatt ccgggcgtgg ggataatcca tatagtggca ggggtgacaa tccctatagt	240
ggtagagggg acaaccgta ttctgggcgc ggggacaatc catattctgg aagaggtgat	300
aacccttatt ctggccgtgg agacaatcct tattcaggac gtggtgataa tccatactct	360
ggtcgtggag ataatccgta ctcggtcgc ggtgataatc cttatagtgg acgcggagat	420
aaccatatt caggtcgggg agataatccc tattcaggcc gaggggataa cccatacagt	480

<210> 17
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 17

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn
1				5					10					15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn
		35					40				45				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn

50

55

60

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn
145 150 155 160

<210> 18

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 18

ggtcgtggtg attctcctta taatgggcgt ggggattcac cttacaatgg acgaggtgat 60

agtccgtata atggaagagg tgactcccca tacaacggta gaggtgatag cccatataat 120

ggacgtggcg attctccata taacggcagg ggagatagtc catataatgg gaggggtgat 180

tccccctata atggtagggg agactctcca tacaatggga gaggtgattc gccgtataac 240

ggaagaggcg atagtcctta taacgggcgc ggtgattcac catataatgg tagaggggac 300

agcccttata atggaagggg cgactctccg tacaatggtc ggggtgactc acctataat 360

ggccgtggag attctcccta caatggcaga ggtgacagtc cttacaacgg acgcggggac 420

tcgccttata atggtcgagg ggatagtcct tataacggtc gcggagattc accctataat 480

<210> 19

<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 19

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
1 5 10 15

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln
145 150 155 160

<210> 20
<211> 480
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 20

```
ggacgtggtg ataatcctta ccagggacgg ggagataacc cgtaccaagg acgcggagat      60
aatccctacc agggccgggg tgataatccc tatcagggta gaggggataa cccctaccaa      120
ggccgtgggg acaaccgta tcaaggtcgg ggcgataacc cataccaagg gaggggtgac      180
aaccctatc aaggacgagg tgataaccct tatcaaggca ggggagacaa cccttaccaa      240
ggtcgcgggg ataatcctta tcagggcaga ggcgacaatc cgtatcaggg aaggggagat      300
aatccgtacc agggtcgagg cgataatcca tatcagggtc gtggcgacaa cccatatcaa      360
ggaagaggtg acaatccata tcaagggaga ggggacaatc cctatcaagg gcgcggtgat      420
aatccatacc aggggcgtgg agacaatcct tatcaaggta gaggtgataa tccgtatcaa      480
```

<210> 21

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 21

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
1           5           10           15
```

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
20           25           30
```

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
35           40           45
```

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
50           55           60
```

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
65           70           75           80
```

```
Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
85           90           95
```

Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn
145 150 155 160

<210> 22
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 22
ggacgtggtg atcaacctta caacggacgc ggagatcaac cgtacaatgg gcgcggggac 60
caaccctata atggttagagg cgaccagccc tataatggca gaggtgatca gccatacaat 120
ggtcgtggcg accaaccgta taacgggcgt ggagatcagc cgtataatgg aagaggggac 180
cagccttata atggtcgagg tgatcaaccg tataatggta ggggagatca accctataac 240
ggtcgcggtg atcaaccata caacggtaga ggggatcaac cttataatgg acgaggcgat 300
caaccatata acggaagggg tgaccagcca tataatggga gaggtgacca accatataat 360
ggtcggggtg atcaacccta caacgggagg ggcgatcagc cctacaatgg acgtggggat 420
cagccttaca atggccgtgg tgaccaacct tataacggcc ggggagatca gccttataac 480

<210> 23
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 23

Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln

1	5	10	15
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	20	25	30
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	35	40	45
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	50	55	60
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	65	70	75
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	85	90	95
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	100	105	110
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	115	120	125
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	130	135	140
Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln	145	150	155
			160

<210> 24
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 24	
ggacgagatg gaagtcctta tcaaggtcgg gatggctctc cgtatcaggg aagagacggt	60
agtccatacc aaggccgtga cggttctcct tatcagggtga gagacgggtc accatatcag	120
ggccgagacg gaagccctta ccagggtcgt gatggttcgc catatcaagg gagggacgga	180

tcccccttatc aagggcgtga tgggtccccc taccaaggga gagatgggag cccataaccag	240
ggtcgtgatg gatcaccta tcaaggaagg gatggatcgc cttatcaagg acgcgatggg	300
agcccgtacc aaggctgaga tggttcccca tatcaaggta gggatgggtc accgtatcaa	360
ggtagagatg gcagtccgta ccagggcagg gatgggagtc cctatcaggg gcgcgacggc	420
tcaccttatc aaggcagaga tggtagtcct taccaaggaa gagatggatc tccatatcaa	480

<210> 25
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 25

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
1				5					10					15	

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			20					25					30		

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			35					40				45			

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			50				55				60				

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
65						70				75				80	

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			85					90					95		

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			100					105					110		

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln
			115				120					125			

Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Gln	Pro	Tyr	Gln

130

135

140

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
 145 150 155 160

<210> 26
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 26
 ggacgtgatg gacaacccta tcagggccga gatggacaac cataccaagg tagagacgga 60
 caaccatatac aaggtaggga tgggtcaacc taccaagggtc gtgatgggtca accgtaccag 120
 gggagagatg gacagcctta ccaagggagg gatggccaac cctatcaagg aagagacggc 180
 caaccttacc agggcagaga tgggcagcct tatcaaggac gagatgggtca gccgtaccaa 240
 ggaagggacg gtcaaccata tcaggggtcgg gatgggcaac cgtatcaggg gcgcatgga 300
 caaccgtatc aaggtcgaga cggtcagcca tatcaaggca gggatggaca accttatcag 360
 ggacgcgacg gacagcccta ccaggaaga gatgggtcaac cttatcaagg gcgtgacggg 420
 caaccttacc aaggccgcga tgggtcaacca taccagggtga gagatggcca gccataccea 480

<210> 27
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 27

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 1 5 10 15

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 20 25 30

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 35 40 45

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
50 55 60

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
65 70 75 80

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
85 90 95

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
100 105 110

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
115 120 125

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
130 135 140

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
145 150 155 160

<210> 28
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 28
ggccgtgatg ggtccccgta caatggtcgg gatggctcac cgtataatgg aagagatggc 60
agtccataca atggcagaga tgggagccca tacaacggaa gagacggctc tccttataac 120
gggcgcgatg gatctccata taatggtcgt gatggatcac cttataatgg gagggacggt 180
tcacatata acggtcgaga tggatcgcca tataatgggc gtgatggttc cccttacaac 240
ggtagagacg ggtcacccta taacggacga gatggtagtc cttacaatgg gagagatgga 300
agtccttata atggtagaga tggttcgcct tataatggcc gagacggatc tccgtataac 360
ggcagggatg gttctcccta taatggtagg gatggatccc catataatgg acgtgacggt 420
agcccttata atggaaggga tgggagtcac tacaatggac gcgacggaag cccctataat 480

<210> 29
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 29

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
1 5 10 15

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
20 25 30

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
35 40 45

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
50 55 60

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
65 70 75 80

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
85 90 95

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
100 105 110

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
115 120 125

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
130 135 140

Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn
145 150 155 160

<210> 30
<211> 480
<212> DNA

Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser

85

90

95

Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser
 100 105 110

Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser
 115 120 125

Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser
 130 135 140

Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser
 145 150 155 160

<210> 32
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 32
 ggacgtgggg acaaccctca ttccggtcga ggggacaatc ctactcagg tagaggggat 60
 aaccctcact ctggtcgtgg agataaccct catagtggga gaggtgacaa ccccccattca 120
 ggtcgggggtg acaatcccca ttccgggtcgc ggtgataatc cgactccgg gcgcggggat 180
 aatccacaca gtggaagggg agataatccc catagtggcc gtggtgataa tccacattca 240
 ggccgaggtg ataatcccca ctctggaaga ggtgataacc cacactcggg acgtggcgat 300
 aatcctcatt ctgggcgtgg agacaaccg catagtggta ggggcgacaa tcctcatagc 360
 ggacgcggag acaatccaca tagtggacgg ggagacaatc cgcatcagg acgaggcgac 420
 aaccacatt ctggcagggg tgataatcct cacagcggca gaggcgataa ccccccagct 480

<210> 33
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 33

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
1 5 10 15

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
20 25 30

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
35 40 45

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
50 55 60

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
65 70 75 80

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
85 90 95

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
100 105 110

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
115 120 125

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
130 135 140

Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn
145 150 155 160

<210> 34

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 34

ggtcgagggg attcacctca caatggtcgc ggggacagtc ctcacaacgg tagaggcgat 60

tcaccccata atggacgcgg agattcacca cataatggta ggggagactc gccacataat 120

gggcgtgggg atagtcccca taacggacga ggtgatagtc cgcacaatgg acgtggagat	180
agccctcata atggtcgtgg tgattcccct cataacgggc gcggcgatag tccacataat	240
ggaaggggag attcgcctca taatgggagg ggcgactcac ctcataatgg cagaggtgat	300
tcaccgcata atggtagagg tgactcacca cacaacggaa gaggggactc cccccacaat	360
ggccggggtg attctccaca taacggcagg ggtgactctc cacacaatgg gagaggtgat	420
agcccgcata acggtcgggg agatagtcct cataatggaa gaggtgacag cccacataat	480

<210> 35
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 35

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
1				5				10					15		

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
			20					25					30		

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
		35					40					45			

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
	50					55					60				

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
65					70				75					80	

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
			85					90					95		

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
			100					105					110		

Gly	Arg	Gly	Asp	Gln	Pro	His	Asn	Gly	Arg	Gly	Asp	Gln	Pro	His	Asn
		115					120					125			

Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn
130 135 140

Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn
145 150 155 160

<210> 36
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 36
ggtcgtggtg atcaaccca taatggacgc ggagatcagc cgcataacgg gagaggggat 60
caacctcata atggcagagg ggaccaacca cataacggta gaggtgacca gcccataat 120
ggtcggggag atcagcccca caacggacgt ggcgatcaac cccacaatgg ccgtggggac 180
cagccacata atggttagagg cgaccaacct cataacggca ggggtgacca accccataac 240
ggaaggggag atcaaccaca caacgggcgc ggggatcagc cacacaatgg acgtggtgac 300
caacctcaca acggccgagg tgatcaacca cataatggaa gaggtgatca gcctcacaat 360
gggcgtggag atcaaccgca caatggtcga ggcgatcagc ctcataacgg tcgcggtgac 420
caaccgcata atggtagggg cgaccagcct cataatggga ggggtgatca acctcacaat 480

<210> 37
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 37

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
1 5 10 15

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
20 25 30

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln

35

40

45

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
50 55 60

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
65 70 75 80

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
85 90 95

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
100 105 110

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
115 120 125

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
130 135 140

Gly Arg Gly Asp Asn Pro His Gln Gly Arg Gly Asp Asn Pro His Gln
145 150 155 160

<210> 38

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 38

ggtcgtggtg ataatccgca ccagggtaga ggcgataacc cccatcaagg aagaggggat 60

aatccccacc aagggcgcg ggataacccg caccaagggtc ggggagataa tcctcaccaa 120

ggccgtgggg acaaccctca tcaaggtaga ggtgacaatc cgcacagagg acgcggtgat 180

aatccacatc aaggagagg tgataatcct catcagggtg ggggagataa ccctcatcag 240

gggaggggtg ataatcccca tcagggccgg ggcgacaacc cccaccaggg caggggtgac 300

aaccgcacatc aaggcagagg ggacaatcca catcagggtc gcggagacaa tcctcatcaa 360

ggacgtggcg ataatccaca ccaggggcgt ggagataacc cacatcaagg tcgaggtgat 420

aaccctcacc aggggaagggg agacaacca caccaaggac gaggcgacaa tccccatcaa

480

<210> 39

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 39

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
20 25 30

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
35 40 45

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
50 55 60

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
85 90 95

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
100 105 110

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
115 120 125

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
130 135 140

Gly Arg Gly Asp Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Ala Ser
145 150 155 160

<210> 40

<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 40
ggccgcggcg attccccagc ctccggaaga ggtgattcgc cagcatctgg ccgaggggat 60
tcacctgctt cggggagggg tgactctcca gccagtggca gaggggatag tccggcatcc 120
ggtagagggg actctcctgc ctccggccgt ggagattcac cagctagtgg taggggcgat 180
agtccagcgt caggacgtgg cgacagtcct gcgagcggtc gtggggacag tccagcttcg 240
ggtcgggggtg attcccctgc aagcggacga ggtgatagtc ctgcatcagg tagaggcgac 300
tccccgcct caggtcgcgg agatagccct gcgtctggga gaggtgactc acccgctagt 360
gggcgtggtg attcaccggc ttctggtcga ggtgacagcc cggcctctgg aaggggagat 420
tctcccgcat cgggacgcgg tgatagccca gcaagtggac ggggagactc gcctgctagt 480

<210> 41
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 41

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
20 25 30

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
35 40 45

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
50 55 60

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
85 90 95

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
100 105 110

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
115 120 125

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
130 135 140

Gly Arg Gly Asp Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Ile Ser
145 150 155 160

<210> 42
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 42
ggccgtgggg attctcccat ctcggtcgg ggtgactctc ctatttcggg acggggagat 60
agtccgattt ctgggagggg tgatagtcct atatccggtc gcggagactc tccaataagc 120
gggcgtggtg attcaccaat ttcaggacgc ggtgattctc ctatcagtgg acgaggggat 180
agtccaatta gtggtcgagg tgattcccca atatctggcc gaggtgacag ccctatatca 240
ggccgtggcg attcacccat ttccggcaga ggggactctc cgatctcagg tagaggcgac 300
agtcctatta gtgggcgcgg cgactcccc ataagtggca ggggcgatag tcccatatca 360
ggaaggggag attcacccat atcagggaga ggtgactcac ctatatctgg taggggagac 420
agtccaatat caggtcgtgg agattctcca atctctggaa gaggtgatag cccaatcagc 480

<210> 43
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 43

Gly Gly Arg Ser Asp Ser Tyr Pro Gly Gly Arg Pro Ser Asp Tyr Ser
1 5 10 15

Ser Asp Arg Pro Ser Tyr Gly Gly Gly Tyr Arg Ser Gly Ser Pro Asp
20 25 30

Ser Pro Asp Gly Tyr Arg Ser Gly Arg Gly Tyr Asp Gly Pro Ser Ser
35 40 45

Arg Gly Ser Pro Gly Tyr Asp Ser Tyr Pro Gly Ser Asp Gly Ser Arg
50 55 60

Asp Tyr Arg Pro Gly Ser Gly Ser Pro Arg Gly Gly Asp Tyr Ser Ser
65 70 75 80

Ser Pro Gly Asp Ser Arg Tyr Gly Gly Gly Arg Tyr Asp Pro Ser Ser
85 90 95

Pro Ser Asp Ser Arg Gly Gly Tyr Ser Pro Tyr Gly Ser Arg Asp Gly
100 105 110

Ser Ser Pro Gly Tyr Gly Arg Asp Arg Ser Asp Ser Gly Gly Tyr Pro
115 120 125

Pro Asp Arg Ser Ser Gly Gly Tyr Asp Gly Tyr Ser Gly Arg Ser Pro
130 135 140

Ser Gly Ser Asp Gly Pro Arg Tyr Ser Tyr Gly Arg Ser Pro Gly Asp
145 150 155 160

<210> 44

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 44

ggccgcagtg acagctatcc aggcggacgc ccgagcgact attcctcgga ccgtccatct

60

tatgggggtg gttaccgttc tggcagcccc gatagccctg acggttatcg ctctggacgc	120
gggtatgacg gtccctcatc ccgcggctct ccaggatacg atagttatcc gggctccgat	180
ggtagtcgcg actatcgtcc cgggtcaggg tccccccgcg gcggggacta ctccagttca	240
ccaggagact cgcgctacgg cgggggtcgt tatgatccca gctccccttc ggatagtcgt	300
ggtggctaca gtccctacgg ttctcgcgac ggtagctctc cagggtacgg acgtgatcgt	360
tctgatagtg gaggttacc gccggatcgt tcaagtgggg gatacgacgg gtattcaggt	420
cgctcaccta gtggtagcga tggccctcgt tactcatacg gtcgctcgcc aggggatggc	480

<210> 45
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 45

Gly	Arg	Asp	Ser	Gly	Tyr	Ser	Pro	Pro	Gly	Arg	Asp	Gly	Tyr	Ser	Ser
1				5					10					15	

Tyr	Ser	Pro	Gly	Asp	Ser	Gly	Arg	Ser	Arg	Ser	Gly	Pro	Asp	Gly	Tyr
			20					25					30		

Ser	Arg	Asp	Ser	Tyr	Gly	Gly	Pro	Ser	Asp	Gly	Tyr	Pro	Arg	Ser	Gly
		35					40					45			

Gly	Asp	Ser	Ser	Pro	Gly	Arg	Tyr	Gly	Pro	Tyr	Arg	Asp	Gly	Ser	Ser
	50					55					60				

Gly	Pro	Gly	Ser	Arg	Asp	Tyr	Ser	Arg	Gly	Ser	Gly	Ser	Tyr	Asp	Pro
65					70					75					80

Tyr	Pro	Arg	Gly	Asp	Ser	Gly	Ser	Pro	Tyr	Arg	Gly	Gly	Asp	Ser	Ser
			85						90					95	

Asp	Ser	Gly	Gly	Tyr	Ser	Pro	Arg	Tyr	Asp	Gly	Pro	Gly	Arg	Ser	Ser
			100					105					110		

Tyr	Gly	Ser	Pro	Asp	Ser	Arg	Gly	Arg	Asp	Ser	Gly	Pro	Gly	Tyr	Ser

115

120

125

Asp Pro Gly Tyr Ser Arg Ser Gly Ser Asp Pro Gly Tyr Gly Ser Arg
 130 135 140

Tyr Ser Asp Pro Ser Arg Gly Gly Arg Ser Pro Asp Gly Tyr Gly Ser
 145 150 155 160

<210> 46
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 46
 ggccgcgact ctggttattc gccccctggt cgcgatggat attcctcata cagccccggc 60
 gatagcggac gtagtcgttc tggaccagac ggctactctc gcgattcgta tggcggggcca 120
 agtgatgggt acccccgag cggaggcgat tcatcccccg gacgctacgg gccgtatcgt 180
 gatggaagca gtggcccggg ttcacgcgac tattcacgcg gtagtgggag ttatgatccg 240
 tacccgcgtg gagattcggg gagcccttat cgcggcggcg atagctccga ttccggtgga 300
 tattcccctc gctacgacgg accaggccgc agctcttatg ggtcccctga tagtcgcggg 360
 cgcgatagcg ggcctggcta ttcagatcca gggtagagtc gctcggggag tgatccaggt 420
 tacggcagcc gctattctga tccgtcgcgt ggaggtcgtt cacctgacgg atacgggtcc 480

<210> 47
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 47

Gly Asp Arg Ser Pro Tyr Ser Gly Gly Ser Arg Pro Gly Ser Asp Tyr
 1 5 10 15

Gly Ser Asp Ser Arg Tyr Pro Gly Gly Pro Tyr Arg Gly Ser Asp Ser
 20 25 30

Ser Gly Arg Ser Tyr Pro Asp Gly Asp Gly Ser Gly Pro Tyr Arg Ser
35 40 45

Ser Ser Asp Arg Pro Tyr Gly Gly Ser Ser Tyr Gly Gly Asp Arg Pro
50 55 60

Gly Tyr Asp Arg Ser Gly Pro Ser Gly Gly Asp Tyr Ser Pro Arg Ser
65 70 75 80

Gly Tyr Arg Ser Pro Ser Asp Gly Ser Gly Pro Tyr Asp Gly Arg Ser
85 90 95

Tyr Gly Pro Gly Ser Arg Ser Asp Ser Asp Gly Arg Ser Gly Pro Tyr
100 105 110

Ser Asp Gly Tyr Pro Ser Gly Arg Asp Pro Arg Ser Gly Gly Tyr Ser
115 120 125

Arg Ser Tyr Asp Gly Ser Gly Pro Tyr Arg Pro Ser Asp Ser Gly Gly
130 135 140

Pro Asp Gly Ser Arg Tyr Ser Gly Ser Arg Asp Ser Gly Tyr Pro Gly
145 150 155 160

<210> 48
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 48
ggcgatcgtt caccttacag tggaggttca cgtcctgggt cggattatgg tagtgactca 60
cgctatccag gaggccctta tcgtggatca gattctagt gtcgttctta tccagatggg 120
gatggcagcg gtccgtatcg ctgctcgtcc gaccgtccat acgggggggc atcctatggc 180
ggtgaccgcc ccggctacga ccgcagtgga cccagtgggt gtgattattc acctcgttcc 240
gggtaccgca gtcccagtga tggatcaggg ctttatgatg gccgcagtta cgggtccgggc 300
agtcgtagtg acagcgatgg ccgctccgga cttactcgg atggctaccc ttctggccgt 360

gacccgcgct ctggtggtta ttcacgcagt tatgatggtt caggtccgta tcgtccatct	420
gattctggag ggcctgatgg cagccgttac agcggttcgc gcgattcagg gtaccctgga	480

<210> 49
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 49

Gly	Pro	Tyr	Ser	Asp	Arg	Gly	Ser	Gly	Asp	Ser	Gly	Ser	Tyr	Pro	Arg
1				5					10					15	

Pro	Arg	Ser	Gly	Gly	Asp	Ser	Tyr	Pro	Gly	Ser	Tyr	Asp	Gly	Arg	Ser
			20					25					30		

Tyr	Ser	Gly	Arg	Pro	Asp	Ser	Gly	Gly	Ser	Asp	Gly	Arg	Tyr	Pro	Ser
		35					40					45			

Arg	Gly	Gly	Pro	Tyr	Ser	Asp	Ser	Arg	Pro	Ser	Gly	Tyr	Gly	Ser	Asp
	50					55					60				

Asp	Pro	Tyr	Ser	Gly	Gly	Ser	Arg	Gly	Arg	Gly	Ser	Pro	Ser	Asp	Tyr
65					70				75						80

Asp	Gly	Ser	Tyr	Arg	Gly	Pro	Ser	Pro	Gly	Asp	Tyr	Ser	Ser	Gly	Arg
				85					90					95	

Gly	Gly	Ser	Arg	Tyr	Asp	Pro	Ser	Asp	Arg	Ser	Pro	Ser	Gly	Tyr	Gly
			100					105					110		

Pro	Asp	Gly	Ser	Gly	Tyr	Arg	Ser	Ser	Arg	Asp	Ser	Gly	Tyr	Gly	Pro
		115					120					125			

Gly	Asp	Gly	Arg	Pro	Ser	Tyr	Ser	Asp	Pro	Gly	Gly	Ser	Tyr	Ser	Arg
	130					135					140				

Arg	Ser	Ser	Asp	Gly	Pro	Gly	Tyr	Asp	Gly	Ser	Arg	Pro	Tyr	Gly	Ser
145					150					155					160

<210> 50
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 50
ggcccgtata gtagcgtgg ctcgggagat agcggatcgt atccgcgccc acgtagtggg 60
ggcgattcat atccaggatc ttatgatggg cgctcatatt ccggacgtcc agattcgggt 120
gggagcgatg gacgctaccc tagtcgtggg ggtccctaca gtgattcccg tccctccggc 180
tacggcagcg acgaccata ctcaggaggt tcccgcggtc gcggaagccc gtccgattac 240
gatggtagct accgcgggtcc ttcacccgga gattactcaa gcggtcgtgg gggtagtcgt 300
tatgaccca gtgacgctc acccagcggc tacggaccag atgggagtgg ctatcgttca 360
tcgcgcgact ctggctatgg gcctggggac ggccgtcctt cttactcaga tcctggaggc 420
agctactcac gtcgttcaag cgatggccca ggatacgacg gtcacgtcc ttatggtagc 480

<210> 51
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 51

Gly Arg Asp Ser Gly Tyr Ser Pro Pro Ser Arg Gly Tyr Ser Asp Gly
1 5 10 15

Gly Asp Ser Tyr Ser Pro Gly Arg Pro Ser Gly Arg Tyr Ser Gly Asp
20 25 30

Gly Ser Gly Pro Asp Ser Arg Tyr Ser Asp Ser Gly Gly Arg Tyr Pro
35 40 45

Pro Gly Ser Tyr Ser Asp Gly Arg Ser Pro Arg Ser Tyr Gly Asp Gly
50 55 60

Ser Tyr Pro Asp Gly Arg Gly Ser Pro Tyr Arg Ser Gly Gly Ser Asp

65		70		75		80									
Pro	Asp	Tyr	Gly	Ser	Arg	Ser	Gly	Gly	Arg	Gly	Ser	Ser	Pro	Asp	Tyr
				85					90					95	

Gly	Tyr	Asp	Ser	Pro	Ser	Arg	Gly	Arg	Pro	Gly	Ser	Asp	Tyr	Ser	Gly
			100					105					110		

Gly	Asp	Pro	Tyr	Ser	Gly	Arg	Ser	Ser	Gly	Arg	Pro	Asp	Ser	Gly	Tyr
		115					120					125			

Tyr	Asp	Arg	Ser	Ser	Gly	Pro	Gly	Tyr	Gly	Asp	Ser	Arg	Pro	Gly	Ser
	130					135					140				

Gly	Asp	Ser	Gly	Pro	Tyr	Arg	Ser	Pro	Ser	Arg	Ser	Gly	Tyr	Gly	Asp
145					150					155					160

<210> 52
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 52	
ggccgtgaca gcggtacttc acctccgagt cgtggctata gcgacggtgg cgattcatac	60
tcaccggggc gtccttccgg tcgttactct ggggacgggt ctggaccaga ctctcgctac	120
tcggacagtg gtggacgcta cccgccgggt tcgtattcag atggccgctc accccgttcg	180
tatggagacg gatcttacct cgatggacgt ggatcaccat accgctcagg aggatctgat	240
cccgattacg gcagtcgttc aggcggacgc ggttctagcc ctgattacgg ctacgactcc	300
ccatcacgtg gtcgtcccgg tagtgactac tctggagggg acccgatatag cggacgctca	360
tcagggcgctc ctgactccgg ttattacgac cgcagttccg gtccagggtta tgggtgattct	420
cgccccggca gcggtgacag cgggtccgtat cgttcaccct cccgtagtgg atatggagac	480

<210> 53
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 53

Gly Gly Ser Pro Asp Tyr Ser Arg Pro Tyr Arg Gly Ser Asp Gly Ser
1 5 10 15

Asp Ser Gly Gly Tyr Arg Pro Ser Gly Ser Gly Asp Ser Arg Tyr Pro
20 25 30

Ser Arg Asp Tyr Ser Pro Gly Gly Tyr Asp Ser Pro Gly Ser Arg Gly
35 40 45

Arg Gly Ser Tyr Asp Ser Gly Pro Pro Ser Arg Ser Tyr Gly Gly Asp
50 55 60

Asp Gly Arg Pro Gly Ser Ser Tyr Ser Asp Arg Ser Tyr Gly Gly Pro
65 70 75 80

Gly Gly Asp Ser Tyr Arg Ser Pro Tyr Asp Gly Ser Ser Gly Pro Arg
85 90 95

Arg Ser Gly Gly Tyr Ser Pro Asp Gly Asp Tyr Ser Gly Pro Ser Arg
100 105 110

Gly Asp Ser Gly Tyr Ser Pro Arg Arg Ser Gly Ser Gly Asp Tyr Pro
115 120 125

Tyr Ser Arg Gly Asp Ser Gly Pro Asp Gly Arg Pro Ser Gly Tyr Ser
130 135 140

Tyr Asp Gly Ser Arg Pro Ser Gly Ser Gly Tyr Pro Gly Asp Arg Ser
145 150 155 160

<210> 54

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 54

ggaagcccgg actatagccg cccataaccgt ggatctgacg gttccgactc cggcggatac	60
cgcccaagtg gttcgggcga cagccgctat ccgtcacgtg attatagtcc ggggggatac	120
gattcccctg gctctcgtgg ccgtggaagt tacgatagtg ggccaccgtc acgttcttac	180
ggcggcgatg atggtcgccc cggctcatcg tacagcgacc gttcatatgg cggaccagga	240
ggcgattcat accgctctcc atatgacggg tcgtcaggcc cacgtcgcag tgggggatat	300
agtccggacg gtgactactc tgggcctagc cgtggggata gcggatattc tccacgccgt	360
agtgggtcgg gagattaccc ctactcgcgc ggggattctg gtcccgatgg tcgtcccagt	420
ggctacagtt acgatggttc gcgcccagat ggtagcgggt atccaggaga ccgctcgggc	480

<210> 55
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 55

Gly	Gly	Asp	Ser	Pro	Gly	Tyr	Tyr	Asp	Gly	Tyr	Arg	Arg	Asp	Ser	Ser
1				5					10					15	

Arg	Pro	Asp	Gly	Gly	Ser	Tyr	Pro	Gly	Ser	Gly	Arg	Ser	Pro	Ser	Ser
			20					25					30		

Gly	Arg	Pro	Ser	Ser	Tyr	Gly	Asp	Ser	Pro	Arg	Asp	Gly	Ser	Ser	Gly
		35				40					45				

Arg	Ser	Pro	Ser	Gly	Gly	Gly	Tyr	Ser	Ser	Ser	Asp	Gly	Ser	Tyr	Tyr
	50				55						60				

Asp	Gly	Arg	Pro	Arg	Tyr	Gly	Pro	Ser	Asp	Pro	Arg	Asp	Gly	Gly	Tyr
65				70					75					80	

Arg	Gly	Ser	Gly	Asp	Asp	Pro	Ser	Ser	Ser	Pro	Ser	Tyr	Asp	Tyr	Tyr
			85					90						95	

Asp	Arg	Ser	Arg	Gly	Pro	Tyr	Pro	Ser	Gly	Ser	Ser	Ser	Gly	Gly	Arg
			100					105					110		

Tyr Pro Gly Asp Gly Arg Gly Gly Tyr Asp Tyr Gly Gly Tyr Pro Arg
115 120 125

Asp Tyr Arg Asp Pro Ser Ser Gly Arg Asp Gly Gly Tyr Ser Ser Pro
130 135 140

Ser Arg Gly Gly Ser Pro Ser Ser Pro Ser Arg Ser Gly Gly Gly Asp
145 150 155 160

<210> 56
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 56
ggagattccc cgggttacta tgatggttat cgtcgtgata gcagccgccc agatgggggc 60
tcatatcccg gctccgggcg ctctccgtcg tcaggacgcc cgtcgagtta cggtgactct 120
ccccgcgacg gctcgtccgg gcgtagccct agtggggggg gatactcgag ttctgatggt 180
agctattatg atggacgccc tcgttacggt ccttcggacc cccgcgatgg tggataccgt 240
ggctctggag acgacccttc ttctcacc agctacgatt attacgatcg ttcccgtggc 300
ccatacccaa gtgggtcgtc gtccggcggt cgttatcccg gtgatggtcg tgggtggttat 360
gattacggag ggtatccacg cgattatcgc gatccaagct ctggtcgcga tggcgggtat 420
tcgtcccca gccgtggcgg gtccccctca tctccatcac gctctggggg tggagatggc 480

<210> 57
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 57

Gly Arg Ser Tyr Arg Gly Asp Gly Tyr Gly Ser Ser Ser Tyr Tyr Tyr
1 5 10 15

Gly Gly Pro Asp Pro Ser Gly Gly Pro Ser Ser Pro Pro Ser Arg Asp

20

25

30

Gly Ser Asp Gly Arg Arg Asp Ser Gly Gly Gly Pro Ser Ser Ser Asp
35 40 45

Tyr Pro Ser Ser Pro Ser Gly Gly Asp Tyr Ser Tyr Gly Pro Asp Gly
50 55 60

Ser Arg Tyr Asp Gly Ser Arg Arg Arg Asp Tyr Pro Arg Ser Gly Gly
65 70 75 80

Ser Arg Gly Tyr Ser Asp Tyr Gly Arg Pro Tyr Gly Gly Ser Gly Gly
85 90 95

Asp Gly Gly Pro Tyr Ser Pro Pro Arg Asp Ser Ser Ser Tyr Gly Pro
100 105 110

Asp Arg Ser Ser Asp Ser Gly Arg Ser Arg Pro Ser Gly Ser Ser Tyr
115 120 125

Pro Tyr Ser Asp Ser Gly Tyr Pro Arg Pro Gly Gly Gly Pro Arg Arg
130 135 140

Asp Ser Ser Gly Asp Gly Gly Tyr Asp Tyr Arg Ser Gly Gly Asp Ser
145 150 155 160

<210> 58

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 58

ggccgctctt accgtgggga cggttacggg tcctcgtcct actactatgg ggggtcccgat 60

ccctcgggag gtcccagctc tccccctca cgcgacggat cggacgggag cccgtgacagt 120

ggcggggggc cttcttctag tgactaccgc tccagtcctt ctggcggcga ctattcttac 180

ggcccagatg ggtcacgcta cgacgggagt cgtcgtcgtg attacccccg ctcaggaggc 240

tcacgcggtt acagtgacta tgggcgtcca tatggcggca gcggtggaga tggggggcca 300

tattctccac cccgcgactc cagctcttat gggcctgacc gtagctccga ttctggtcgt	360
tctcgtccct cgggtagttc ttacccttat tcagatagtg gctatccacg tcctggcggg	420
ggacctcgcc gtgacagctc aggagacgga ggctacgatt atcgttcggg gggtgactcc	480

<210> 59
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 59

Gly	Asp	Tyr	Tyr	Arg	Gly	Tyr	Pro	Ser	Pro	Arg	Gly	Ser	Pro	Gly	Pro
1				5					10					15	

Gly	Ser	Ser	Gly	Ser	Asp	Asp	Ser	Arg	Tyr	Pro	Gly	Asp	Ser	Gly	Asp
			20					25					30		

Ser	Arg	Arg	Tyr	Ser	Ser	Gly	Gly	Gly	Tyr	Ser	Arg	Gly	Ser	Asp	Arg
		35					40					45			

Arg	Tyr	Asp	Ser	Ser	Ser	Gly	Gly	Gly	Pro	Tyr	Pro	Tyr	Asp	Arg	Asp
	50					55					60				

Ser	Arg	Ser	Gly	Tyr	Asp	Gly	Pro	Ser	Ser	Ser	Gly	Pro	Gly	Gly	Pro
65					70					75					80

Ser	Asp	Ser	Pro	Gly	Gly	Arg	Pro	Ser	Gly	Ser	Tyr	Pro	Asp	Asp	Gly
				85					90					95	

Gly	Gly	Arg	Ser	Asp	Ser	Ser	Pro	Tyr	Arg	Gly	Tyr	Asp	Ser	Arg	Ser
			100					105					110		

Ser	Pro	Gly	Tyr	Tyr	Gly	Gly	Arg	Ser	Pro	Tyr	Arg	Asp	Ser	Pro	Arg
		115					120					125			

Asp	Tyr	Gly	Pro	Pro	Ser	Asp	Asp	Arg	Gly	Ser	Asp	Gly	Gly	Arg	Tyr
	130					135					140				

Pro	Ser	Gly	Ser	Ser	Gly	Gly	Gly	Arg	Ser	Gly	Tyr	Gly	Ser	Tyr	Ser

145

150

155

160

<210> 60
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 60
 ggcgactatt atcgcgggta cccatctccc cgcgggtctc ccgggcctgg gtcaagcggc 60
 agcgatgatt cacgttacct aggtgattct ggcgattctc gtcgttacag ttccggaggt 120
 gggtattctc gcggatcgga tcgtcgttat gattcgtcat ccggaggcgg tccctaccct 180
 tatgaccgcg acagtcgtag cgggtatgat gggccgtcca gttctggccc tggcggacct 240
 agtgactcac ccgggtgggcg tcccagcggg tcatacccggt atgatggggg gggacgttcc 300
 gattcgagtc cctatcgcg ttacgatagt cgtagctcgc ctgggtacta tgggtggacgt 360
 tccccttacc gtgactcacc ccgtgattac ggcccacat ccgatgatcg cggatcagac 420
 ggtggccgtt acccctcagg ttcttcggga gggggtcgct ctgggtacgg ttcttatagc 480

<210> 61
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 61

Gly Tyr Ser Gly Ser Ser Pro Tyr Arg Pro Gly Ser Ser Arg Pro Ser
 1 5 10 15

Asp Gly Tyr Gly Pro Gly Asp Gly Gly Pro Ser Arg Asp Ser Arg Ser
 20 25 30

Tyr Ser Tyr Asp Asp Gly Gly Arg Gly Gly Ser Pro Asp Pro Gly Gly
 35 40 45

Ser Arg Ser Arg Arg Pro Gly Asp Gly Gly Tyr Ser Tyr Ser Ser Pro
 50 55 60

Tyr Gly Ser Gly Tyr Asp Gly Arg Tyr Arg Asp Ser Ser Asp Pro Ser
65 70 75 80

Asp Asp Gly Arg Pro Pro Arg Arg Gly Tyr Asp Gly Pro Ser Tyr Gly
85 90 95

Gly Gly Arg Tyr Gly Gly Ser Arg Pro Ser Asp Tyr Ser Pro Ser Ser
100 105 110

Asp Ser Ser Ser Gly Tyr Ser Gly Gly Asp Gly Gly Ser Ser Arg Asp
115 120 125

Gly Tyr Tyr Tyr Asp Arg Gly Ser Ser Gly Pro Ser Tyr Ser Asp Gly
130 135 140

Pro Arg Ser Ser Gly Asp Pro Tyr Arg Pro Arg Gly Pro Gly Ser Ser
145 150 155 160

<210> 62
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 62
ggctactcgg gcagttcacc ctaccgcccc ggctcttccc gtccatccga tggatatggt 60
ccgggcatg gtggtccaag ccgcgatagt cgttcgtact catatgacga cggggggcgc 120
ggggggagtc ccgatccggg aggatcacgc tcccgccgcc ctggagatgg agggtagcgc 180
tattctagtc cctatggctc gggatacgac ggccgctacc gcgactcgtc agatccctcg 240
gacgacggac gtccaccacg ccgcgggtac gatgggccgt cttacggcgg tggacgttat 300
gggggctccc gtccttctga ttactcccct tcttctgata gttcgtctgg ctactcaggt 360
ggggacggag gaagcagccg cgatggatat tactacgacc gcggttctag tggaccatct 420
tactcagatg gtccgcgttc cagtgggtgac ccgtaccgcc ctcgtgggcc tggttcttcg 480

<210> 63
<211> 160
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 63

Gly Tyr Asp Ser Ser Tyr Gly Gly Asp Ser Pro Tyr Pro Ser Gly Gly
1 5 10 15

Ser Arg Gly Tyr Arg Gly Pro Pro Asp Arg Arg Arg Gly Gly Asp Ser
20 25 30

Ser Ser Ser Ser Pro Asp Gly Tyr Arg Pro Ser Asp Gly Pro Gly Ser
35 40 45

Asp Arg Tyr Asp Ser Ser Gly Gly Ser Ser Tyr Ser Arg Gly Tyr Arg
50 55 60

Ser Pro Ser Pro Gly Asp Asp Gly Tyr Ser Gly Arg Gly Pro Gly Tyr
65 70 75 80

Asp Gly Arg Tyr Tyr Pro Gly Arg Ser Arg Ser Gly Ser Ser Pro Gly
85 90 95

Ser Gly Pro Gly Ser Ser Tyr Pro Arg Ser Asp Asp Gly Asp Gly Ser
100 105 110

Pro Tyr Ser Tyr Asp Gly Arg Gly Ser Pro Ser Pro Ser Gly Tyr Gly
115 120 125

Pro Gly Ser Arg Gly Asp Gly Arg Asp Tyr Arg Asp Gly Gly Asp Ser
130 135 140

Ser Ser Asp Gly Pro Gly Arg Arg Pro Tyr Ser Tyr Ser Gly Ser Tyr
145 150 155 160

<210> 64

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 64
ggctacgata gctcctatgg tggcgattct ccgtatccta gtggtggtag tcgcfgggtat 60
cgtggtcctc ctgaccgccg ccgtggggga gattcatcct caagttcccc agacggatac 120
cgcccgagtg atggcccagg gagtgaccgc tacgactcta gcggcgggtc gtcttacagt 180
cgcggatata gtagtccatc acccggcgat gacggatact cggggcgtgg gcctggttac 240
gatggtcgtt actatccagg acgttcgcgt tctgggtcat cgcctgggtc cgggccaggt 300
tcgtcctacc ctcgtagcga cgacggtgac ggctcccat acagctacga cggacgtggg 360
agcccatctc cttctgggta tgggtccggt agtcgtggag acggtcgtga ctatcgtgat 420
ggaggcgaca gtagttctga tggaccgggt cgtcgccgt actcgtactc gggctcttac 480

<210> 65
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 65

Gly Asp Gly Ser Tyr Pro Arg Ser Pro Ser Pro Ser Tyr Gly Gly Gly
1 5 10 15

Ser Gly Pro Ser Arg Arg Arg Asp Ser Tyr Arg Gly Asp Gly Asp Gly
20 25 30

Tyr Tyr Gly Asp Ser Ser Ser Pro Gly Asp Ser Gly Gly Arg Gly Ser
35 40 45

Asp Asp Gly Tyr Pro Ser Ser Ser Asp Ser Tyr Ser Arg Ser Arg Gly
50 55 60

Gly Ser Ser Pro Asp Gly Tyr Pro Tyr Pro Gly Pro Arg Arg Tyr Gly
65 70 75 80

Tyr Gly Pro Gly Ser Gly Tyr Tyr Ser Ser Ser Asp Asp Gly Ser Arg
85 90 95

Asp Ser Pro Arg Tyr Arg Gly Gly Pro Tyr Arg Gly Pro Ser Asp Gly

100

105

110

Gly Arg Ser Gly Ser Asp Ser Pro Gly Gly Ser Tyr Ser Ser Gly Arg
 115 120 125

Gly Ser Asp Ser Tyr Gly Gly Gly Asp Arg Pro Arg Pro Gly Arg Asp
 130 135 140

Asp Tyr Gly Pro Tyr Pro Ser Pro Ser Asp Ser Tyr Ser Ser Arg Gly
 145 150 155 160

<210> 66
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 66
 ggcgatggga gttatccacg cagtccttcg cccagctacg gtggcggaag cgggccaagt 60
 cgccgtcgtg actcatatcg tggatgatggc gacgggttact acggtgattc atcttcgcca 120
 ggggacagtg gcgggcgtgg gagtcatgac ggctaccctt cttccagtga ttcgtattcg 180
 cgttcccgtg gcggttcacg gccggatgga tacccttacc ccggaccgcg ccgttacgga 240
 tatgggcctg gcagcgggta ttattcttct agcgatgacg ggtctcgcga ttcgccccgt 300
 taccgtggag gaccctaccg tggaccgtct gatgggggac gttccggcag tgatagccct 360
 ggcggttcgt attcatctgg acgtggcagt gacagctacg gcggcggaga tcgtcctcgc 420
 cctggtcgcg acgactatgg accgtatcca tcaccctcgg attcgtattc atcacgcggg 480

<210> 67
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 67

Gly Gly Arg Ser Asp Ser Tyr Pro Gly Gly Arg Pro Ser Asp Tyr Ser
 1 5 10 15

Ser Asp Arg Pro Ser Tyr Gly Gly Gly Tyr Arg Ser Gly Ser Pro Asp
20 25 30

Ser Pro Asp Gly Tyr Arg Ser Gly Arg Gly Tyr Asp Gly Pro Ser Ser
35 40 45

Arg Gly Ser Pro Gly Tyr Asp Ser Tyr Pro Gly Ser Asp Gly Ser Arg
50 55 60

Asp Tyr Arg Pro Gly Ser Gly Ser Pro Arg Gly Gly Asp Tyr Ser Ser
65 70 75 80

Ser Pro Gly Asp Ser Arg Tyr Gly Gly Gly Arg Tyr Asp Pro Ser Ser
85 90 95

Pro Ser Asp Ser Arg Gly Gly Tyr Ser Pro Tyr Gly Ser Arg Asp Gly
100 105 110

Ser Ser Pro Gly Tyr Gly Arg Asp Arg Ser Asp Ser Gly Gly Tyr Pro
115 120 125

Pro Asp Arg Ser Ser Gly Gly Tyr Asp Gly Tyr Ser Gly Arg Ser Pro
130 135 140

Ser Gly Ser Asp Gly Pro Arg Tyr Ser Tyr Gly Arg Ser Pro Gly Asp
145 150 155 160

<210> 68
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 68
ggcggcagggt ctgactctta tccaggaggt cgacctagt attatagctc cgacaggcca 60
tcttatggcg gcggatatcg cagcggttca ccggattctc ctgacgggta tcgcagtgga 120
cgcggatacg atggcccagag ttcccgcgga agcccgggggt acgattccta tcctggctca 180
gatggaagtc gcgactaccg accaggtagt ggctcacctc gaggtggcga ttatagttct 240

tcacctggag actcacgata cggcgggggt agatatgata cctcttcccc atccgacagc	300
agaggagggt attcccctta tgggtcccgg gatggctctt caccggata cggaagagac	360
cgaagtgata gcggtgggta cccccctgat cgggtccagcg ggggatacga tgggtacagc	420
ggacggtcac ctagcggttag cgatggcccc agatactcct acggaagatc cccaggtgat	480

<210> 69
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 69

Gly	Arg	Asp	Ser	Gly	Tyr	Ser	Pro	Pro	Gly	Arg	Asp	Gly	Tyr	Ser	Ser
1				5					10					15	

Tyr	Ser	Pro	Gly	Asp	Ser	Gly	Arg	Ser	Arg	Ser	Gly	Pro	Asp	Gly	Tyr
			20					25					30		

Ser	Arg	Asp	Ser	Tyr	Gly	Gly	Pro	Ser	Asp	Gly	Tyr	Pro	Arg	Ser	Gly
		35					40					45			

Gly	Asp	Ser	Ser	Pro	Gly	Arg	Tyr	Gly	Pro	Tyr	Arg	Asp	Gly	Ser	Ser
	50					55					60				

Gly	Pro	Gly	Ser	Arg	Asp	Tyr	Ser	Arg	Gly	Ser	Gly	Ser	Tyr	Asp	Pro
65					70					75					80

Tyr	Pro	Arg	Gly	Asp	Ser	Gly	Ser	Pro	Tyr	Arg	Gly	Gly	Asp	Ser	Ser
			85						90					95	

Asp	Ser	Gly	Gly	Tyr	Ser	Pro	Arg	Tyr	Asp	Gly	Pro	Gly	Arg	Ser	Ser
			100					105					110		

Tyr	Gly	Ser	Pro	Asp	Ser	Arg	Gly	Arg	Asp	Ser	Gly	Pro	Gly	Tyr	Ser
			115				120					125			

Asp	Pro	Gly	Tyr	Ser	Arg	Ser	Gly	Ser	Asp	Pro	Gly	Tyr	Gly	Ser	Arg
	130					135					140				

Tyr Ser Asp Pro Ser Arg Gly Gly Arg Ser Pro Asp Gly Tyr Gly Ser
 145 150 155 160

<210> 70
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 70
 ggccgggatt ccgatacag tccccaggc agagatgggt actcaagcta tagtccaggg 60
 gatagcggtc gatctcgaag cggcccagat ggctattccc gcgatatgta cggcgggtccg 120
 agcgacgggt acccccgaag cggcgggtgat tctagtccgg ggcgctacgg gccatatcgg 180
 gacgggtcta gtggtcctgg atcacgggat tattctcgag ggtccgggttc ctatgatcca 240
 tatcccaggg gggactccgg tagtccttat agggggggcg acagttctga tagtggaggg 300
 tattcccca ggtacgatgg tcctggcaga tcaagctatg gaagtcccga cagtcgagga 360
 cgcgactcag ggcctggcta ctctgatccg ggctacagca ggagtggatc tgatcctggc 420
 tacggatcaa gatattccga cccgtcacgc ggtggtagaa gtcccgacgg gtatggttcc 480

<210> 71
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 71

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
 20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln

50

55

60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

<210> 72

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 72

ggccgtgggg attctcctta tagtggtcga ggggatagtc cgtactcagg acggggtgat 60

agtccttatt cgggacgcgg cgatcaacca taccaagggtc gtggcgattc accctactcg 120

ggtcgggggag attctccata ctctgggaga ggcgactctc catatagtgg gcgcggtgat 180

cagccatatac aaggaggagg tgacagccca tatagcgggc gtggtgattc accatattca 240

ggccgtggag atagtcctta ttctggcaga ggggaccagc cttatcaggg aagaggtgat 300

agcccttatt ccggtcgcgg agattcccc tatagtggac gaggtgattc tccctacagt 360

ggccgaggtg accaacctta ccagggtaga ggtgactcac cttattcagg taggggagac 420

agtccttact ccggcagggg cgatagtcca tattctggaa ggggagatca accgtatcaa 480

<210> 73

<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 73

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

<210> 74
<211> 480
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 74

```
gggcgcggcg actcaccata ttccggtcgg ggtgaccaac cttaccaagg tcgcggtgat      60
agccatact ctggcagggg agaccaacca taccagggtc gaggtgacag tccatatagt      120
gggagagggg atcaacccta tcagggtaga ggcgattccc cctatagcgg gcgtggtgat      180
caaccttatc agggaagggg tgatagtccc tattcaggac gtggcgatca accatatcaa      240
gggagggggc atagtccgta ttctgggcgc ggagatcagc cctatcaagg taggggagat      300
tctccttata gtggacgggg agatcaaccg tatcaaggca gaggtgactc tccatacagt      360
ggtcgtgggg atcagccata tcagggccgt ggagatagtc cttactcagg ccgaggggac      420
cagccttatc aaggaagagg tgattcacct tattcgggac gaggtgatca gccgtaccaa      480
```

<210> 75

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 75

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
1           5           10           15
```

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser
20           25           30
```

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35           40           45
```

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser
50           55           60
```

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65           70           75           80
```

```
Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser
85           90           95
```

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 76
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 76
ggccggggtg accaaccgta tcagggccgt ggagaccagc cataccaggg tcgcggagat 60
caaccctacc aaggccgagg tgattctcca tattccggtc gtggggacca accataccea 120
ggtcggggag atcagccgta tcaaggacgc ggggatcagc cctatcaggg aaggggagat 180
tcaccttatt ctgggcgcgg tgatcagcct taccagggac gtggcgacca accctatcaa 240
ggtaggggag accaacctta ccaagggcgt ggtgactctc cttatagtgg acgaggggat 300
caaccatatc agggtagagg ggaccagcct tatcaaggga gaggtgatca acctatcag 360
gggaggggtg atagtcctta ctcaggtcga ggtgaccagc cctaccaggg cagaggcgat 420
cagccatatc aaggcagggg cgatcaaccg taccaaggaa gaggtgacag tccatacagc 480

<210> 77
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 77

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

1	5	10	15
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser	20	25	30
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	35	40	45
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser	50	55	60
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	65	70	75
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser	85	90	95
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	100	105	110
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser	115	120	125
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	130	135	140
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser	145	150	155
			160

<210> 78
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 78	
ggacgagggg actcacctta tagtgggcgc ggcgactctc catattccgg tcggggagat	60
tcaccatata gtggccgtgg cgatagtcct gtgtctggta ggggagactc tccgtattca	120
ggacgcggtg attcacccta cagtggacgg ggtgattctc cttattcggg tcgtggggat	180

tctccagttt caggtagagg tgatagccct tattcaggcc gaggtgacag tccttactcc	240
ggcaggggtg actccccata ctcgggacgt ggtgatagtc cagtatcagg aaggggagat	300
agtccctact ctgggagagg ggatagtccg tactcaggtc gaggtgattc cccctattct	360
ggaagaggtg actctcctgt atctggcaga ggcgacagtc catacagcgg gcgtggagat	420
tctccctata gtggtcgcgg agacagccca tattcaggga ggggcgattc acctgtagt	480

<210> 79
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 79

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
1				5				10					15		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
65					70					75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
				85				90					95		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		115					120					125			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser

130

135

140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 145 150 155 160

<210> 80

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 80

```

ggacgcggag attctccata ctctggtcga ggggatagtc cggcttcagg aagaggcgat      60
agtccatatt caggacgagg tgacagtcca gtatctggca gaggggactc tccgtattcc      120
ggcagggggag acagccctgt ttcaggccga ggtgattctc cttactcagg tcggggagat      180
agtcctgtgt ctggtagggg tgactcccc tattctggaa ggggagattc acctgtaagt      240
gggcgtggtg attcacccta ctcgggtcgt ggagactctc cagttagtgg tcgcggtgat      300
tccccatata gcgggcgcgg cgattctccc gtttctggga ggggcgacag tccttattcg      360
ggacgtggcg actctcctgt atcagggaga ggtgatagtc cctacagtgg ccgtggggat      420
tcaccagtgt caggtagagg tgactcacct tatagtggac ggggtgatag cccagtcagt      480

```

<210> 81

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 81

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 20 25 30

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
100 105 110

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 82
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 82
ggacggggtg atagccctgt atctggaagg ggagattcac cagtcagtgg acgcggtgat 60
tcccctgtta gtggccgagg tgatagtcct tactcaggac gtggcgactc tccagtatcg 120
ggacgagggg acagcccagt aagcggcagg ggcgattctc ctgtaagtgg gagaggatgat 180
tctccatata gtggtcgcgg agattctccc gtttcaggta ggggagactc gcctgtctca 240
ggtcgaggtg acagtcctgt gtctggtcgg ggagatagtc cctattctgg tagaggggat 300
agtccggttt cgggtcgtgg agattcgccg gtctctggca gaggtgactc acctgtttct 360
gggcgtggtg attcacctta ttcagggagg ggtgactccc cagtgtcagg ccgtggggat 420
tcacccgtat caggaagagg cgatagtcca gtttccgggc gcggggactc tccttatagt 480

<210> 83
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 83

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
20 25 30

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
35 40 45

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
50 55 60

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
85 90 95

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
100 105 110

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
115 120 125

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
145 150 155 160

<210> 84
<211> 480
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 84

```
ggacgaggtg attcgctgt tagtggccga ggggatagtc ccgtatctgg gaggggcgat      60
agtccggtct caggtagggg agatagtcct gtatcaggga gaggcgactc tccagttagt      120
ggtcgaggtg acagtccagt gagcggcagg ggtgatagtc cagtatcagg acggggagat      180
tcccctgtgt caggccgtgg cgattctccc gtgtctggaa gaggtgatag ccctgtctct      240
ggtcgcgggg actctcctgt gagtggacgc ggtgattcac cggtatcagg tcggggtgac      300
tcgccggttt caggaagggg agactcccca gtaagcggac gtggagattc tcctgtttcc      360
gggcgcggag attcaccagt ttctggcaga ggtgactcac ctgtaagtgg gcgtggggat      420
tcaccggttt cgggtcgtgg tgattctcca gtcagtggta gaggggacag cccagtgtcg      480
```

<210> 85

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 85

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1           5           10           15
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
          20           25           30
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
          35           40           45
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
          50           55           60
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
          65           70           75           80
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
```

85

90

95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
 145 150 155 160

<210> 86
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 86
 ggacggggtg actctccgta ttccggtcga ggtgatagcc cttattcggg tcggggagat 60
 tcaccctact cgggacgcgg cgattctcct gcttcagggtc gtggcgatag tccttatagt 120
 ggtagaggcg actctcctta ctccggcaga ggtgactccc catactcagg taggggagat 180
 agtccagctt ctggccgtgg agacagccca tttcaggac gtggtgatag tccgtactct 240
 ggtcgcggtg attcacctta ttcaggccga ggggactcac ctgcatctgg gcgcggagat 300
 tctccctatt cagggagggg tgattccccc tatagtggca ggggagactc tccatattct 360
 ggaagaggtg attctccagc atcaggaagg ggcgacagtc catacagcgg gcgtggggat 420
 tcacatata gtgggagagg ggatagtccc tacagtggac gaggtgacag tcctgcgagc 480

<210> 87
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 87

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ala Ser
145 150 155 160

<210> 88

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 88

ggacggggag actctccata ttcaggacga ggtgattccc ctgcctcagg aagaggcgac 60

tctccgtatt ccggtcgtgg agattctccc gcatcaggta gaggggactc tccttacagt 120

ggacgtggcg atagtccggc ttcaggccgt ggggacagtc cttatagcgg acgcggtgat	180
tcaccagcat ctggtagagg tgactcccc tattctggca gaggggattc tccagcgtca	240
ggtcgcggcg attcaccta tagtggtcgg ggtgatagcc cagctagtgg gcgcggagat	300
agtcctact ccgggcgtgg tgattctcct gcgagtggta ggggcgacag cccttactca	360
gggaggggtg actcacctgc aagtggccga ggggatagtc catactctgg gagaggtgat	420
agtcctgctt ctggaagggg agattcacct tattcgggtc gaggtgacag tccagccagt	480

<210> 89
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 89

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Ile	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Ile	Ser
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Ile	Ser
			85					90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Ile	Ser
		115					120					125			

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
145 150 155 160

<210> 90
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 90
ggacgtggag attcacccta ctctggcaga ggcgactctc catacagtgg aagaggtgac 60
tccccatact cgggtcgcgg cgatagtcca atatcaggtc gaggggatag tccgtattct 120
gggagaggtg atagcccata ttccggtcgt ggtgattccc cctatagtgg tcggggagat 180
tctccaattt cagggagggg cgacagccct tattctggaa ggggagatag tccttactcc 240
ggcaggggag actctcctta ttcaggtaga ggggactctc cgataagtgg gcgcggagac 300
agtccatatt caggacgggg tgactcacct tatagtggcc gtggcgattc accgtactca 360
ggccgaggtg acagtcctat atctggtagg ggtgattctc cctattcggg acgaggtgat 420
tcaccatata gtggacgcgg tgatagtcctc tacagcgggc gtggggattc tcctattagt 480

<210> 91
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 91

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser

35

40

45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Ile Ser
145 150 155 160

<210> 92

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 92

ggacgcggcg attctcccta ttctggccgt ggtgattcac ctattagtgg gcgcggtgat 60

agcccttaca gtggtagggg cgactcccc atctctggaa ggggagatag tccttactca 120

gggaggggtg attccccaat aagtggacgt ggagattctc cttatagcgg gcgtggcgac 180

agtcctatat caggccgagg ggatagtccg tattccggtc gcggagactc tccgatatcc 240

ggcagggggag acagcccata tagtggcaga ggggactctc ctatttcagg acggggagat 300

tcaccctact cgggtcgtgg ggattcacca atctcaggaa gaggtgactc acctatttcg 360

ggacgaggtg atagtcccat ttctggtaga ggtgattctc catactctgg tcgaggtgac 420

agtccaatat ctgggagagg cgatagtcca tattcagggtc ggggtgactc tccaatttcc

480

<210> 93

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 93

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Met	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Met	Ser
50						55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65					70					75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Met	Ser
				85					90					95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Met	Ser
		115					120					125			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		130				135					140				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Met	Ser
145					150					155				160	

<210> 94

<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 94
ggccgcggtg attctcccta ctcaggtaga ggggactccc catattcagg acggggtgac 60
tcaccttatt ctggcagagg tgacagtcct atgagtggcc gaggtgattc cccctatagt 120
ggacgtggtg atagtcctta ttcaggccgt ggggattcac catattcggg acgaggggat 180
agtccaatgt ctggtcgtgg agactctccg tactccggca ggggagattc accctacagt 240
ggaagaggtg atagccctta ttcaggtcga ggtgactctc caatgagcgg gcgtggcgcac 300
agtccatatt ctgggcgcgg cgatagtcct tactcgggtc gcggagattc tccatatagt 360
gggagaggcg actctcctat gtcagggagg ggcgattctc cttatagtgg taggggagac 420
agcccatact ctggaagggg tgattcaccg tattccggtc ggggagatag tccgatgtcc 480

<210> 95
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Met Ser
145 150 155 160

<210> 96
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 96
ggccgtggag actctcctta tagtgaaga ggggatagtc caatgagcgg gcgtggggat 60
tcaccctatt ccggtcgagg tgatagtccg atgtccggca ggggagacag tccataactca 120
ggccgtggtg attcacctat gtctggaagg ggcgattctc catatagtgg ccgaggtgac 180
tcccccatga gtgggcgcgg agattcacca tacagtggtc gcggtgattc cccaatgagt 240
ggacgcggcg acagtcctta ctctggtaga ggtgacagcc ctatgtcagg acggggtgat 300
agcccatatt caggaggagg tgactctcca atgtcaggtc gtggcgactc accttattct 360
gggagaggcg atagtcccat gtctggcaga ggtgattctc cctatagtgg taggggagat 420
agtcctatgt cgggacgagg ggactctccg tattcgggtc ggggagattc tcctatgagt 480

<210> 97
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 97

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
145 150 155 160

<210> 98

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 98

ggacgtgggg attcaccata ttcaggtcgc ggagattctc cctatagtg caggggac

60

tctccttatt ccggcagagg tgactcacct cattcaggac ggggagattc accttattca	120
gggaggggtg attccccata ttctggccgt ggtgatagcc cttatagtgg aagaggcgac	180
agtccacatt ctggacgagg ggatagtccc tacagtggtc gtggcgattc accgtactcc	240
ggtcggggtg actctccgta ttctggtagg ggagatagtc cgcattcggg tcgaggtgat	300
agtccatata gtgggagagg ggactctcca tacagcgggc gtggagactc cccctattca	360
ggccgaggtg acagtcctca tagtggtaga ggtgattcac cctactcggg acgcggcgat	420
agtccttact caggaagggg agacagccca tactctgggc gcggtgattc tccacactct	480

<210> 99
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 99

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
			85					90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	His	Ser

115

120

125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser
 145 150 155 160

<210> 100
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 100
 ggacggggag attcacccta tagtggtagg ggagatagtc cgcactctgg ccgtggtgat 60
 tctccttact caggacgcgg ggattcacct cattcaggcc gaggggatag tccatacagt 120
 ggtcggagtg acagtccaca ctccgggctgc ggtgattccc cttattcagg tcgtggagac 180
 agccctcata gcggtcgggg tgatagtccc tattcaggaa gaggggactc gccgcattcg 240
 ggacgtgggg acagtcctta tagtggaagg ggcgattctc cacattccgg cagaggtgac 300
 tcacatatt ctggacgagg tgatagccca catagtggca ggggagactc acctatttct 360
 gggcgtggcg atagtcctca ctcggtctgc ggagattctc cgtattcagg gaggggtgac 420
 tccccccatt ctggtagagg cgactctcca tatagtggga gaggtgattc accacacagt 480

<210> 101
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 101

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 20 25 30

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
35 40 45

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
100 105 110

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser
130 135 140

Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 102
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 102
ggacgaggtg attccctca tagtggccga ggtgactccc cccatagtgg taggggtgac 60
tcacctcact ccgggcgcgg ggattctcct tactcaggaa gaggggacag cccacattct 120
ggcaggggag acagtccaca tagtgggaga ggtgacagtc ctcatcggg acgtggagat 180
tctccgtata gtggaagggg agattcacct cattcaggcc gtggcgattc tccacattca 240
ggacggggtg atagccctca ttctgggcgt ggtgattctc cctattctgg tagaggcgac 300
tcgccgcact ctggacgcgg tgattcacca cactcgggtc gtggggatag tccacacagc 360

ggtcgctggag actctccata ttcagggagg ggcgatagtc cccattccgg cagaggtgat 420
 agtcctcaca gtggtcgggg agatagtccg cattcaggtc gaggggattc accctatagt 480

<210> 103
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 103

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 145 150 155 160

<210> 104
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 104
ggacgtggtg atagtccgta ctcaggtcga ggtgatagcc catattctgg aaggggagac 60
tctccgtata gtggaaaagg ggactctcct tatagtggcc gaggtgacag tccatacagt 120
ggaagagggg attcacccta ttctggcaga ggtgactctc catatagtgg gaagggtgat 180
tctccttact ctgggcgtgg agacagccct tattccggtc ggggtgactc accttattca 240
ggccgtggcg atagtcccta ttcagggaaa ggtgattcac cgtattcagg acggggagat 300
tcaccatatt cgggacgcgg agattctccc tactcgggtc gtggggatag tccatattca 360
ggtaagggcg actcccccta tagtggtagg ggcgattctc catactccgg caggggagat 420
agtccttatt ctggtcgcgg tgattcccca tatagcggga aaggcgacag tccttacagt 480

<210> 105
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 105

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser

65		70		75		80									
Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
				85					90					95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
		115					120					125			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
	130					135					140				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
145					150					155					160

<210> 106
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 106	
ggccgcggag attccccgta tagcgggaag ggcgattctc cttattctgg cagaggggat	60
agtccttact caggaaaagg tgactcccca tattccgggtc gtggagattc accgtattca	120
ggcaaggggg acagtcctta tagtggccgt ggtgattcac catattcagg taaaggcgac	180
tcaccttatt caggacgtgg ggattctccc tactccggca aaggtgattc tccatatagt	240
ggtcgagggtg atagcccata cagtggtaag ggagatagtc cgtatagtgg aagaggcgat	300
agtccatatt ctgggaaagg agacagtcca tactcgggca ggggagactc tccttacagc	360
ggtaaagggg actcgccgta ctctggtaga ggtgacagcc cctattctgg aaagggtgat	420
agtccctata gtgggagggg tgattcgcca tattcgggta aaggagattc tccgtacagt	480

<210> 107
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 107

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
145 150 155 160

<210> 108

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 108

ggacgagggg atagtccgta ttcagggcgc ggagattctc cgtacagcgg tcgcggtgat	60
agcccttatt ctgggagagg tgagagtcct tatagtggca gaggtgactc tccatatagt	120
ggtagggggag atagtcccta ttctggaagg ggtgattctc catactctgg tagaggcgaa	180
tctccttact ccggcagggg cgattctcct tattccggta gaggggacag cccgtatagt	240
gggcgtggtg attcccccta tagtggacgc ggcgagtctc cctactcagg tcgtggcgac	300
tcaccgtact cgggtcgagg tgattcacc tattcaggcc gtggagattc accatattct	360
ggtcgggggag aaagcccata ttcaggacgt ggggattcac cttattcagg tagaggtgat	420
agtccatatt cgggacgggg tgacagtcct tacagtggaa gaggtgaaag tccatacagt	480

<210> 109
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 109

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
		35					40				45				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
50						55				60					

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
				85				90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Glu	Ser	Pro	Tyr	Ser
			100					105					110		

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu Ser Pro Tyr Ser
145 150 155 160

<210> 110
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 110
ggacggggtg attcaccata ttcaggccgt ggtgagtctc cctattctgg tcggggagat 60
agtccgtact caggtcgtgg agagagtcca tacagcggta gaggggacag cccatattcg 120
ggacgcggtg aatctcctta cagtggaaga ggtgattctc catatagtgg caggggtgaa 180
tccccctata gtggacgagg tgatagtcca tattctgggc gcggcgagtc accctattca 240
ggacgtgggg atagtcctta ttcagggcgt ggcgaatctc catactctgg taggggcgac 300
tctccttata gtgggagagg tgaaagtcct tactccggtc gcggagattc tccgtatagt 360
ggtagagggtg agagcccgtta ttcaggtaga ggcgattcac cttattctgg aaggggagaa 420
agcccttatt ccggcagagg tgacagtccc tactcgggtc gaggggaatc accgtacagt 480

<210> 111
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 111

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

20

25

30

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 112

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 112

ggcaggccag attcacccta ttctgggaga ggtgacagtc cttacagtgg tcgaggagac 60

tctccatatt cagggcggtgg cgactcgccg tatagtccta gaggcgattc cccctattca 120

ggaagaggtg attcaccata ttccgggagg ggtgattctc catacagcgg tcgaggtgat 180

agcccatatt ctggtaggcc cgattctcct tattcgggtc gtggggacag cccttattct 240

ggacgcggtg atagtcctta tagtgggagc ggggattcac cgtactctcc gagaggcgat 300

tctccctact ccggcagggg agattctccg tattcaggcc gtggtgactc accttactcg	360
ggacgagggg atagtccata tagtggtaga ccagactccc catactcagg acgtggagat	420
agtccctata gtggaagggg cgattcacct tattcaggta gaggcgatag tccgtacagt	480

<210> 113
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 113

Gly	Arg	Pro	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Pro	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			20					25					30		

Gly	Arg	Pro	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Pro	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
	50					55					60				

Gly	Arg	Pro	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65					70					75				80	

Pro	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
				85				90						95	

Gly	Arg	Pro	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Pro	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		115					120					125			

Gly	Arg	Pro	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
	130					135					140				

Pro	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser

145

150

155

160

<210> 114
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 114
 ggccgtcctg actctcctta tagtggtcgc ggagattctc cgtatagtcc tcgtggagac 60
 tcaccttatt caggccgtgg tgatagtccc tatagtggaa gaccagactc cccctattca 120
 ggtagaggcg attctcccta ctctcccaga ggtgatagcc cttattcggg acgtggggat 180
 agtccttaca gtggtaggcc agattcacc tacagcggca ggggagatag tccgtacagt 240
 ccaagagggg attcaccgta ctcggtcga ggtgattccc catattctgg tagaccgat 300
 tctccatact caggaagggg tgacagtcct tattctccta gaggtgactc gccgtattca 360
 gggcgtggcg atagtccata tagtggcaga cctgattctc cttactctgg acgcggtgat 420
 tcaccatatt cacctagggg cgactctcca tattccgggc gcggggacag cccatacagt 480

<210> 115
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 115

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
 1 5 10 15

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 20 25 30

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser
 35 40 45

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 50 55 60

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser
100 105 110

Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 116
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 116
ggccgtcctg atagtccata cagtcccagg ggcgactcgc cgtattcagg tagaccggat 60
tcaccgtatt ctgggcgtgg ggacagccca tattcaccta ggggagattc accttattca 120
ggaaggcccg attcacccta tagtccaagg ggtgattccc cttattcggg acgcggagac 180
agtccttaca gtgggagacc agattctcct tatagtcctc gtggagactc accatattct 240
ggaagacctg attctcccta ctcagggcgc ggtgactcac cttactctcc gagaggtgat 300
tcgccttatt ccgggaggcc tgactctcca tattcccccc gtggcgatag tccgtacagc 360
ggacgtggtg attcaccata ctctggtagg ccagatagtc cctattctcc aagaggtgac 420
agtccatata gtggccgtcc agactcccca tatagcggtc gcggggatag tccttattct 480

<210> 117
<211> 160
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 117

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 118

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 118
ggccgacctg actctccata cagtccccgt ggtgatagtc catatagcgg taggcctgat 60
tcgccgtact ctccgagagg cgactcacc tttcagggc gtccagatag tccctactca 120
ccaagaggtg actcgccata ttccgggagg ccagattcac catattcacc taggggtgac 180
agtccttact caggaaggcc cgattcaccg tatagtccac gcggagactc cccatatagt 240
ggtcgtcctg attcacctta ttctcctaga ggggattctc catattctgg gagaccggat 300
agtccttata gtcctcgtgg agacagccca tactctggta gacccgatag tccgtattct 360
ccaaggggcg attctcctta cagtggaaga cctgatagcc cttattcccc ccgaggtgat 420
tctccctata gtggcagacc agactctcct tattcaccca ggggagattc tccgtacagt 480

<210> 119
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 119

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser

100

105

110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
 145 150 155 160

<210> 120
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 120
 ggccgcggag attctccata ctccggtaga ggggacagtc cagtttcagg cagaggcgat 60
 tcaccgtata gtggaaaagg agactccccc tatagtggca ggggcgatag tccgtattcc 120
 gggcgcgggg attctcctgt aagtggacgt ggagattccc catatagcgg caagggtgat 180
 agtccttact caggtcgcgg tgattcacca tatagtggtc gtggcgactc acctgtgtct 240
 ggccgtgggg actctcctta ttctgggaaa ggtgattcgc cgtactctgg aagaggtgat 300
 agcccttatt cagggcgtgg tgattctccc gtttctggta ggggtgacag cccatacagt 360
 ggtaaaggag attcacctta ttcgggtcga ggggatagtc cctattcagg acgaggtgac 420
 tctccagtat caggaagggg agatagtcca tattcaggta agggagacag tccttatagt 480

<210> 121
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 121

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
145 150 155 160

<210> 122
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 122
ggccgcggag attctccata ctctggtcga ggggatagtc cggcttcagg aagaggcgat 60
agtccatatt caggacgagg tgacagtcca gtatctggca gaggggactc tccgtattcc 120
ggcaggggag acagccctgt ttcaggccga ggtgattctc cttactcagg taaggagat 180
agtccttatt ctggtagggg tgactcccc tattctggaa ggggagattc acctgtaagt 240

gggcgtggtg attcacccta ctcgggtcgt ggagactctc cagttagtgg tcgcggtgat	300
tccccatata gcgggcgcgg cgattctccc gtttctggga ggggcgacag tccttattcg	360
ggaaaaggcg actctcctta ttcagggaga ggtgatagtc cctacagtgg ccgtggggat	420
tcaccagtgt caggtagagg tgactcacct tatagtggac ggggtgatag cccagtcagt	480

<210> 123
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 123

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
65					70					75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
				85					90					95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		115					120					125			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Asp	Ser	Pro	Tyr	Ser
	130					135					140				

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 124
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 124
ggccgcggag attccccgta tagcgggaag ggcgattctc cttattctgg cagaggggat 60
agtccttact caggaaaagg tgactcccca tattccgggtc gtggagattc accgtattca 120
ggcaaggggg acagtcctta tagtggccgt ggtgattcac catattcagg tcgcggcgac 180
tcacctgtct caggacgtgg ggattctccc tactccggca aaggtgattc tccatatagt 240
ggtcgaggtg atagcccata cagtggtaag ggagatagtc cgtatagtgg aagaggcgat 300
agtccatatt ctgggaaagg agacagtcca tactcgggca ggggagactc tccttacagc 360
ggtcgtgggg actcgccggt gtctggtaga ggtgacagcc cctattctgg aaagggtgat 420
agtcctata gtgggagggg tgattcgcca tattcgggta aaggagattc tccgtacagt 480

<210> 125
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser

50

55

60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
145 150 155 160

<210> 126

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 126

ggacgtggcg acagccctta ttcaggtaga ggcgactctc cttattcggg acggggtgac 60

tcccatatt ctggacgcgg tgattctcct ttgtcaggga ggggtgattc cccctatagt 120

ggaaggggag actcacccta cagtgggaga ggtgattcac cgtactcggg tcggggagat 180

agtccgttat caggacgagg tgatagccca tacagcgggc gtggtgatag tccctattca 240

ggccgtgggg atagtcctta ctgaggtcga ggggactctc cattgtctgg ccgaggtgac 300

tctccgtatt ccggcagggg agattcacct tatagtggca gaggtgacag tccatatagt 360

ggtcgtggag acagtcctct atctgggcgc ggagattctc cctactccgg tcgcggcgat 420

tcacatatt caggaagagg ggattctcca tactctggta ggggcgatag tccactttct 480

<210> 127

<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 127

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Leu Ser
145 150 155 160

<210> 128
<211> 480
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 128

```
ggacgtggtg attcacctta ttctggtaga ggtgattctc cattaagtgg gcgcggtgat      60
tccccctatt cgggtcgtgg ggattcacca ttgagtggca ggggagactc tccgtattcc      120
ggtcgcggcg attctccttt atcaggccgt ggcgactctc catatagcgg gcgtggagac      180
agtccacttt caggacgagg ggactctcct tatagtggaa ggggtgatag tcccttgtct      240
ggccgaggtg atagcccata ttcaggagg ggcatagtc cgttatctgg acggggtgac      300
tcaccataca gtggtcgagg tgacagccct ttgtcaggtc ggggagattc tccctactct      360
gggagaggtg actccccatt atccggcaga ggggatagtc catactcagg taggggagat      420
agtcctctct caggaagagg cgacagtcct tactcgggac gcggagattc acccttaagc      480
```

<210> 129

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 129

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1           5           10           15
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
20           25           30
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35           40           45
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50           55           60
```

```
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65           70           75           80
```

```
Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85           90           95
```

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 130
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 130
ggccggggtg attcgccgta ctccggtcgc ggagattcac cctattctgg aaggggcgat 60
agtccttatt ctggtcgagg tgatagtcca tattcgggta ggggagattc tccctatagt 120
ggacgcggtg atagccctta ttccgggcgc ggggattcac cgtatagtgg gagaggtgat 180
agtccgtatt ctgggcgtgg tgattcacct tattcagggtc gtggcgattc tccatactct 240
ggtgatggag attccccata tagcggcagg ggtgactctc cttacagtgg aagaggcgac 300
tctccatata gtggccgtgg agacagccca tattcaggcc gaggggatag tccctactcg 360
ggacgaggtg attctcctta tagtggtaga ggggactcac catattctgg ccgtggagac 420
tccccctatt caggacgtgg ggacagtcct tactcaggta gaggtgacag tccatacagt 480

<210> 131
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 131

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

1	5	10	15
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	20	25	30
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	35	40	45
Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	50	55	60
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	65	70	75
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	85	90	95
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Asp Gly Asp Ser Pro Tyr Ser	100	105	110
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	115	120	125
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	130	135	140
Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser	145	150	155
			160

<210> 132
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 132	
ggccggggtg attcgccgta ctccggtcgc ggagattcac cctattctgg aaggggcgat	60
agtccttatt ctggtcgagg tgatagtcca tattcgggta ggggagattc tccctatagt	120
ggacgcggtg atagccctta ttccggggac ggggattcac cgtatagtgg gagaggtgat	180

agtccgtatt ctgggcgtgg tgattcacct tattcaggtc gtggcgattc tccatactct	240
ggtagggggag attccccata tagcggcagg ggtgactctc cttacagtgg aagaggcgac	300
tctccatata gtggcgatgg agacagccca tattcaggcc gaggggatag tccctactcg	360
ggacgaggtg attctcctta tagtggtaga ggggactcac catattctgg ccgtggagac	420
tccccctatt caggacgtgg ggacagtcct tactcaggta gaggtgacag tccatacagt	480

<210> 133
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 133

Gly	Arg	Gly	Arg	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		20						25					30		

Gly	Arg	Gly	Arg	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35						40					45		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		50					55				60				

Gly	Arg	Gly	Arg	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65							70			75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
				85					90					95	

Gly	Arg	Gly	Arg	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100						105					110	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		115							120				125		

Gly	Arg	Gly	Arg	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser

130

135

140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 145 150 155 160

<210> 134
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 134
 ggacgaggga ggtcacccta tagtggaaga ggcgatagtc catatagtgg ccgtggagat 60
 tccccctatt ctggacgcgg tgactctcct tattctggta gaggaaggtc tccatattcc 120
 ggacgaggatg attcaccata ttctgggcgc ggagactcgc cgtactcagg tcgcggggac 180
 agtccttata gtgggagagg taggagccca tattcaggac gtggcgattc tccctactcc 240
 ggtcgggggtg attctcctta ctctggcagg ggagatagtc cctattcagg ccgaggaaga 300
 tcaccgtata gtggtagggg cgactcacct tattcagggc gtggtgatag tccttacagt 360
 ggtcgagggtg atagccctta ttcgggaagg ggtagaagtc catacagcgg tagaggggat 420
 tctccatact cgggtcgtgg ggatagtcgc tattcaggta gaggtgacag cccgtacagt 480

<210> 135
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 135

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 1 5 10 15

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 20 25 30

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Arg Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 136
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 136
ggtagaggaa ggtcaccata tagcggtcgg ggtgacagtc catatagtgg aaggggcaga 60
tcaccgtatt ctgggagagg tgattcacct tattctggta ggggtagatc cccctattca 120
ggccgaggtg actctccata ttctggcaga ggacgcagtc cttatagtgg ccgtggcgat 180
agtccctact caggtagagg taggagtcct tactctggtc gtggtgatag tccatactcg 240
ggtcgagggg ggtctcctta ttcaggacgg ggagatagcc cttattcggg acgaggaaga 300
tctccttaca gtggacgtgg agactacccc tattctggaa gaggtcgttc tccctatagt 360
ggtagagggg attcgcctta ttccggtaga ggcagaagtc cgtatagtgg gcgtggggac 420
agcccgtact ccggcagggg aagaagccca tattcaggtc gcggagattc tccatacagt 480

<210> 137
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 137

Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 138
<211> 480
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 138

```
ggggatggag actctcctta tagtgaaga ggggattctc cctactctgg aaggggcgac      60
tcaccttatt ccggtagagg cgattcaccc tattcaggtg atggagatag tccttattca      120
ggcagaggtg actcccccta tagtggtcgc ggtgacagtc catatagcgg tcgtggggat      180
agtccctatt ctggagatgg tgatagtcca tacagtggac gtggcgatag tccgtattct      240
gggaggggtg attcgccgta tagtggcagg ggagattccc catattcagg agacggggac      300
agcccatata gtgggagagg tgattcaccc tactccgggc gtggagattc tccttactcg      360
ggacgaggtg atagccctta ttctggtgac ggagattcac catattctgg ccgtggtgat      420
tctccatatt cgggtcgagg ggactctcca tactcaggac gcggagacag tccttacagt      480
```

<210> 139

<211> 159

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 139

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
1           5           10           15
```

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
          20           25           30
```

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
          35           40           45
```

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
          50           55           60
```

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
          65           70           75           80
```

```
Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
```


85

90

95

Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
 100 105 110

Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
 115 120 125

Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly
 130 135 140

Asp Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 145 150 155

<210> 140
 <211> 477
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 140
 gacggagaca gtccttatag tgggaggggt gatagtcctt attcaggaga tggcgatagt 60
 ccctacagcg gtcgaggtga ttccccttat tcgggagatg gggatagtcc atatagcgga 120
 agaggcgact ctccatacag tggagacggt gattctcctt actcaggacg tggggattct 180
 ccatattctg gagatggaga ctctccttat tcaggcagag gtgactcccc ctattcaggt 240
 gatggtgatt caccatatag tggacgcgga gattcgcctt actcgggtga cggcgattca 300
 ccctattctg gtagagggga ctcaccttac tctggtgatg gagattctcc ctatagtggg 360
 cgtggtgata gcccatattc aggggatggt gacagtccat actccggtag gggagattca 420
 ccttattctg gggacgggga cagcccgtat agtggccgtg gagatagtcc ttacagt 477

<210> 141
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 141

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
145 150 155 160

<210> 142
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 142
ggacgcggag attcaccata ttctggacga ggggacagtc cttattcagg tcggggagat 60
tctccttata gtggtcgtgg agataatcct tataatggcc gaggtgactc tccatattca 120

ggccgtgggg attcacccta cagtgggaga ggcgactccc catactcagg acggggtgac	180
aacccttaca atggaagagg ggatagtccc tatagtggaa ggggagatag tccgtattca	240
gggaggggtg atagccctta ttcgggtcga ggtgataatc catacaacgg tcgcggcgat	300
tctccctact ctggcagagg tgattcccc tattctggta gaggtgacag cccatattcc	360
ggcaggggcg acaatccata taatggtagg ggagactcac cttattctgg gcgcggtgat	420
agtccatata gcgggcgtgg cgatagtcct tactcgggac gtggtgataa cccatataac	480

<210> 143
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 143

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
1				5				10						15	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
				85				90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn
		115					120					125			

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Asn
145 150 155 160

<210> 144
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 144
ggtcggggag attcccccta tagtggtagg ggagacaatc cttataatgg aaggggtgac 60
agtccctatt caggtcgagg ggacaacca tataatggcc gtggtgatag cccttacagt 120
ggaagaggtg acaatccata caatgggcgt ggcgattcac cctactccgg caggggagat 180
aaccctaca atggacgcgg cgactctcct tactctggga ggggcgataa tccctataat 240
ggtcgtggag atagtccata ttctggcaga ggcgacaatc cctacaatgg tagaggtgat 300
tctccatact caggccgagg tgataatcct tacaacggac gaggtgactc accatatagc 360
gggcgcggag ataatccgta taatgggaga ggggattcac cttattcggg acgtggggat 420
aatccatata acggtcgcgg tgatagtcct tattcaggac ggggtgataa cccttataac 480

<210> 145
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 145

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
1 5 10 15

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn

35

40

45

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
65 70 75 80

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
100 105 110

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn
130 135 140

Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

<210> 146

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 146

ggacgaggtg actcaccata ttctggacgc ggagataatc cgtacaatgg cagaggggat 60

aatccttata acggcagggg agacaatccc tataatggga ggggtgatag cccttattcc 120

gggagaggcg acaatccata caacggacgt ggagacaacc cttacaatgg gcgtggggat 180

aaccataca atggaagagg tgattcacct tatagtgggtc gcggggacaa cgccaactat 240

ggtcgaagtt atcacccgta ttatggacgg cgagatcacc cttattatgg ttggggagat 300

tctccttatt caggccgagg ggacaatccg tataacggta gaggtgacaa tccttacaac 360

ggtcgtggtg ataatccata taacgggcgc ggtgatagtc cttactcagg tcgggggtgac 420

aacccatata atggccgtgg cgataacccc tataacggaa ggggcgataa tccctacaac

480

<210> 147

<211> 160

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 147

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
145 150 155 160

<210> 148

<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 148
gggcgtggag accagccgta tcaagggaga ggtgaccagc cttatcaagg tcggggagat 60
caaccttatc aaggcagggg cgatcaacct catcagggta gaggggacca accctaccaa 120
ggccgggggtg atcaaccgta ccaaggacgt ggtgatcaac catatcaggg ccgtggagat 180
caaccccatc aaggaagggg agatcagcca taccagggaag gaggcgacca accgtatcag 240
ggacgaggtg atcaacccta tcagggtcgc ggggatcaac cacaccaggg tcgtggggac 300
cagccatatac aaggtagagg tgatcagccc tatcaaggac gcggtgatca accttaccag 360
ggcagagggg atcagccgca ccaaggtagg ggagaccaac cttatcaggg gaggggtgac 420
caaccatacc aaggtcgagg cgatcagcct taccaagggc gcggagatca accgcatcaa 480

<210> 149
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 149

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro His Gln
145 150 155 160

<210> 150
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 150
gggcgcggtg atcaacccta tcaaggacgt ggagatcaac ctcatcaggg aagaggtgac 60
cagccatatc aagggagagg ggaccagccc catcaaggaa ggggtgatca accttacaa 120
ggacgcggag atcaaccca ccaagggagg ggcgatcagc cctatcaggg caggggagat 180
caaccgcatc aagggcgtgg tgatcaacca tatcagggac gaggcgatca accacatcaa 240
ggccgtgggg atcaaccata ccaaggtagg ggagaccaac cacaccaggg ccggggtgac 300
caaccgtatc aaggtcgcgg ggaccaacct caccaaggtc gtggagacca gccttatcag 360
ggtagagggg atcagccaca tcagggtcga ggtgatcaac cgtaccaggg tcggggagat 420
cagcctcatc aaggtagagg cgaccaacc taccaaggca gaggtgatca gccgcaccaa 480

<210> 151
<211> 160
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 151

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro His Gln
1 5 10 15

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro His Gln
35 40 45

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro His Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro His Gln
100 105 110

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro His Gln
130 135 140

Gly Arg Gly Asp Gln Pro His Gln Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

<210> 152

<211> 480

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 152

gggcgtgggg accaaccgca ccaagggaga ggggatcagc cgcacaaagg gcgcggggat

60

caacctcatc aggggagggg cgatcaacct tatcaaggac gaggtgatca acctcaccaa	120
ggacgtggtg atcaaccgca tcagggccgt ggagaccaac cccaccaagg caggggtgat	180
caaccatacc aaggtagggg agaccagcca catcaaggta gaggcgacca accacaccaa	240
ggtcgaggcg atcagcctca ccaggaagg ggagatcaac cctatcaggg tcggggagat	300
cagccccatc agggtagagg ggaccagcct catcaaggaa gaggtgatca gccacaccag	360
ggtcgtggag atcaaccgta ccagggcaga ggtgaccaac ctcatcaagg tcgcggagat	420
caaccacatc agggacgcgg tgatcaaccc catcaaggcc ggggtgacca gccctatcaa	480

<210> 153
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 153

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
1				5				10						15	

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
			20					25						30	

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
			35				40					45			

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
			50			55					60				

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
65					70				75					80	

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
				85				90						95	

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln
			100					105					110		

Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln	Gly	Arg	Asp	Gly	Ser	Pro	Tyr	Gln

115

120

125

Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln
 130 135 140

Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln
 145 150 155 160

<210> 154
 <211> 480
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 154
 ggacgagatg gaagtcctta tcaaggtcgg gatggctctc cgtatcaggg aagagacggt 60
 agtccatacc aaggccgtga cggttctcct tatcagggtga gagacgggtc accatatcag 120
 ggccgagacg gaagccctta ccagggtcgt gatgggttcgc catatcaagg gagggacgga 180
 tccccttatc aagggtcgtga tgggtccccc taccaaggga gagatgggag cccataccag 240
 ggtcgtgatg gatcaccta tcaaggaagg gatggatcgc cttatcaagg acgcatggt 300
 agcccgtacc aaggtcgaga tgggtcccca tatcaaggta gggatgggtc accgtatcaa 360
 ggtagagatg gcagtcgta ccagggtcagg gatgggagtc cctatcaggg gcgacgagc 420
 tcaccttatc aaggcagaga tggtagtcct taccaaggaa gagatggatc tccatatcaa 480

<210> 155
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 155

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
 1 5 10 15

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
 20 25 30

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
35 40 45

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
50 55 60

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
65 70 75 80

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
85 90 95

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
100 105 110

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
115 120 125

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
130 135 140

Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln
145 150 155 160

<210> 156
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 156
ggacgtgatg gacaacccta tcagggccga gatggacaac cataccaagg tagagacgga 60
caaccatatc aaggtaggga tgggtcaacc taccaagggtc gtgatgggtca accgtaccag 120
gggagagatg gacagcctta ccaagggagg gatggccaac cctatcaagg aagagacggc 180
caaccttacc agggcagaga tgggcagcct tatcaaggac gagatgggtca gccgtaccaa 240
ggaagggtac gtcaaccata tcaggggtcgg gatgggcaac cgtatcaggg gcgcgatgga 300
caaccgtatc aaggtcgaga cggtcagcca tatcaaggca gggatggaca accttatcag 360

ggacgcgacg gacagcccta ccagggaaga gatggtcaac cttatcaagg gcgtgacggg 420
 caaccttacc aaggccgcga tgggtcaacca taccagggtg gagatggcca gccataccaa 480

<210> 157
 <211> 160
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 157

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 1 5 10 15

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 20 25 30

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 35 40 45

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 50 55 60

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 65 70 75 80

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 85 90 95

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 100 105 110

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 115 120 125

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 130 135 140

Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn
 145 150 155 160

<210> 158
<211> 480
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 158
ggcgtgatg ggtccccgta caatggtcgg gatggctcac cgtataatgg aagagatggc 60
agtccataca atggcagaga tgggagccca tacaacggaa gagacggctc tccttataac 120
gggcgcatg gatctccata taatggtcgt gatggatcac cttataatgg gagggacggt 180
tcaccatata acggtcgaga tggatcgcca tataatgggc gtgatggttc cccttacaac 240
ggtagagacg ggtcacccta taacggacga gatggtagtc cttacaatgg gagagatgga 300
agtccttata atggtagaga tggttcgcct tataatggcc gagacggatc tccgtataac 360
ggcagggatg gttctcccta taatggtagg gatggatccc catataatgg acgtgacggt 420
agcccttata atggaaggga tgggagtccc tacaatggac gcgacggaag cccctataat 480

<210> 159
<211> 58
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 159

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
1 5 10 15

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln
20 25 30

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

<210> 160

<211> 174
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 160
gtggacaata agttcaataa ggagcagcag aatgcctttt acgagattct ccacctgccc 60
aacctcaacg aagagcagag aaatgcgttt atccagagtc tgaaagacga cccaagccag 120
tccgcaaacc tgctggctga ggccaagaag cttaacgacg cacaggcccc aaag 174

<210> 161
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 161
Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu Lys Ile Gly Lys Glu
1 5 10 15
Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe Leu Arg Asn Leu Val
20 25 30
Pro Arg Thr Glu Ser
35

<210> 162
<211> 111
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 162
cttctggggg attttttttcg caaatctaag gaaaaaatcg ggaaggaatt taaacgcac 60
gttcaacgca ttaaagactt ccttcgtaac cttgtccctc gtacagagag t 111

<210> 163
<211> 20
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 163

Arg	Trp	Trp	Arg	Met	Met	Arg	Arg	Gly	Pro	Gly	Arg	Gly	Met	Met	Arg
1				5					10					15	

Arg	Gly	Trp	Glu
			20

<210> 164

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 164

cgctggtggc gtatgatgcg tcgcggccct ggccgcggta tgatgcgccg cggctgggaa 60

<210> 165

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 165

Arg	Trp	Trp	Arg	Met	Met	Arg	Arg	Gly	Pro	Arg	Trp	Gly	Met	Met	Arg
1				5					10					15	

Arg	Gly	Trp	Glu
			20

<210> 166

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 166

cgctggtggc gtatgatgcg tcgcggccct cgctggggta tgatgcgccg cggctgggaa 60

<210> 167
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 167

Trp Trp Arg Arg Met Met Arg Arg Gly Pro Arg Trp Gly Met Met Arg
1 5 10 15

Arg Gly Trp Glu
20

<210> 168
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 168
tgggtggcgcc gtatgatgcg tcgcggccct cgctggggta tgatgcgccg tggctgggaa 60

<210> 169
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 169

Arg Val Lys Arg Val Trp Pro Leu Val Ile Arg Thr Val Ile Ala Gly
1 5 10 15

Tyr Asn Leu Tyr Arg Ala Ile Lys Lys Lys
20 25

<210> 170
<211> 78
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 170

cgcgtgaaac gcgtgtggcc gctggtgatt cgcaccgtga ttgcgggcta taacctgtat 60

cgcgcgataa aaaagaaa 78

<210> 171

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 171

Gly Arg Ile Gly Ser Ile Leu Gly Arg Leu Ala Lys Gly Leu Pro Thr
1 5 10 15

Leu Lys Ser Trp Ile Lys Asn Arg
20

<210> 172

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 172

ggcagaatag gctctatcct tggaagactt gccaaaggggc tgcctactct aaagagctgg 60

attaagaacc gc 72

<210> 173

<211> 190

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 173

Gly Thr Glu Ser Leu Val Leu Ser Pro Ala Pro Ala Lys Pro Lys Arg

1	5	10	15
Val	Lys	Ala	Ser
	Arg	Arg	Ser
	20	25	30
Ile	Ala	Ala	Ala
	35	40	45
Gln	Ser	Ile	Gln
	50	55	60
Ala	Asp	Leu	Gln
65		70	75
Val	Leu	Lys	Gln
	85	90	95
Ala	Lys	Ser	Asp
	100	105	110
Val	Arg	Arg	Ser
	115	120	125
Arg	Ser	Pro	Ala
130		135	140
Lys	Ser	Arg	Ala
145		150	155
Ala	Lys	Ser	Arg
	165	170	175
Pro	Arg	Ala	Lys
	180	185	190

<210> 174
 <211> 573
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic

<400> 174
atgggcaccg aaagccttgt tttatctcca gctccagcca aacccaaacg cgttaaagca 60
agccgccgca gtgccagcca tccgacctac agcgaaatga ttgccgcggc gattcgtgcg 120
gaaaaatcac gcggcggcag ctcccgccag tcgattcaga aatatattaa aagccactat 180
aaagtgggtc ataacgccga tctgcaaadc aaactgagca ttcgccgtct gctggcagcg 240
ggcgtgctga aacagaccaa aggcgttggc gcgagcggca gtttccgcct ggcgaaatcc 300
gataaagcga aacggagtcc gggcaaaaaa aaaaaggcgg tgcgtcgcag caccagccccg 360
aaaaaagcgg cacgtccgcg taaagcgcgt tctccggcaa aaaagccgaa ggcaacggcg 420
cgcaaagcac gaaaaaaaaag tcgcgccctcg ccgaaaaaag cgaagaaacc gaaaaccgtg 480
aaagctaaaa gccgtaaggc tagcaaagcc aaaaaagtca aacgttcaaa accgcgcgca 540
aagagcgggtg cccgtaaadc gccaaaaaag aag 573

<210> 175
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 175
Gly Val Gly His Asn Ala Asp Leu Gln Ile Lys Leu Ser Ile Arg Arg
1 5 10 15

Leu Leu Ala Ala Gly Val Leu Lys Gln Thr Lys Gly Val Gly Ala
20 25 30

<210> 176
<211> 93
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 176
ggcgtcggac ataatgcgga tctgcaaadc aaactgagca ttcgccgtct gctggcggcg 60
ggcgttctga aacagaccaa aggcgtgggc gca 93

<210> 177
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 177

Ala Ala His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu
1 5 10 15

Glu Glu Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala
20 25 30

<210> 178
<211> 96
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 178

gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60

gcaaaagagt ttattgcgtg gcttgtgaaa ggagca 96

<210> 179
<211> 235
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 179

Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ser Leu Pro Ala Thr His
1 5 10 15

Glu Leu His Ile Phe Gly Ser Ile Asn Gly Val Asp Phe Asp Met Val
20 25 30

Gly Gln Gly Thr Gly Asn Pro Asn Asp Gly Tyr Glu Glu Leu Asn Leu
35 40 45

Lys Ser Thr Lys Gly Asp Leu Gln Phe Ser Pro Trp Ile Leu Val Pro
50 55 60

His Ile Gly Tyr Gly Phe His Gln Tyr Leu Pro Tyr Pro Asp Gly Met
65 70 75 80

Ser Pro Phe Gln Ala Ala Met Val Asp Gly Ser Gly Tyr Gln Val His
85 90 95

Arg Thr Met Gln Phe Glu Asp Gly Ala Ser Leu Thr Val Asn Tyr Arg
100 105 110

Tyr Thr Tyr Glu Gly Ser His Ile Lys Gly Glu Ala Gln Val Lys Gly
115 120 125

Thr Gly Phe Pro Ala Asp Gly Pro Val Met Thr Asn Ser Leu Thr Ala
130 135 140

Ala Asp Trp Cys Arg Ser Lys Lys Thr Tyr Pro Asn Asp Lys Thr Ile
145 150 155 160

Ile Ser Thr Phe Lys Trp Ser Tyr Thr Thr Gly Asn Gly Lys Arg Tyr
165 170 175

Arg Ser Thr Ala Arg Thr Thr Tyr Thr Phe Ala Lys Pro Met Ala Ala
180 185 190

Asn Tyr Leu Lys Asn Gln Pro Met Tyr Val Phe Arg Lys Thr Glu Leu
195 200 205

Lys His Ser Lys Thr Glu Leu Asn Phe Lys Glu Trp Gln Lys Ala Phe
210 215 220

Thr Asp Val Met Gly Met Asp Glu Leu Tyr Lys
225 230 235

<210> 180
<211> 705
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 180

```
gtgagcaagg gcgaggaaga taacatggcc tctctcccag cgacacatga gttacacatc      60
tttggctcca tcaacggtgt ggactttgac atggtgggtc agggcaccgg caatccaaat      120
gatggttatg aagagttaaa cctcaagtcc accaaggggtg acctccagtt ctccccctgg      180
attctggtcc ctcatatcgg gtatggcttc catcagtacc tgccctaccc tgacgggatg      240
tcgcctttcc aggccgcat ggtagatggc tccggatacc aagtccatcg cacaatgcag      300
tttgaagatg gtgcctccct tactgttaac taccgctaca cctacgaggg aagccacatc      360
aaaggagagg cccaggtgaa ggggactggg ttccctgctg acggtcctgt gatgaccaac      420
tcgctgaccg ctgcggactg gtgcaggtcg aagaagactt accccaacga caaaaccatc      480
atcagtacct ttaagtggag ttacaccact ggaaatggca agcgctaccg gagcactgcg      540
cggaccacct acacctttgc caagccaatg gcggctaact atctaaagaa ccagccgatg      600
tacgtgttcc gtaagacgga gctcaagcac tccaagaccg agctcaactt caaggagtgg      660
caaaaggcct ttaccgatgt gatgggcatg gacgagctgt acaag                        705
```

<210> 181

<211> 236

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 181

```
Val Ser Lys Gly Glu Glu Leu Ile Lys Glu Asn Met Arg Met Lys Val
1              5              10              15
```

```
Val Met Glu Gly Ser Val Asn Gly His Gln Phe Lys Cys Thr Gly Glu
          20              25              30
```

```
Gly Glu Gly Arg Pro Tyr Glu Gly Val Gln Thr Met Arg Ile Lys Val
          35              40              45
```

```
Ile Glu Gly Gly Pro Leu Pro Phe Ala Phe Asp Ile Leu Ala Thr Ser
          50              55              60
```

Phe Met Tyr Gly Ser Arg Thr Phe Ile Lys Tyr Pro Ala Asp Ile Pro
65 70 75 80

Asp Phe Phe Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Val
85 90 95

Thr Arg Tyr Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Thr Ser
100 105 110

Leu Glu Asp Gly Glu Leu Val Tyr Asn Val Lys Val Arg Gly Val Asn
115 120 125

Phe Pro Ser Asn Gly Pro Val Met Gln Lys Lys Thr Lys Gly Trp Glu
130 135 140

Pro Asn Thr Glu Met Met Tyr Pro Ala Asp Gly Gly Leu Arg Gly Tyr
145 150 155 160

Thr Asp Ile Ala Leu Lys Val Asp Gly Gly Gly His Leu His Cys Asn
165 170 175

Phe Val Thr Thr Tyr Arg Ser Lys Lys Thr Val Gly Asn Ile Lys Met
180 185 190

Pro Gly Val His Ala Val Asp His Arg Leu Glu Arg Ile Glu Glu Ser
195 200 205

Asp Asn Glu Thr Tyr Val Val Gln Arg Glu Val Ala Val Ala Lys Tyr
210 215 220

Ser Asn Leu Gly Gly Gly Met Asp Glu Leu Tyr Lys
225 230 235

<210> 182
<211> 708
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 182

gtgtctaagg gcgaagagct gatcaaggaa aatatgcgta tgaagggtgt catggaaggt	60
tcgggtcaacg gccaccaatt caaatgcaca ggtgaaggag aaggcagacc gtacgagggg	120
gtgcaaacca tgaggatcaa agtcatcgag ggaggacccc tgccatttgc ctttgacatt	180
cttgccacgt cgttcatgta tggcagccgt acctttatca agtaccggc cgacatccct	240
gatttcttta aacagtcctt tcctgagggt ttacttggg aaagagttac gagatacgaa	300
gatggtggag tcgtcacctg cacgcaggac accagccttg aggatggcga gctcgtctac	360
aacgtcaagg tcagaggggt aaactttccc tccaatgggt ccgtgatgca gaagaagacc	420
aagggttggg agcctaatac agagatgatg tatccagcag atggtggtct gagaggatac	480
actgacatcg cactgaaagt tgatggtggt ggccatctgc actgcaactt cgtgacaact	540
tacaggtcaa aaaagaccgt cgggaacatc aagatgcccc gtgtccatgc cgttgatcac	600
cgcctggaaa ggatcgaaga gagtgacaat gaaacctacg tagtgcaaag agaagtggca	660
gttgccaaat acagcaacct tggtggtggc atggacgagc tgtacaag	708

<210> 183
 <211> 347
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 183

Arg	Ser	Arg	Leu	Leu	Glu	Asp	Phe	Arg	Asn	Asn	Arg	Tyr	Pro	Asn	Leu
1			5						10					15	

Gln	Leu	Arg	Glu	Ile	Ala	Gly	His	Ile	Met	Glu	Phe	Ser	Gln	Asp	Gln
			20					25					30		

His	Gly	Ser	Arg	Phe	Ile	Gln	Leu	Lys	Leu	Glu	Arg	Ala	Thr	Pro	Ala
		35					40					45			

Glu	Arg	Gln	Leu	Val	Phe	Asn	Glu	Ile	Leu	Gln	Ala	Ala	Tyr	Gln	Leu
	50					55					60				

Met	Val	Asp	Val	Phe	Gly	Asn	Tyr	Val	Ile	Gln	Lys	Phe	Phe	Glu	Phe
65					70					75				80	

Gly Ser Leu Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His
85 90 95

Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys
100 105 110

Ala Leu Glu Phe Ile Pro Ser Asp Gln Gln Asn Glu Met Val Arg Glu
115 120 125

Leu Asp Gly His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His
130 135 140

Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe
145 150 155 160

Ile Ile Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro
165 170 175

Tyr Gly Cys Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro Asp
180 185 190

Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln His Thr Glu Gln Leu
195 200 205

Val Gln Asp Gln Tyr Gly Asn Tyr Val Ile Gln His Val Leu Glu His
210 215 220

Gly Arg Pro Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly Asn
225 230 235 240

Val Leu Val Leu Ser Gln His Lys Phe Ala Ser Asn Val Val Glu Lys
245 250 255

Cys Val Thr His Ala Ser Arg Thr Glu Arg Ala Val Leu Ile Asp Glu
260 265 270

Val Cys Thr Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met Met
275 280 285

Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys Met Ile Asp Val Ala

290

295

300

Glu Pro Gly Gln Arg Lys Ile Val Met His Lys Ile Arg Pro His Ile
 305 310 315 320

Ala Thr Leu Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys Leu
 325 330 335

Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
 340 345

<210> 184
 <211> 1041
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 184
 cgcagtcggt tattagagga tttccgtaac aaccgttacc ctaatttgca actgcgtgag 60
 attgctggcc acattatgga attttcacaa gaccagcacg gatcgcggtt cattcaactt 120
 aaattagaac gcgctacgcc agccgaacgc cagtttagttt tcaacgaaat ttacaagcg 180
 gcataccaac tgatggtgga cgtttttggg aattatgtta tccagaagtt cttcgagttt 240
 ggaagcctgg agcagaaaact tgccctggcg gaacgcattc gtggtcacgt cttaagtttg 300
 gcactgcaga tgtatgggtg ccgtgttatc caaaaagctc ttgagtttat cccatctgat 360
 cagcagaacg aaatggtacg cgagctggac ggccatgttc ttaaagtcgt aaaggaccag 420
 aacggtaatc atgttggtaca gaaatgcac gaatgcgtcc agccacagtc tctgcagttc 480
 atcattgatg ctttcaaagg ccaagttttt gcccttagca cgcatcccta cgggtgtcgt 540
 gtcaccaac gcattcttga gcattgctta ccagatcaaa ctttgccaat cctggaggaa 600
 ttgcaccaac aactgaaca gctggtacaa gatcaatatg gtaactatgt aattcagcac 660
 gttctggaac atggacgccc tgaggacaag tctaaaattg tcgcggaaat ccgtggaaac 720
 gtattggtgt tgtccaaca caaatgtgcc agtaatgtcg tggagaaatg cgtaacccat 780
 gctagccgta ccgaacgcgc agtcttaatc gacgaagttt gcacaatgaa tgacggcccc 840
 cattcggctt tatatacaat gatgaaggac cagtacgcta attatgtcgt gcagaaaatg 900

attgatgtag cggagcctgg tcagcgcaag attgtgatgc acaagatccg cccgcacatt 960
gcgacattgc gtaagtatac gtacggcaaa cacatcttgg cgaaacttga aaagtactac 1020
atgaaaaatg gcgtggacct t 1041

<210> 185
<211> 182
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 185

Lys His Pro Leu Gln Asn Arg Trp Ala Leu Trp Phe Phe Lys Asn Asp
1 5 10 15

Lys Ser Lys Thr Trp Gln Ala Asn Leu Arg Leu Ile Ser Lys Phe Asp
20 25 30

Thr Val Glu Asp Phe Trp Ala Leu Tyr Asn His Ile Gln Leu Ser Ser
35 40 45

Asn Leu Met Pro Gly Cys Asp Tyr Ser Leu Phe Lys Asp Gly Ile Glu
50 55 60

Pro Met Trp Glu Asp Glu Lys Asn Lys Arg Gly Gly Arg Trp Leu Ile
65 70 75 80

Thr Leu Asn Lys Gln Gln Arg Arg Ser Asp Leu Asp Arg Phe Trp Leu
85 90 95

Glu Thr Leu Leu Cys Leu Ile Gly Glu Ser Phe Asp Asp Tyr Ser Asp
100 105 110

Asp Val Cys Gly Ala Val Val Asn Val Arg Ala Lys Gly Asp Lys Ile
115 120 125

Ala Ile Trp Thr Thr Glu Cys Glu Asn Arg Glu Ala Val Thr His Ile
130 135 140

Gly Arg Val Tyr Lys Glu Arg Leu Gly Leu Pro Pro Lys Ile Val Ile

145 150 155 160

Lys Asn Arg Phe Val Val
180

<220>
<223> Synthetic

<210>	187
<211>	173
<212>	PRT
<213>	Artificial Sequence

<400> 187

Thr Glu Ala Met Leu Tyr Glu Lys Phe Ser Pro Ala Gly Pro Ile Leu
20 25 30

Ser Ile Arg Val Cys Arg Asp Met Ile Thr Arg Arg Ser Leu Gly Tyr
35 40 45

Ala Tyr Val Asn Phe Gln Gln Pro Ala Asp Ala Glu Arg Ala Leu Asp
50 55 60

Thr Met Asn Phe Asp Val Ile Lys Gly Lys Pro Val Arg Ile Met Trp
65 70 75 80

Ser Gln Arg Asp Pro Ser Leu Arg Lys Ser Gly Val Gly Asn Ile Phe
85 90 95

Ile Lys Asn Leu Asp Lys Ser Ile Asp Asn Lys Ala Leu Tyr Asp Thr
100 105 110

Phe Ser Ala Phe Gly Asn Ile Leu Ser Cys Lys Val Val Cys Asp Glu
115 120 125

Asn Gly Ser Lys Gly Tyr Gly Phe Val His Phe Glu Thr Gln Glu Ala
130 135 140

Ala Glu Arg Ala Ile Glu Lys Met Asn Gly Met Leu Leu Asn Asp Arg
145 150 155 160

Lys Val Phe Val Gly Arg Phe Lys Ser Arg Lys Glu Arg
165 170

<210> 188
<211> 519
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 188
agctacccaa tggcgagcct gtatgtcggg gaccttcacc ctgatgttac cgaggccatg 60
ctgtatgaga aattcagccc agctggtccg atcctttcca ttcgcgtgtg ccgcgatatg 120

atcacacgtc gttcccttgg ttacgcctat gtaaattttc aacaaccagc cgatgcagaa	180
cgcgcccttgg acactatgaa tttcgaatgtg attaagggtg aaccggttcg cattatgtgg	240
tcccaacgtg atccttcgct tcgcaagtct ggggtaggga acatctttat taaaaatctg	300
gacaagtcca ttgataacaa agcattatat gataccttct cagcgttcgg gaacatttta	360
tcctgtaagg ttgtgtgcga cgaaaatgga agcaaaggct atggctttgt acattttgag	420
acacaggagg cggcagagcg tgccattgaa aagatgaatg gaatgttact taatgaccgt	480
aaggtgttcg tcggtcgttt taaatcgcgc aaggaacgc	519

<210> 189
 <211> 70
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 189

Ser	Thr	Arg	Tyr	Lys	Thr	Glu	Leu	Cys	Arg	Pro	Phe	Glu	Glu	Ser	Gly
1				5					10					15	

Thr	Cys	Lys	Tyr	Gly	Glu	Lys	Cys	Gln	Phe	Ala	His	Gly	Phe	His	Glu
			20					25					30		

Leu	Arg	Ser	Leu	Thr	Arg	His	Pro	Lys	Tyr	Lys	Thr	Glu	Leu	Cys	Arg
		35					40					45			

Thr	Phe	His	Thr	Ile	Gly	Phe	Cys	Pro	Tyr	Gly	Pro	Arg	Cys	His	Phe
	50					55					60				

Ile	His	Asn	Ala	Asp	Glu
65					70

<210> 190
 <211> 210
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 190

agcaccgct ataaaaccga actgtgccgc ccgtttgaag aaagcggcac gtgcaaatac 60
 ggcgagaaat gccagttcgc ccatggcttc catgaactgc gcagtctgac gcgccatccg 120
 aagtacaaaa ccgagctgtg ccgcaccttc cataccatcg gcttttgtcc gtacggcccg 180
 cgctgccact tcatccataa tgcggatgaa 210

<210> 191
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 191

Gly Pro Arg Arg Gly Asp Gly Arg Arg Arg Gly Gly Gly Gly Arg Gly
 1 5 10 15

Gln Gly Gly Arg Gly Arg Gly Gly Gly Phe
 20 25

<210> 192
 <211> 78
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 192

gggcctcgtc gtggtgatgg ccgacgtcgt ggcggtggag gacgtggcca aggtggacgt 60
 ggacgtggtg gaggtttc 78

<210> 193
 <211> 95
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 193

Asn Arg Pro Pro Ser Ala Gly Glu Ser Val Gln Ile Thr Leu Pro Lys
 1 5 10 15

Asn Glu Val Gln Leu Asn Ala Tyr Val Leu Gln Glu Pro Pro Lys Gly
20 25 30

Glu Thr Tyr Thr Tyr Asp Trp Gln Leu Ile Thr His Pro Arg Asp Tyr
35 40 45

Ser Gly Glu Met Glu Gly Lys His Ser Gln Ile Leu Lys Leu Ser Lys
50 55 60

Leu Thr Pro Gly Leu Tyr Glu Phe Lys Val Ile Val Glu Gly Gln Asn
65 70 75 80

Ala His Gly Glu Gly Tyr Val Asn Val Thr Val Lys Pro Glu Pro
85 90 95

<210> 194
<211> 285
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 194
aatcgtccgc ccagcgcggg cgaaagcgtg cagatcacgc tgccgaaaaa cgaagtgcag 60
ctgaacgcct acgtgctgca agaaccgccg aaaggcgaaa cctacaccta cgattggcag 120
ctgatcacc atccgcgcga ttacagcggc gaaatggaag gcaagcacag ccagattctg 180
aaactgagca agctgacccc gggctctgtac gagttcaagg tgatcgtgga aggccagaat 240
gcccattggcg aaggctacgt taatgtgacg gtgaagccgg aaccg 285

<210> 195
<211> 98
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 195

Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln Phe Gln Glu Ile Ser
1 5 10 15

Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser Gln Ser Thr Asp Asp
20 25 30

Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu Lys Gly Pro Leu Arg
35 40 45

Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu Lys Leu Ser Lys Leu
50 55 60

Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val Val Asp Ser Asp Gly
65 70 75 80

Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val Asn Lys Ala Val Asp
85 90 95

Tyr Pro

<210> 196
<211> 294
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 196
aatcgtccgc ccatcgctat tgtcagccct caatttcagg agatcagctt gccgacaacc 60
tccactgtaa ttgatggttc ccagtcgacc gacgacgata aaatcgtaaca ataccactgg 120
gaggaactca aggggccgct gcgtgaggaa aagatcagcg aggataccgc aattttgaaa 180
cttagtaaac tggttcccg gcaactacaca ttttctttaa cggttgtaga ctcggatggt 240
gccaccaact ctacgaccgc taatcttaca gtgaacaaag cggtcgatta tccg 294

<210> 197
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 197

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Tyr
165

<210> 198
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 198

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

210

215

220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 199

<211> 486

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 199

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

50

55

60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Ser Pro Tyr Ser Gly Tyr

<210> 200
 <211> 646
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 200

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

165

170

175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
485 490 495

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
500 505 510

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
515 520 525

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
530 535 540

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
545 550 555 560

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
565 570 575

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
580 585 590

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

595

600

605

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 610 615 620

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 625 630 635 640

Ser Pro Tyr Ser Gly Tyr
 645

<210> 201
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 201

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

115

120

125

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 145 150 155 160

Gln Pro Tyr Gln Gly Tyr
 165

<210> 202
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 202

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

115

120

125

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Gln Gly Tyr
325

<210> 203
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 203

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Gln Gly Tyr
325

<210> 204
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 204

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

225		230		235		240									
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			245					250						255	
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			260					265					270		
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		275					280					285			
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	290						295				300				
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
305					310					315					320
Gln	Pro	Tyr	Gln	Gly	Tyr										
			325												
<210>	205														
<211>	326														
<212>	PRT														
<213>	Artificial Sequence														
<220>															
<223>	Synthetic														
<400>	205														
Ser	Lys	Gly	Pro	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
1				5				10					15		
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			20					25					30		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	35						40					45			
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	50						55				60				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp

65						70						75						80
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
				85					90					95				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
			100					105					110					
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
		115					120					125						
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
	130					135					140							
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
145					150					155					160			
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
			165					170						175				
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
			180					185						190				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
		195					200					205						
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
		210					215					220						
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
225					230					235					240			
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
			245						250					255				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
			260					265						270				
Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp			
		275					280					285						

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 206
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 206

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Val Ser Gly Tyr
325

<210> 207

<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 207

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

180

185

190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 195 200 205

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Val Ser Gly Tyr
 325

<210> 208
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 208

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp

20

25

30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
35 40 45

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
100 105 110

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
130 135 140

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
165 170 175

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
195 200 205

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
260 265 270

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
290 295 300

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Val Ser Gly Tyr
325

<210> 209
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 209

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

290

295

300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 210
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 210

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp

130

135

140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 211

<211> 486

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 211

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
370 375 380

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
385 390 395 400

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

405

410

415

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 420 425 430

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 435 440 445

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 450 455 460

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 465 470 475 480

Gln Pro Tyr Gln Gly Tyr
 485

<210> 212
 <211> 646
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 212

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

85

90

95

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
370 375 380

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
385 390 395 400

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
405 410 415

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
420 425 430

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
435 440 445

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
450 455 460

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
465 470 475 480

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
485 490 495

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
500 505 510

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

515

520

525

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 530 535 540

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 545 550 555 560

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 565 570 575

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 580 585 590

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 595 600 605

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 610 615 620

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 625 630 635 640

Gln Pro Tyr Gln Gly Tyr
 645

<210> 213
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 213

Ser Lys Phe Pro Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
 1 5 10 15

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
 20 25 30

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp

35

40

45

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
50 55 60

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
65 70 75 80

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
85 90 95

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
100 105 110

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
115 120 125

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
130 135 140

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
145 150 155 160

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
165 170 175

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
180 185 190

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
195 200 205

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
210 215 220

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
225 230 235 240

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
245 250 255

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
260 265 270

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
275 280 285

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
290 295 300

Thr Pro Tyr Thr Gly Arg Gly Asp Thr Pro Tyr Thr Gly Arg Gly Asp
305 310 315 320

Thr Pro Tyr Thr Gly Tyr
325

<210> 214
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 214

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Asn Gly Tyr
165

<210> 215
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 215

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp

305

310

315

320

Asn Pro Tyr Asn Gly Tyr
325

<210> 216

<211> 486

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 216

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp

145		150		155		160									
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			165					170						175	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			180					185						190	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			195					200						205	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			210					215						220	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			225					230						235	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			245					250						255	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			260					265						270	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			275					280						285	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			290					295						300	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			305					310						315	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			325					330						335	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			340					345						350	
Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Asn	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			355					360						365	

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
370 375 380

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
385 390 395 400

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
405 410 415

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
420 425 430

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
435 440 445

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
450 455 460

Asn Pro Tyr Asn Gly Arg Gly Asp Asn Pro Tyr Asn Gly Arg Gly Asp
465 470 475 480

Asn Pro Tyr Asn Gly Tyr
485

<210> 217
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 217

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
20 25 30

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
35 40 45

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
50 55 60

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
100 105 110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro His Ser Gly Tyr
165

<210> 218
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 218

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
20 25 30

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
35 40 45

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
50 55 60

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
100 105 110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
165 170 175

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
180 185 190

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
195 200 205

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
210 215 220

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
245 250 255

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp

260

265

270

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 275 280 285

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 290 295 300

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro His Ser Gly Tyr
 325

<210> 219
 <211> 486
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 219

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 20 25 30

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 35 40 45

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 50 55 60

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
 85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp

100

105

110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
165 170 175

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
180 185 190

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
195 200 205

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
210 215 220

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
245 250 255

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
260 265 270

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
275 280 285

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
290 295 300

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
325 330 335

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
340 345 350

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
355 360 365

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
370 375 380

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
385 390 400

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
405 410 415

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
420 425 430

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
435 440 445

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
450 455 460

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
465 470 475 480

Ser Pro His Ser Gly Tyr
485

<210> 220
<211> 646
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 220

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
20 25 30

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
35 40 45

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
50 55 60

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
100 105 110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
165 170 175

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
180 185 190

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
195 200 205

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp

210

215

220

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
245 250 255

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
260 265 270

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
275 280 285

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
290 295 300

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
325 330 335

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
340 345 350

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
355 360 365

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
370 375 380

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
385 390 395 400

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
405 410 415

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
420 425 430

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
435 440 445

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
450 455 460

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
465 470 475 480

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
485 490 495

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
500 505 510

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
515 520 525

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
530 535 540

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
545 550 555 560

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
565 570 575

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
580 585 590

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
595 600 605

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
610 615 620

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
625 630 635 640

Ser Pro His Ser Gly Tyr

<210> 221
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 221

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 85 90 95

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 100 105 110

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 115 120 125

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 130 135 140

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 145 150 155 160

Ser Pro Phe Ser Gly Tyr

<210> 222
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 222

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 85 90 95

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 100 105 110

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 115 120 125

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 130 135 140

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 145 150 155 160

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp

165

170

175

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 180 185 190

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 195 200 205

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 210 215 220

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 245 250 255

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Phe Ser Gly Arg Gly Asp Ser Pro Phe Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Phe Ser Gly Tyr
 325

<210> 223
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 223

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp

1	5	10	15												
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			20					25					30		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			35				40					45			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			50				55					60			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
65					70					75					80
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
				85						90				95	
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			100					105					110		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			115				120					125			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			130				135					140			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
145					150					155					160
Ser	Pro	Tyr	Gln	Gly	Tyr										
				165											

<210> 224
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 224

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp

1	5	10	15
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
20	25	30	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
35	40	45	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
50	55	60	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
65	70	75	80
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
85	90	95	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
100	105	110	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
115	120	125	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
130	135	140	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
145	150	155	160
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
165	170	175	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
180	185	190	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
195	200	205	
Ser Pro Tyr Gln Gly Arg Gly Asp	Ser Pro Tyr Gln Gly Arg Gly Asp		
210	215	220	

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Gln Gly Tyr
325

<210> 225
<211> 486
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 225

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp

275

280

285

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
370 375 380

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
385 390 395 400

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
405 410 415

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
420 425 430

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
435 440 445

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
450 455 460

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
465 470 475 480

Ser Pro Tyr Gln Gly Tyr
485

<210> 226
<211> 646
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 226

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
370 375 380

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp

385		390		395		400									
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
				405					410					415	
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			420					425					430		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
		435					440					445			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	450					455					460				
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
465					470					475				480	
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			485					490					495		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
		500						505					510		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	515						520					525			
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	530					535					540				
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
545					550					555				560	
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
			565					570					575		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	580							585					590		
Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Gln	Gly	Arg	Gly	Asp
	595						600					605			

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
610 615 620

Ser Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Gln Gly Arg Gly Asp
625 630 635 640

Ser Pro Tyr Gln Gly Tyr
645

<210> 227
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 227

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Ser Gly Tyr
165

<210> 228
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 228

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Ser Gly Tyr
325

<210> 229

<211> 486
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 229

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp

180

185

190

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Gln Pro Tyr Ser Gly Tyr
485

<210> 230
<211> 646
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 230

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp

290

295

300

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
485 490 495

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
500 505 510

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
515 520 525

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
530 535 540

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
545 550 555 560

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
565 570 575

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
580 585 590

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
595 600 605

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
610 615 620

Gln Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Ser Gly Arg Gly Asp
625 630 635 640

Gln Pro Tyr Ser Gly Tyr
645

<210> 231
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 231

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Ser Gly Tyr
165

<210> 232
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 232

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp

245

250

255

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Ser Gly Tyr
325

<210> 233
<211> 484
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 233

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp

85

90

95

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Asn Pro Tyr Ser

<210> 234
<211> 645
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 234

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp

195

200

205

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
325 330 335

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
340 345 350

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
355 360 365

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
370 375 380

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
385 390 395 400

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
405 410 415

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
420 425 430

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
435 440 445

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
450 455 460

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
465 470 475 480

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
485 490 495

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
500 505 510

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
515 520 525

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
530 535 540

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
545 550 555 560

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
565 570 575

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
580 585 590

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
595 600 605

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp
610 615 620

Asn Pro Tyr Ser Gly Arg Gly Asp Asn Pro Tyr Ser Gly Arg Gly Asp

625

630

635

640

Asn Pro Tyr Ser Gly
645

<210> 235

<211> 166

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 235

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp

145

150

155

160

Ser Pro Tyr Asn Gly Tyr
165

<210> 236

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 236

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp

145		150		155		160									
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			165					170						175	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			180					185						190	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			195					200						205	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			210					215						220	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			225					230						235	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			245					250						255	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			260					265						270	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			275					280						285	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			290					295						300	
Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Asn	Gly	Arg	Gly	Asp
			305					310						315	
Ser	Pro	Tyr	Asn	Gly	Tyr										
			325												

<210> 237
 <211> 486
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Synthetic

<400> 237

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
325 330 335

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
340 345 350

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
355 360 365

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
370 375 380

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
385 390 395 400

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
405 410 415

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp

420

425

430

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
435 440 445

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
450 455 460

Ser Pro Tyr Asn Gly Arg Gly Asp Ser Pro Tyr Asn Gly Arg Gly Asp
465 470 475 480

Ser Pro Tyr Asn Gly Tyr
485

<210> 238
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 238

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp

100

105

110

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Gln Cys Tyr
165

<210> 239
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 239

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp

100

105

110

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Gln Gly Tyr
325

<210> 240
<211> 486
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 240

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp

370

375

380

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 385 390 395 400

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 405 410 415

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 420 425 430

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 435 440 445

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 450 455 460

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 465 470 475 480

Asn Pro Tyr Gln Gly Tyr
 485

<210> 241
 <211> 646
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 241

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 1 5 10 15

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 20 25 30

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
 35 40 45

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp

50

55

60

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
290 295 300

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
305 310 315 320

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
325 330 335

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
340 345 350

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
355 360 365

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
370 375 380

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
385 390 395 400

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
405 410 415

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
420 425 430

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
435 440 445

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
450 455 460

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
465 470 475 480

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp

485

490

495

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
500 505 510

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
515 520 525

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
530 535 540

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
545 550 555 560

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
565 570 575

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
580 585 590

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
595 600 605

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
610 615 620

Asn Pro Tyr Gln Gly Arg Gly Asp Asn Pro Tyr Gln Gly Arg Gly Asp
625 630 635 640

Asn Pro Tyr Gln Gly Tyr
645

<210> 242
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 242

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp

1	5	10	15
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
20	25	30	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
35	40	45	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
50	55	60	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
65	70	75	80
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
85	90	95	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
100	105	110	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
115	120	125	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
130	135	140	
Gln Pro Tyr Asn Gly Arg Gly Asp	Gln Pro Tyr Asn Gly Arg Gly Asp		
145	150	155	160
Gln Pro Tyr Asn Gly Tyr			
165			

<210> 243
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 243

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp

1	5	10	15
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	20	25	30
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	35	40	45
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	50	55	60
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	65	70	75
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	85	90	95
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	100	105	110
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	115	120	125
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	130	135	140
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	145	150	155
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	165	170	175
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	180	185	190
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	195	200	205
Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp	210	215	220

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Asn Gly Tyr
325

<210> 244
<211> 486
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 244

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp

275

280

285

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
325 330 335

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
340 345 350

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
355 360 365

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
370 375 380

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
385 390 395 400

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
405 410 415

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
420 425 430

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
435 440 445

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
450 455 460

Gln Pro Tyr Asn Gly Arg Gly Asp Gln Pro Tyr Asn Gly Arg Gly Asp
465 470 475 480

Gln Pro Tyr Asn Gly Tyr
485

<210> 245
<211> 410
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 245

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro
165 170 175

Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val
180 185 190

Arg Gly Glu Gly Glu Gly Asp Ala Thr Asn Gly Lys Leu Thr Leu Lys
195 200 205

Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val
210 215 220

Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His
225 230 235 240

Met Lys Arg His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val
245 250 255

Gln Glu Arg Thr Ile Ser Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg
260 265 270

Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu
275 280 285

Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu
290 295 300

Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln
305 310 315 320

Lys Asn Gly Ile Lys Ala Asn Phe Lys Ile Arg His Asn Ile Glu Asp
325 330 335

Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly
340 345 350

Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser
355 360 365

Val Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu
370 375 380

Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr

400

405

410

246

570

PRT

Artificial Sequence

$\langle 220 \rangle$

<223> Synthetic

246

1

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

Se

Gl

Se

Ar

145		150		155		160									
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
				165					170					175	
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			180					185					190		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		195					200					205			
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	210					215					220				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
225					230					235				240	
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			245					250					255		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		260						265					270		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	275						280					285			
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	290					295					300				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
305					310					315				320	
Ser	Pro	Tyr	Ser	Gly	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro
			325						330					335	
Ile	Leu	Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val
		340						345					350		
Arg	Gly	Glu	Gly	Glu	Gly	Asp	Ala	Thr	Asn	Gly	Lys	Leu	Thr	Leu	Lys
		355					360					365			

Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val
370 375 380

Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His
385 390 395 400

Met Lys Arg His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val
405 410 415

Gln Glu Arg Thr Ile Ser Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg
420 425 430

Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu
435 440 445

Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu
450 455 460

Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln
465 470 475 480

Lys Asn Gly Ile Lys Ala Asn Phe Lys Ile Arg His Asn Ile Glu Asp
485 490 495

Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly
500 505 510

Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser
515 520 525

Val Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu
530 535 540

Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr
545 550 555 560

Lys Glu Leu His His His His His Gly
565 570

<210> 247

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 247

Ser Lys Gly Pro Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
1 5 10 15

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
20 25 30

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
35 40 45

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
50 55 60

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
65 70 75 80

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
85 90 95

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
100 105 110

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
115 120 125

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
130 135 140

Ser Pro Tyr Gln Gly Arg Asp Gly Ser Pro Tyr Gln Gly Arg Asp Gly
145 150 155 160

Ser Pro Tyr Gln Gly Tyr
165

<210> 248

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 248

Ser Lys Gly Pro Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
1 5 10 15

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
20 25 30

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
35 40 45

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
50 55 60

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
65 70 75 80

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
85 90 95

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
100 105 110

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
115 120 125

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
130 135 140

Gln Pro Tyr Gln Gly Arg Asp Gly Gln Pro Tyr Gln Gly Arg Asp Gly
145 150 155 160

Gln Pro Tyr Gln Gly Tyr
165

<210> 249

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 249

Ser Lys Gly Pro Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
1 5 10 15

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
20 25 30

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
35 40 45

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
50 55 60

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
65 70 75 80

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
85 90 95

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
100 105 110

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
115 120 125

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
130 135 140

Ser Pro Tyr Asn Gly Arg Asp Gly Ser Pro Tyr Asn Gly Arg Asp Gly
145 150 155 160

Ser Pro Tyr Asn Gly Tyr
165

<210> 250

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 250

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
1 5 10 15

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
20 25 30

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
35 40 45

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
50 55 60

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
65 70 75 80

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
85 90 95

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
100 105 110

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
115 120 125

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
130 135 140

Asn Pro His Asn Gly Arg Gly Asp Asn Pro His Asn Gly Arg Gly Asp
145 150 155 160

Asn Pro His Asn Gly Tyr
165

<210> 251

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 251

Ser Lys Gly Pro Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
1 5 10 15

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
20 25 30

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
35 40 45

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
50 55 60

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
65 70 75 80

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
85 90 95

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
100 105 110

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
115 120 125

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
130 135 140

Asn Pro His Ser Gly Arg Gly Asp Asn Pro His Ser Gly Arg Gly Asp
145 150 155 160

Asn Pro His Ser Gly Tyr
165

<210> 252

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 252

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
1 5 10 15

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
20 25 30

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
35 40 45

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
50 55 60

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
65 70 75 80

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
85 90 95

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
100 105 110

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
115 120 125

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
130 135 140

Ser Pro His Asn Gly Arg Gly Asp Ser Pro His Asn Gly Arg Gly Asp
145 150 155 160

Ser Pro His Asn Gly Tyr
165

<210> 253

<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 253

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
1 5 10 15

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
20 25 30

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
35 40 45

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
50 55 60

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
65 70 75 80

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
85 90 95

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
100 105 110

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
115 120 125

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
130 135 140

Gln Pro His Asn Gly Arg Gly Asp Gln Pro His Asn Gly Arg Gly Asp
145 150 155 160

Gln Pro His Asn Gly Tyr
165

<210> 254

<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 254

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

180

185

190

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Gln Pro Tyr Gln Gly Tyr
 325

<210> 255
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 255

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

20

25

30

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Gln Pro Tyr Gln Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Gln Pro Tyr Gln Gly Tyr
325

<210> 256
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 256

Ser Lys Gly Pro Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
1 5 10 15

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
35 40 45

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
65 70 75 80

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
100 105 110

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
130 135 140

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
165 170 175

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
195 200 205

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
225 230 235 240

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
260 265 270

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp

290

295

300

Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 257

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 257

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

130

135

140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Val Ser Gly Tyr
325

<210> 258

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 258

Ser Lys Phe Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Val Ser Gly Tyr
325

<210> 259
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 259

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
35 40 45

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
100 105 110

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
130 135 140

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
165 170 175

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
195 200 205

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp

245

250

255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
260 265 270

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
290 295 300

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 260
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 260

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
35 40 45

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp

85

90

95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
100 105 110

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
130 135 140

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
165 170 175

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
195 200 205

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
260 265 270

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
290 295 300

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Val Ser Gly Tyr
325

<210> 261
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 261

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Ala Ser Gly Tyr
325

<210> 262

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 262

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

195

200

205

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Ala Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Ala Ser Gly Tyr
325

<210> 263
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 263

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

35

40

45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Ile Ser Gly Tyr
325

<210> 264
<211> 358
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 264

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Ile Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

305		310		315		320									
Ser	Pro	Ile	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
				325					330					335	
Ser	Pro	Ile	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			340					345					350		
Ser	Pro	Ile	Ser	Gly	Tyr										
			355												
<210> 265															
<211> 326															
<212> PRT															
<213> Artificial Sequence															
<220>															
<223> Synthetic															
<400> 265															
Ser	Lys	Gly	Pro	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
1				5					10					15	
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			20					25					30		
Ser	Pro	Met	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		35					40					45			
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	50					55				60					
Ser	Pro	Met	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
65					70				75					80	
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			85					90					95		
Ser	Pro	Met	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		100						105					110		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp

115

120

125

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Met Ser Gly Tyr
325

<210> 266
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 266

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Met Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Met Ser Gly Tyr
325

<210> 267
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 267

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

225		230		235		240									
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
				245				250						255	
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
			260					265					270		
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		275					280					285			
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	290						295				300				
Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
305					310					315				320	
Ser	Pro	His	Ser	Gly	Tyr										
				325											
<210>	268														
<211>	326														
<212>	PRT														
<213>	Artificial Sequence														
<220>															
<223>	Synthetic														
<400>	268														
Ser	Lys	Gly	Pro	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
1				5				10					15		
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
		20						25					30		
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	35						40					45			
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp
	50					55				60					
Ser	Pro	His	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp

65

70

75

80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 85 90 95

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 100 105 110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 115 120 125

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 145 150 155 160

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 165 170 175

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 180 185 190

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 195 200 205

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 210 215 220

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro His Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro His Ser Gly Tyr
325

<210> 269
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 269

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
35 40 45

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
100 105 110

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
130 135 140

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
165 170 175

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
195 200 205

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
260 265 270

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
290 295 300

Ser Pro His Ser Gly Arg Gly Asp Ser Pro His Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 270

<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 270

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp

180

185

190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 271
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 271

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp

20

25

30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Lys Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 272
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 272

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
20 25 30

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
50 55 60

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
85 90 95

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
115 120 125

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
145 150 155 160

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
180 185 190

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
210 215 220

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
245 250 255

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
275 280 285

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu

290

295

300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Glu
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 273

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 273

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 85 90 95

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 115 120 125

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

130

135

140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 145 150 155 160

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 180 185 190

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 210 215 220

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Trp Ser Gly Tyr
 325

<210> 274

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 274

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Trp Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Trp Ser Gly Tyr
325

<210> 275
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 275

Ser Lys Gly Pro Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

245

250

255

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Tyr Ser Gly Tyr
 325

<210> 276
 <211> 326
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 276

Ser Lys Gly Pro Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 1 5 10 15

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 20 25 30

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 35 40 45

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 50 55 60

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 65 70 75 80

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

85

90

95

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
195 200 205

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
260 265 270

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 277
<211> 326
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 277

Ser Lys Gly Pro Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp
35 40 45

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp
100 105 110

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp
195 200 205

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
210 215 220

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
225 230 235 240

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
245 250 255

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Pro Asp
260 265 270

Ser Pro Tyr Ser Pro Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
275 280 285

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Pro Arg Gly Asp
290 295 300

Ser Pro Tyr Ser Gly Arg Pro Asp Ser Pro Tyr Ser Gly Arg Gly Asp
305 310 315 320

Ser Pro Tyr Ser Gly Tyr
325

<210> 278
<211> 570
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 278

Ser Lys Gly Pro Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
1 5 10 15

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
20 25 30

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
35 40 45

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
50 55 60

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
65 70 75 80

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
85 90 95

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
100 105 110

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
115 120 125

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
130 135 140

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
145 150 155 160

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
165 170 175

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
180 185 190

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp

195

200

205

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 210 215 220

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 225 230 235 240

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 245 250 255

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 260 265 270

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 275 280 285

Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 290 295 300

Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp
 305 310 315 320

Ser Pro Val Ser Gly Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro
 325 330 335

Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val
 340 345 350

Arg Gly Glu Gly Glu Gly Asp Ala Thr Asn Gly Lys Leu Thr Leu Lys
 355 360 365

Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val
 370 375 380

Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His
 385 390 395 400

Met Lys Arg His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val
 405 410 415

Gln Glu Arg Thr Ile Ser Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg
420 425 430

Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu
435 440 445

Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu
450 455 460

Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln
465 470 475 480

Lys Asn Gly Ile Lys Ala Asn Phe Lys Ile Arg His Asn Ile Glu Asp
485 490 495

Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly
500 505 510

Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser
515 520 525

Val Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu
530 535 540

Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr
545 550 555 560

Lys Glu Leu His His His His His His Gly
565 570

<210> 279
<211> 323
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X = azido-phenylalanine (AzF)

<220>
<221> MISC_FEATURE
<222> (162)..(162)
<223> X = azido-phenylalanine (AzF)

<220>
<221> MISC_FEATURE
<222> (323)..(323)
<223> X = azido-phenylalanine (AzF)

<400> 279

Xaa Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr
1 5 10 15

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val
20 25 30

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr
35 40 45

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val
50 55 60

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr
65 70 75 80

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val
85 90 95

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr
100 105 110

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val
115 120 125

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr
130 135 140

Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val
145 150 155 160

Ser Xaa Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro

165

170

175

Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 180 185 190

Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 195 200 205

Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 210 215 220

Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 225 230 235 240

Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 245 250 255

Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 260 265 270

Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 275 280 285

Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 290 295 300

Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro
 305 310 315 320

Val Ser Xaa

<210> 280
 <211> 246
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 280

Gly Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu

1	5	10	15
Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Arg Gly Glu Gly	20	25	30
Glu Gly Asp Ala Thr Asn Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr	35	40	45
Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr	50	55	60
Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg His	65	70	75
Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr	85	90	95
Ile Ser Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys	100	105	110
Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp	115	120	125
Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr	130	135	140
Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln Lys Asn Gly Ile	145	150	155
Lys Ala Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln	165	170	175
Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val	180	185	190
Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Val Leu Ser Lys	195	200	205
Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr	210	215	220

Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys Glu Leu His
225 230 235 240

His His His His His Gly
245

<210> 281
<211> 237
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 281

Gly Val Ser Lys Gly Glu Glu Leu Ile Lys Glu Asn Met Arg Met Lys
1 5 10 15

Val Val Met Glu Gly Ser Val Asn Gly His Gln Phe Lys Cys Thr Gly
20 25 30

Glu Gly Glu Gly Arg Pro Tyr Glu Gly Val Gln Thr Met Arg Ile Lys
35 40 45

Val Ile Glu Gly Gly Pro Leu Pro Phe Ala Phe Asp Ile Leu Ala Thr
50 55 60

Ser Phe Met Tyr Gly Ser Arg Thr Phe Ile Lys Tyr Pro Ala Asp Ile
65 70 75 80

Pro Asp Phe Phe Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg
85 90 95

Val Thr Arg Tyr Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Thr
100 105 110

Ser Leu Glu Asp Gly Glu Leu Val Tyr Asn Val Lys Val Arg Gly Val
115 120 125

Asn Phe Pro Ser Asn Gly Pro Val Met Gln Lys Lys Thr Lys Gly Trp
130 135 140

Glu Pro Asn Thr Glu Met Met Tyr Pro Ala Asp Gly Gly Leu Arg Gly
145 150 155 160

Tyr Thr Asp Ile Ala Leu Lys Val Asp Gly Gly Gly His Leu His Cys
165 170 175

Asn Phe Val Thr Thr Tyr Arg Ser Lys Lys Thr Val Gly Asn Ile Lys
180 185 190

Met Pro Gly Val His Ala Val Asp His Arg Leu Glu Arg Ile Glu Glu
195 200 205

Ser Asp Asn Glu Thr Tyr Val Val Gln Arg Glu Val Ala Val Ala Lys
210 215 220

Tyr Ser Asn Leu Gly Gly Gly Met Asp Glu Leu Tyr Lys
225 230 235

<210> 282
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 282
ctcactatag ggagacccaa gctggctagc atgagcaaag ggccgggacg cggcgatagt 60

<210> 283
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 283
ttagccgtga tggtgatggt gatggagctc gttgattgtc gagggccctc tagactcgag 60

<210> 284
<211> 378
<212> PRT
<213> Artificial Sequence

<220>

<223> Synthetic

<400> 284

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
165 170 175

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
180 185 190

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln

195

200

205

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 210 215 220

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 225 230 235 240

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 245 250 255

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 260 265 270

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 275 280 285

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 290 295 300

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 305 310 315 320

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
 325 330 335

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln
 340 345 350

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
 355 360 365

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
 370 375

<210> 285

<211> 1134

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 285
 gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 60
 cagccttatc aaggtcgcgg tgatcaaccg tatcaaggta gaggggacca accatatcag 120
 ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 180
 caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 240
 ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 300
 cagccatacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa 360
 ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcgat 420
 caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag 480
 gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 540
 cagccttatc aaggtcgcgg tgatcaaccg tatcaaggta gaggggacca accatatcag 600
 ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 660
 caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 720
 ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 780
 cagccatacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa 840
 ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcgat 900
 caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag 960
 gtggacaata agttcaataa ggagcagcag aatgcctttt acgagattct ccacctgccc 1020
 aacctcaacg aagagcagag aaatgcgttt atccagagtc tgaaagacga cccaagccag 1080
 tccgcaaacc tgctggctga ggccaagaag cttaacgacg cacaggcccc aaag 1134

<210> 286
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 286

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 1 5 10 15

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
165 170 175

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln
180 185 190

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
195 200 205

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
210 215

<210> 287

<211> 654
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 287
gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 60
cagccttatc aaggtcgcgg tgatcaaccg tatcaaggta gaggggacca accatatcag 120
ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 180
caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 240
ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 300
cagccatacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa 360
ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcgat 420
caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag 480
gtggacaata agttcaataa ggagcagcag aatgcctttt acgagattct ccacctgccc 540
aacctcaacg aagagcagag aaatgcgttt atccagagtc tgaaagacga cccaagccag 600
tccgcaaacc tgctggctga ggccaagaag cttaacgacg cacaggcccc aaag 654

<210> 288
<211> 418
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 288

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

50

55

60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
180 185 190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
195 200 205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
260 265 270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
305 310 315 320

Asn Arg Pro Pro Ile Ala Ile Val Ser Pro Gln Phe Gln Glu Ile Ser
325 330 335

Leu Pro Thr Thr Ser Thr Val Ile Asp Gly Ser Gln Ser Thr Asp Asp
340 345 350

Asp Lys Ile Val Gln Tyr His Trp Glu Glu Leu Lys Gly Pro Leu Arg
355 360 365

Glu Glu Lys Ile Ser Glu Asp Thr Ala Ile Leu Lys Leu Ser Lys Leu
370 375 380

Val Pro Gly Asn Tyr Thr Phe Ser Leu Thr Val Val Asp Ser Asp Gly
385 390 395 400

Ala Thr Asn Ser Thr Thr Ala Asn Leu Thr Val Asn Lys Ala Val Asp
405 410 415

Tyr Pro

<210> 289
<211> 1254
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 289
ggacgcggcg atagtccata ttcaggtcgg ggagatagtc cctactcagg taggggagac 60
agcccatata gcgggcgtgg cgactctcca tatagtggga gaggggactc tccgtactct 120

gggcgcggtg attcaccata ttctggtcga ggtgactcac cttattctgg caggggtgat	180
agtccgtatt caggccgtgg tgattcccc tatagtggaa ggggagattc accgtatagt	240
ggtagaggcg acagtcctta ttcgggacga ggtgattctc cttatagtgg ccgaggggat	300
tcaccctatt ctggaagagg tgatagccct tattcaggga ggggcgattc tccctattca	360
ggacggggtg actctcctta ctccggtcgc ggagattctc catactcggg tcgtggagac	420
tccccatatt ccggcagagg tgacagtcca tacagtggac gtggggatag tccttacagt	480
ggacgcggcg atagtccata ttcaggtcgg ggagatagtc cctactcagg taggggagac	540
agcccatata gcgggcgtgg cgactctcca tatagtggga gaggggactc tccgtactct	600
gggcgcggtg attcaccata ttctggtcga ggtgactcac cttattctgg caggggtgat	660
agtccgtatt caggccgtgg tgattcccc tatagtggaa ggggagattc accgtatagt	720
ggtagaggcg acagtcctta ttcgggacga ggtgattctc cttatagtgg ccgaggggat	780
tcaccctatt ctggaagagg tgatagccct tattcaggga ggggcgattc tccctattca	840
ggacggggtg actctcctta ctccggtcgc ggagattctc catactcggg tcgtggagac	900
tccccatatt ccggcagagg tgacagtcca tacagtggac gtggggatag tccttacagt	960
aatcggtccg ccatcgctat tgtcagccct caatttcagg agatcagctt gccgacaacc	1020
tccactgtaa ttgatggttc ccagtcgacc gacgacgata aaatcgta ataccactgg	1080
gaggaactca aggggccgct gcgtgaggaa aagatcagcg aggataccgc aattttgaaa	1140
cttagtaaac tggttcccg caactacaca ttttctttaa cggttgtaga ctcggatggt	1200
gccaccaact ctacgaccgc taatcttaca gtgaacaaag cggtcgatta tccg	1254

<210> 290
 <211> 555
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 290

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
1				5				10						15	

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

20

25

30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 180 185 190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 195 200 205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
260 265 270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
305 310 315 320

Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ser Leu Pro Ala Thr His
325 330 335

Glu Leu His Ile Phe Gly Ser Ile Asn Gly Val Asp Phe Asp Met Val
340 345 350

Gly Gln Gly Thr Gly Asn Pro Asn Asp Gly Tyr Glu Glu Leu Asn Leu
355 360 365

Lys Ser Thr Lys Gly Asp Leu Gln Phe Ser Pro Trp Ile Leu Val Pro
370 375 380

His Ile Gly Tyr Gly Phe His Gln Tyr Leu Pro Tyr Pro Asp Gly Met
385 390 395 400

Ser Pro Phe Gln Ala Ala Met Val Asp Gly Ser Gly Tyr Gln Val His
405 410 415

Arg Thr Met Gln Phe Glu Asp Gly Ala Ser Leu Thr Val Asn Tyr Arg
420 425 430

Tyr Thr Tyr Glu Gly Ser His Ile Lys Gly Glu Ala Gln Val Lys Gly
435 440 445

Thr Gly Phe Pro Ala Asp Gly Pro Val Met Thr Asn Ser Leu Thr Ala

450

455

460

Ala Asp Trp Cys Arg Ser Lys Lys Thr Tyr Pro Asn Asp Lys Thr Ile
 465 470 475 480

Ile Ser Thr Phe Lys Trp Ser Tyr Thr Thr Gly Asn Gly Lys Arg Tyr
 485 490 495

Arg Ser Thr Ala Arg Thr Thr Tyr Thr Phe Ala Lys Pro Met Ala Ala
 500 505 510

Asn Tyr Leu Lys Asn Gln Pro Met Tyr Val Phe Arg Lys Thr Glu Leu
 515 520 525

Lys His Ser Lys Thr Glu Leu Asn Phe Lys Glu Trp Gln Lys Ala Phe
 530 535 540

Thr Asp Val Met Gly Met Asp Glu Leu Tyr Lys
 545 550 555

<210> 291
 <211> 1665
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 291
 ggacgcggcg atagtccata ttcaggtcgg ggagatagtc cctactcagg taggggagac 60
 agcccatata gcgggcgtgg cgactctcca tatagtggga gaggggactc tccgtactct 120
 gggcgcggtg attcaccata ttctggtcga ggtgactcac cttattctgg caggggtgat 180
 agtccgtatt caggccgtgg tgattcccc tatagtggaa ggggagattc accgtatagt 240
 ggtagaggcg acagtcctta ttcgggacga ggtgattctc cttatagtgg ccgaggggat 300
 tcaccctatt ctggaagagg tgatagccct tattcaggga ggggcgattc tccctattca 360
 ggacgggggtg actctcctta ctccggtcgc ggagattctc catactcggg tcgtggagac 420
 tcccatatt ccggcagagg tgacagtcca tacagtggac gtggggatag tccttacagt 480
 ggacgcggcg atagtccata ttcaggtcgg ggagatagtc cctactcagg taggggagac 540

agcccatata gcgggcgtgg cgactctcca tatagtggga gaggggactc tccgtactct	600
gggcgcggtg attcaccata ttctggtcga ggtgactcac cttattctgg caggggtgat	660
agtccgtatt caggccgtgg tgattcccc tatagtggaa ggggagattc accgtatagt	720
ggtagaggcg acagtcctta ttcgggacga ggtgattctc cttatagtgg ccgaggggat	780
tcaccctatt ctggaagagg tgatagccct tattcaggga ggggcgattc tccctattca	840
ggacggggtg actctcctta ctccggtcgc ggagattctc catactcggg tcgtggagac	900
tcccatatt ccggcagagg tgacagtcca tacagtggac gtggggatag tccttacagt	960
gtgagcaagg gcgaggaaga taacatggcc tctctcccag cgacacatga gttacacatc	1020
tttggtcca tcaacggtgt ggactttgac atggtgggtc agggcaccgg caatccaaat	1080
gatggttatg aagagttaaa cctcaagtcc accaagggtg acctccagtt ctccccctgg	1140
attctggtcc ctcatatcgg gtatggcttc catcagtacc tgccctaccc tgacgggatg	1200
tcgcctttcc aggccgcat ggtagatggc tccggatacc aagtccatcg cacaatgcag	1260
tttgaagatg gtgcctccct tactgttaac taccgtaca cctacgaggg aagccacatc	1320
aaaggagagg cccaggtgaa ggggactggt ttccctgctg acggtcctgt gatgaccaac	1380
tcgctgaccg ctgcggactg gtgcaggtcg aagaagactt accccaacga caaaaccatc	1440
atcagtacct ttaagtggag ttacaccact ggaaatggca agcgctaccg gagcactgcg	1500
cggaccacct acacctttgc caagccaatg gcggctaact atctaaagaa ccagccgatg	1560
tacgtgttcc gtaagacgga gctcaagcac tccaagaccg agctcaactt caaggagtgg	1620
caaaaggcct ttaccgatgt gatgggcatg gacgagctgt acaag	1665

<210> 292
 <211> 192
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 292

Ala	Ala	His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu
1				5					10					15	

Glu	Glu	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Ala

20

25

30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 180 185 190

<210> 293
 <211> 576
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 293
 gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct

60

gcaaaagagt ttattgctg gcttgtgaaa ggagcaggac gaggggactc accttatagt	120
gggcgcggcg actctccata ttccggtcgg ggagattcac catatagtgg ccgtggcgat	180
agtcctgtgt ctggtagggg agactctccg tattcaggac gcggtgattc accctacagt	240
ggacggggtg attctcctta ttcgggtcgt ggggattctc cagtttcagg tagaggtgat	300
agcccttatt caggccgagg tgacagtcct tactccggca ggggtgactc cccatactcg	360
ggacgtggtg atagtccagt atcaggaagg ggagatagtc cctactctgg gagaggggat	420
agtccgtact caggtcgagg tgattcccc tattctggaa gaggtgactc tcctgtatct	480
ggcagaggcg acagtccata cagcgggcgt ggagattctc cctatagtgg tcgcggagac	540
agcccatatt cagggagggg cgattcacct gttagt	576

<210> 294
 <211> 192
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 294

Ala	Ala	His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu
1				5					10					15	

Glu	Glu	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Ala
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		50				55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
65					70					75				80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
				85				90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser

100

105

110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 180 185 190

<210> 295
 <211> 576
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 295
 gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
 gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac gcggagattc tccatactct 120
 ggtcgagggg atagtccggt ctcaggaaga ggcgatagtc catattcagg acgaggtgac 180
 agtccagtat ctggcagagg ggactctccg tattccggca ggggagacag ccctgtttca 240
 ggccgaggtg attctcctta ctcaggtcgg ggagatagtc ctgtgtctgg taggggtgac 300
 tccccctatt ctggaagggg agattcacct gtaagtgggc gtggtgattc accctactcg 360
 ggtcgtggag actctccagt tagtggtcgc ggtgattccc catatagcgg gcgcggcgat 420
 tctcccgttt ctgggagggg cgacagtcct tattcgggac gtggcgactc tcctgtatca 480
 gggagaggtg atagtcccta cagtggccgt ggggattcac cagtgtcagg tagaggtgac 540
 tcaccttata gtggacgggg tgatagccca gtcagt 576

<210> 296

<211> 192
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 296

Ala Ala His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu
1 5 10 15

Glu Glu Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala
20 25 30

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
35 40 45

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
100 105 110

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
165 170 175

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser

180

185

190

<210> 297
 <211> 576
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 297
 gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
 gcaaaagagt ttattgctg gcttgtgaaa ggagcaggac ggggtgatag ccctgtatct 120
 ggaaggggag attcaccagt cagtggacgc ggtgattccc ctgttagtgg ccgaggtgat 180
 agtccttact caggacgtgg cgactctcca gtatcgggac gaggggacag cccagtaagc 240
 ggcagggggcg attctcctgt aagtgggaga ggtgattctc catatagtgg tcgcggagat 300
 tctcccgttt caggtagggg agactcgcct gtctcaggtc gaggtgacag tcctgtgtct 360
 ggtcggggag atagtcctta ttctggtaga ggggatagtc cggtttcggg tcgtggagat 420
 tcgccggtct ctggcagagg tgactcacct gtttctgggc gtggtgattc accttattca 480
 gggaggggtg actccccagt gtcaggccgt ggggattcac ccgtatcagg aagaggcgat 540
 agtccagttt ccgggcgcgg ggactctcct tatagt 576

<210> 298
 <211> 352
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 298

Ala Ala His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu
 1 5 10 15

Glu Glu Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala
 20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
180 185 190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
195 200 205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

260

265

270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 305 310 315 320

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 325 330 335

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 340 345 350

<210> 299
 <211> 1056
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 299
 gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
 gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac gcggcgatag tccatattca 120
 ggtcggggag atagtcctta ctcaggtagg ggagacagcc catatagcgg gcgtggcgac 180
 tctccatata gtgggagagg ggactctccg tactctgggc gcggtgattc accatattct 240
 ggtcgaggtg actcacctta ttctggcagg ggtgatagtc cgtattcagg ccgtggtgat 300
 tccccctata gtggaagggg agattcaccg tatagtggta gaggcgacag tccttattcg 360
 ggacgaggtg attctcctta tagtggccga ggggattcac cctattctgg aagaggtgat 420
 agcccttatt caggaggggg cgattctccc tattcaggac ggggtgactc tccttactcc 480
 ggtcgcggag attctccata ctcgggtcgt ggagactccc catattccgg cagaggtgac 540
 agtccataca gtggacgtgg ggatagtcct tacagtggac gcggcgatag tccatattca 600
 ggtcggggag atagtcctta ctcaggtagg ggagacagcc catatagcgg gcgtggcgac 660

tctccatata gtgggagagg ggactctccg tactctgggc gcggtgattc accatattct	720
ggtcgaggtg actcacctta ttctggcagg ggtgatagtc cgtattcagg ccgtggtgat	780
tccccctata gtggaagggg agattcaccg tatagtggta gaggcgacag tccttattcg	840
ggacgaggtg attctcctta tagtggccga ggggattcac cctattctgg aagaggtgat	900
agcccttatt cagggagggg cgattctccc tattcaggac ggggtgactc tccttactcc	960
ggtcgcggag attctccata ctcgggtcgt ggagactccc catattccgg cagaggtgac	1020
agtccataca gtggacgtgg ggatagtcct tacagt	1056

<210> 300
 <211> 192
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 300

Ala	Ala	His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu
1				5					10					15	

Glu	Glu	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Ala
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
	50					55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			85					90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser

115

120

125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 180 185 190

<210> 301
 <211> 576
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 301
 gctgcccattg gggaggaggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
 gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac gcggcgatag tccatattca 120
 ggtcggggag atagtcctta ctcaggtagg ggagacagcc catatagcgg gcgtggcgac 180
 tctccatata gtgggagagg ggactctccg tactctgggc gcggtgattc accatattct 240
 ggtcgagggtg actcacctta ttctggcagg ggtgatagtc cgtattcagg ccgtgggtgat 300
 tccccctata gtggaagggg agattcaccg tatagtggta gaggcgacag tccttattcg 360
 ggacgagggtg attctcctta tagtggccga ggggattcac cctattctgg aagaggtgat 420
 agcccttatt caggaggagg cgattctccc tattcaggac ggggtgactc tccttactcc 480
 ggtcgcggag attctccata ctcgggtcgt ggagactccc catattccgg cagaggtgac 540
 agtccataca gtggacgtgg ggatagtcct tacagt 576

<210> 302
 <211> 352
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 302

Ala Ala His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu
1 5 10 15

Glu Glu Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Ala
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
180 185 190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser

195

200

205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 260 265 270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 305 310 315 320

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 325 330 335

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 340 345 350

<210> 303

<211> 1056

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 303

gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60

gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac gaggggactc acctatagtg 120

gggcgcggcg actctccata ttccggtcgg ggagattcac catatagtg cgtggcgat 180

agtcctgtgt ctggtagggg agactctccg tattcaggac gcggtgattc accctacagt	240
ggacgggggtg attctcctta ttcgggtcgt ggggattctc cagtttcagg tagaggtgat	300
agcccttatt caggccgagg tgacagtcct tactccggca ggggtgactc ccataactcg	360
ggacgtggtg atagtccagt atcaggaagg ggagatagtc cctactctgg gagaggggat	420
agtccgtact caggtcgagg tgattcccc tattctggaa gaggtgactc tcctgtatct	480
ggcagaggcg acagtccata cagcgggcgt ggagattctc cctatagtgg tcgcggagac	540
agcccatatt cagggagggg cgattcacct gttagtggac gaggggactc acctatagt	600
gggcgcggcg actctccata ttccggtcgg ggagattcac catatagtgg ccgtggcgat	660
agtcctgtgt ctggtagggg agactctccg tattcaggac gcggtgattc accctacagt	720
ggacgggggtg attctcctta ttcgggtcgt ggggattctc cagtttcagg tagaggtgat	780
agcccttatt caggccgagg tgacagtcct tactccggca ggggtgactc ccataactcg	840
ggacgtggtg atagtccagt atcaggaagg ggagatagtc cctactctgg gagaggggat	900
agtccgtact caggtcgagg tgattcccc tattctggaa gaggtgactc tcctgtatct	960
ggcagaggcg acagtccata cagcgggcgt ggagattctc cctatagtgg tcgcggagac	1020
agcccatatt cagggagggg cgattcacct gttagt	1056

<210> 304
 <211> 352
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 304

Ala	Ala	His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu
1				5					10					15	

Glu	Glu	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Ala
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		35					40				45				

Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser

50

55

60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
180 185 190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
195 200 205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
260 265 270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
305 310 315 320

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
325 330 335

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
340 345 350

<210> 305
<211> 1056
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 305
gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac gcggagattc tccatactct 120
ggtcgagggg atagtccggt ctgaggaaga ggcgatagtc catattcagg acgaggtgac 180
agtccagtat ctggcagagg ggactctccg tattccggca ggggagacag ccctgtttca 240
ggccgaggtg attctcctta ctgaggtcgg ggagatagtc ctgtgtctgg taggggtgac 300
tccccctatt ctggaagggg agattcacct gtaagtgggc gtggtgattc accctactcg 360
ggtcgtggag actctccagt tagtggtcgc ggtgattccc catatagcgg gcgcggcgat 420
tctcccgttt ctgggagggg cgacagtcct tattcgggac gtggcgactc tcctgtatca 480
gggagaggtg atagtcccta cagtggccgt ggggattcac cagtgtcagg tagaggtgac 540
tcaccttata gtggacgggg tgatagccca gtcagtggac gcggagattc tccatactct 600
ggtcgagggg atagtccggt ctgaggaaga ggcgatagtc catattcagg acgaggtgac 660
agtccagtat ctggcagagg ggactctccg tattccggca ggggagacag ccctgtttca 720

ggccgaggtg attctcctta ctcaggtcgg ggagatagtc ctgtgtctgg taggggtgac	780
tccccctatt ctggaagggg agattcacct gtaagtgggc gtggtgattc accctactcg	840
ggtcgtggag actctccagt tagtggtcgc ggtgattccc catatagcgg gcgcggcgat	900
tctcccgttt ctgggagggg cgacagtcct tattcgggac gtggcgactc tcctgtatca	960
gggagaggtg atagtcctta cagtggccgt ggggattcac cagtgtcagg tagaggtgac	1020
tcaccttata gtggacgggg tgatagccca gtcagt	1056

<210> 306
 <211> 352
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 306

Ala	Ala	His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu
1				5					10					15	

Glu	Glu	Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Ala
			20					25					30		

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
		35					40					45			

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		50				55					60				

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
65					70				75					80	

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
			85					90						95	

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser
			100					105					110		

Gly	Arg	Gly	Asp	Ser	Pro	Val	Ser	Gly	Arg	Gly	Asp	Ser	Pro	Tyr	Ser
		115					120					125			

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
130 135 140

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
165 170 175

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
180 185 190

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
195 200 205

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
210 215 220

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
225 230 235 240

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
245 250 255

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
260 265 270

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
275 280 285

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
290 295 300

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser
305 310 315 320

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Val Ser
325 330 335

Gly Arg Gly Asp Ser Pro Val Ser Gly Arg Gly Asp Ser Pro Tyr Ser

340

345

350

<210> 307
 <211> 1056
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 307
 gctgcccattg gggaggggac attcacctcg gacgtaagca gttacttaga agaacaggct 60
 gcaaaagagt ttattgcgtg gcttgtgaaa ggagcaggac ggggtgatag ccctgtatct 120
 ggaaggggag attcaccagt cagtggacgc ggtgattccc ctgttagtgg ccgaggtgat 180
 agtccttact caggacgtgg cgactctcca gtatcgggac gaggggacag cccagtaagc 240
 ggcaggggagc attctcctgt aagtgggaga ggtgattctc catatagtgg tcgcggagat 300
 tctcccgttt caggtagggg agactcgcct gtctcaggtc gaggtgacag tcctgtgtct 360
 ggtcggggag atagtcctta ttctggtaga ggggatagtc cggtttcggg tcgtggagat 420
 tcgccggtct ctggcagagg tgactcacct gtttctgggc gtggtgattc acctattca 480
 gggaggggtg actccccagt gtcaggccgt ggggattcac ccgtatcagg aagaggcgat 540
 agtccagttt ccgggcgcgg ggactctcct tatagtggac ggggtgatag ccctgtatct 600
 ggaaggggag attcaccagt cagtggacgc ggtgattccc ctgttagtgg ccgaggtgat 660
 agtccttact caggacgtgg cgactctcca gtatcgggac gaggggacag cccagtaagc 720
 ggcaggggagc attctcctgt aagtgggaga ggtgattctc catatagtgg tcgcggagat 780
 tctcccgttt caggtagggg agactcgcct gtctcaggtc gaggtgacag tcctgtgtct 840
 ggtcggggag atagtcctta ttctggtaga ggggatagtc cggtttcggg tcgtggagat 900
 tcgccggtct ctggcagagg tgactcacct gtttctgggc gtggtgattc acctattca 960
 gggaggggtg actccccagt gtcaggccgt ggggattcac ccgtatcagg aagaggcgat 1020
 agtccagttt ccgggcgcgg ggactctcct tatagt 1056

<210> 308
 <211> 344
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 308

Gly Arg Ile Gly Ser Ile Leu Gly Arg Leu Ala Lys Gly Leu Pro Thr
1 5 10 15

Leu Lys Ser Trp Ile Lys Asn Arg Gly Arg Gly Asp Gln Pro Tyr Gln
20 25 30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
165 170 175

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
180 185 190

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln

195

200

205

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 210 215 220

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 225 230 235 240

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 245 250 255

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 260 265 270

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 275 280 285

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 290 295 300

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 305 310 315 320

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
 325 330 335

Gly Arg Gly Asp Gln Pro Tyr Gln
 340

<210> 309

<211> 1032

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 309

ggcagaatag gctctatcct tggaagactt gccaaaggggc tgcctactct aaagagctgg 60

attaagaacc gcgggcgcgg ggaccagcca tatcaaggaa gaggtgacca accttatcag 120

ggtagaggcg atcagcctta tcaaggtcgc ggtgatcaac cgtatcaagg tagaggggac 180

caaccatatc aggggaagggg agatcaacct taccaagggtc ggggagatca gccctaccaa	240
ggcagaggggg atcaaccgta ccaggggagg ggtgatcaac cataccaggg tcgaggcgac	300
caaccctatc agggccgagg tgatcagccg taccaagggtc gtggcgacca gccctatcaa	360
ggacgtgggg atcagccata ccaaggacgc ggagatcaac catatcaagg gagaggtgat	420
caaccctatc aaggtagggg tgaccaaccg tatcagggtc gtggagatca gccttaccag	480
ggcagggggcg atcaacccta ccaggggacgt ggtgatcaac cttatcaagg ccgtggtgac	540
cagccttatc aggggcgcg ggaccagcca tatcaaggaa gaggtgacca accttatcag	600
ggtagaggcg atcagcctta tcaaggtcgc ggtgatcaac cgtatcaagg tagaggggac	660
caaccatatc aggggaagggg agatcaacct taccaagggtc ggggagatca gccctaccaa	720
ggcagaggggg atcaaccgta ccaggggagg ggtgatcaac cataccaggg tcgaggcgac	780
caaccctatc agggccgagg tgatcagccg taccaagggtc gtggcgacca gccctatcaa	840
ggacgtgggg atcagccata ccaaggacgc ggagatcaac catatcaagg gagaggtgat	900
caaccctatc aaggtagggg tgaccaaccg tatcagggtc gtggagatca gccttaccag	960
ggcagggggcg atcaacccta ccaggggacgt ggtgatcaac cttatcaagg ccgtggtgac	1020
cagccttatc ag	1032

<210> 310
 <211> 351
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 310

Gly	Val	Gly	His	Asn	Ala	Asp	Leu	Gln	Ile	Lys	Leu	Ser	Ile	Arg	Arg
1				5					10					15	

Leu	Leu	Ala	Ala	Gly	Val	Leu	Lys	Gln	Thr	Lys	Gly	Val	Gly	Ala	Gly
			20					25					30		

Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly
		35					40					45			

Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly

50

55

60

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
65 70 75 80

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
85 90 95

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
100 105 110

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
115 120 125

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
130 135 140

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
145 150 155 160

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
165 170 175

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
180 185 190

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
195 200 205

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
210 215 220

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
225 230 235 240

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
245 250 255

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
260 265 270

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
275 280 285

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
290 295 300

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
305 310 315 320

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly
325 330 335

Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
340 345 350

<210> 311
<211> 1053
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 311
ggcgtcggac ataatgcgga tctgcaaatc aaactgagca ttcgccgtct gctggcggcg 60
ggcgttctga aacagaccaa aggcgtgggc gcagggcgcg gggaccagcc atatcaagga 120
agaggtgacc aaccttatca gggtagaggc gatcagcctt atcaaggctc cggtgatcaa 180
ccgtatcaag gtagagggga ccaaccatat cagggaaggg gagatcaacc ttaccaaggt 240
cggggagatc agccctacca aggcagaggg gatcaaccgt accaggggag gggtgatcaa 300
ccataccagg gtcgaggcga ccaaccctat cagggccgag gtgatcagcc gtaccaaggg 360
cgtggcgacc agccctatca aggacgtggg gatcagccat accaaggacg cggagatcaa 420
ccatatcaag ggagaggtga tcaaccctat caaggtaggg gtgaccaacc gtatcagggt 480
cgtggagatc agccttacca gggcaggggc gatcaaccct accagggacg tggtgatcaa 540
ccttatcaag gccgtggtga ccagccttat caggggcgcg gggaccagcc atatcaagga 600
agaggtgacc aaccttatca gggtagaggc gatcagcctt atcaaggctc cggtgatcaa 660
ccgtatcaag gtagagggga ccaaccatat cagggaaggg gagatcaacc ttaccaaggt 720

cggggagatc agccctacca aggcagaggg gatcaaccgt accaggggag gggatgatcaa	780
ccataccagg gtcgaggcga ccaaccctat cagggccgag gtgatcagcc gtaccaaggg	840
cgtggcgacc agccctatca aggacgtggg gatcagccat accaaggacg cggagatcaa	900
ccatatcaag ggagaggtga tcaaccctat caaggtaggg gtgaccaacc gtatcagggt	960
cgtggagatc agccttacca gggcaggggc gatcaaccct accagggacg tggatgatcaa	1020
ccttatcaag gccgtggtga ccagccttat cag	1053

<210> 312
 <211> 357
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 312

Leu	Leu	Gly	Asp	Phe	Phe	Arg	Lys	Ser	Lys	Glu	Lys	Ile	Gly	Lys	Glu
1				5					10					15	

Phe	Lys	Arg	Ile	Val	Gln	Arg	Ile	Lys	Asp	Phe	Leu	Arg	Asn	Leu	Val
			20					25					30		

Pro	Arg	Thr	Glu	Ser	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
		35					40					45			

Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
	50					55					60				

Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
65					70					75				80	

Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
				85					90					95	

Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
			100					105					110		

Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly
		115					120					125			

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
130 135 140

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
145 150 155 160

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
165 170 175

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
180 185 190

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
195 200 205

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
210 215 220

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
225 230 235 240

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
245 250 255

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
260 265 270

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
275 280 285

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
290 295 300

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
305 310 315 320

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly
325 330 335

Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly

340

345

350

Asp Gln Pro Tyr Gln
355

<210> 313
<211> 1071
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 313
cttctggggg attttttttcg caaatctaag gaaaaaatcg ggaaggaatt taaacgcac 60
gttcaacgca ttaaagactt ctttcgtaac cttgtccctc gtacagagag tgggcgcggg 120
gaccagccat atcaaggaag aggtgaccaa cttatcagg gtagaggcga tcagccttat 180
caaggtcgcg gtgatcaacc gtatcaaggt agaggggacc aaccatatca gggaagggga 240
gatcaacctt accaaggtcg gggagatcag ccctaccaag gcagagggga tcaaccgtac 300
caggggaggg gtgatcaacc ataccagggt cgaggcgacc aaccctatca gggccgaggt 360
gatcagccgt accaagggcg tggcgaccag ccctatcaag gacgtgggga tcagccatac 420
caaggacgcg gagatcaacc atatcaaggg agaggtgatc aaccctatca aggtaggggt 480
gaccaaccgt atcagggtcg tggagatcag cttaccagg gcaggggcga tcaaccctac 540
cagggacgtg gtgatcaacc ttatcaaggc cgtggtgacc agccttatca ggggcgcggg 600
gaccagccat atcaaggaag aggtgaccaa cttatcagg gtagaggcga tcagccttat 660
caaggtcgcg gtgatcaacc gtatcaaggt agaggggacc aaccatatca gggaagggga 720
gatcaacctt accaaggtcg gggagatcag ccctaccaag gcagagggga tcaaccgtac 780
caggggaggg gtgatcaacc ataccagggt cgaggcgacc aaccctatca gggccgaggt 840
gatcagccgt accaagggcg tggcgaccag ccctatcaag gacgtgggga tcagccatac 900
caaggacgcg gagatcaacc atatcaaggg agaggtgatc aaccctatca aggtaggggt 960
gaccaaccgt atcagggtcg tggagatcag cttaccagg gcaggggcga tcaaccctac 1020
cagggacgtg gtgatcaacc ttatcaaggc cgtggtgacc agccttatca g 1071

<210> 314

<211> 667
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 314

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
1 5 10 15

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
20 25 30

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
35 40 45

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
50 55 60

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
65 70 75 80

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
85 90 95

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
100 105 110

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
115 120 125

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
130 135 140

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
145 150 155 160

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
165 170 175

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser

180

185

190

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 195 200 205

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 210 215 220

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 225 230 235 240

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 245 250 255

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 260 265 270

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 275 280 285

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Tyr Ser
 290 295 300

Gly Arg Gly Asp Ser Pro Tyr Ser Gly Arg Gly Asp Ser Pro Val Ser
 305 310 315 320

Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn Arg Tyr Pro Asn Leu
 325 330 335

Gln Leu Arg Glu Ile Ala Gly His Ile Met Glu Phe Ser Gln Asp Gln
 340 345 350

His Gly Ser Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro Ala
 355 360 365

Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln Ala Ala Tyr Gln Leu
 370 375 380

Met Val Asp Val Phe Gly Asn Tyr Val Ile Gln Lys Phe Phe Glu Phe
 385 390 395 400

Gly Ser Leu Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His
405 410 415

Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys
420 425 430

Ala Leu Glu Phe Ile Pro Ser Asp Gln Gln Asn Glu Met Val Arg Glu
435 440 445

Leu Asp Gly His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His
450 455 460

Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe
465 470 475 480

Ile Ile Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro
485 490 495

Tyr Gly Cys Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro Asp
500 505 510

Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln His Thr Glu Gln Leu
515 520 525

Val Gln Asp Gln Tyr Gly Asn Tyr Val Ile Gln His Val Leu Glu His
530 535 540

Gly Arg Pro Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly Asn
545 550 555 560

Val Leu Val Leu Ser Gln His Lys Phe Ala Ser Asn Val Val Glu Lys
565 570 575

Cys Val Thr His Ala Ser Arg Thr Glu Arg Ala Val Leu Ile Asp Glu
580 585 590

Val Cys Thr Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met Met
595 600 605

Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys Met Ile Asp Val Ala

610

615

620

Glu Pro Gly Gln Arg Lys Ile Val Met His Lys Ile Arg Pro His Ile
 625 630 635 640

Ala Thr Leu Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys Leu
 645 650 655

Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
 660 665

<210> 315
 <211> 2001
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 315
 ggacgagggg actcacctta tagtgggagc ggcgactctc catattccgg tcggggagat 60
 tcacatata gtggccgtgg cgatagtcct gtgtctggta ggggagactc tccgtattca 120
 ggacgcggtg attcacccta cagtggacgg ggtgattctc cttattcggg tcgtggggat 180
 tctccagttt caggtagagg tgatagccct tttcaggcc gaggtgacag tccttactcc 240
 ggacgggggtg actccccata ctggggacgt ggtgatagtc cagtatcagg aaggggagat 300
 agtccctact ctgggagagg ggatagtcg tactcaggtc gaggtgattc cccctattct 360
 ggaagaggtg actctcctgt atctggcaga ggcgacagtc catacagcgg gcgtggagat 420
 tctccctata gtggtcgcgg agacagccca tttcaggga ggggcgattc acctgttagt 480
 ggacgagggg actcacctta tagtgggagc ggcgactctc catattccgg tcggggagat 540
 tcacatata gtggccgtgg cgatagtcct gtgtctggta ggggagactc tccgtattca 600
 ggacgcggtg attcacccta cagtggacgg ggtgattctc cttattcggg tcgtggggat 660
 tctccagttt caggtagagg tgatagccct tttcaggcc gaggtgacag tccttactcc 720
 ggacgggggtg actccccata ctggggacgt ggtgatagtc cagtatcagg aaggggagat 780
 agtccctact ctgggagagg ggatagtcg tactcaggtc gaggtgattc cccctattct 840
 ggaagaggtg actctcctgt atctggcaga ggcgacagtc catacagcgg gcgtggagat 900

tctccctata gtggtcgcgg agacagccca tattcaggga ggggcgattc acctgttagt	960
cgcagtcgtt tattagagga tttccgtaac aaccgttacc ctaatttgca actgcgtgag	1020
attgctggcc acattatgga attttcacaa gaccagcacg gatcgcgttt cattcaactt	1080
aaattagaac gcgctacgcc agccgaacgc cagttagttt tcaacgaaat tttacaagcg	1140
gcataccaac tgatggtgga cgtttttggg aattatgtta tccagaagtt cttcgagttt	1200
ggaagcctgg agcagaaaact tgccctggcg gaacgcattc gtggtcacgt cttaagtttg	1260
gcactgcaga tgtatgggtg ccgtgttatc caaaaagctc ttgagtttat cccatctgat	1320
cagcagaacg aaatggtacg cgagctggac ggccatgttc ttaaatacggt aaaggaccag	1380
aacggtaatc atgttgtaca gaaatgcac gaatgcgtcc agccacagtc tctgcagttc	1440
atcattgatg ctttcaaagg ccaagttttt gcccttagca cgcattcccta cgggtgtcgt	1500
gtcatccaac gcattcttga gcattgctta ccagatcaaa ccttgccaat cctggaggaa	1560
ttgcaccaac aactgaaca gctggtacaa gatcaatatg gtaactatgt aattcagcac	1620
gttctggaac atggacgccc tgaggacaag tctaaaattg tcgcggaaat ccgtggaaac	1680
gtattggtgt tgtccaaca caaatgtgcc agtaatgtcg tggagaaatg cgtaacccat	1740
gctagccgta ccgaacgcgc agtcttaatc gacgaagttt gcacaatgaa tgacggccccg	1800
cattcggtt tatatacaat gatgaaggac cagtacgcta attatgtcgt gcagaaaatg	1860
attgatgtag cggagcctgg tcagcgcaag attgtgatgc acaagatccg cccgcacatt	1920
gcgacattgc gtaagtatac gtacggcaaa cacatcttgg cgaaacttga aaagtactac	1980
atgaaaaatg gcgtggacct t	2001

<210> 316
 <211> 667
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 316

Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln	Gly	Arg	Gly	Asp	Gln	Pro	Tyr	Gln
1				5				10					15		

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln

20

25

30

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
35 40 45

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
50 55 60

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
65 70 75 80

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
85 90 95

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
100 105 110

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
115 120 125

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
130 135 140

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
145 150 155 160

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
165 170 175

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
180 185 190

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
195 200 205

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
210 215 220

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
225 230 235 240

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
245 250 255

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
260 265 270

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
275 280 285

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
290 295 300

Gly Arg Gly Asp Gln Pro Tyr Gln Gly Arg Gly Asp Gln Pro Tyr Gln
305 310 315 320

Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn Arg Tyr Pro Asn Leu
325 330 335

Gln Leu Arg Glu Ile Ala Gly His Ile Met Glu Phe Ser Gln Asp Gln
340 345 350

His Gly Ser Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro Ala
355 360 365

Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln Ala Ala Tyr Gln Leu
370 375 380

Met Val Asp Val Phe Gly Asn Tyr Val Ile Gln Lys Phe Phe Glu Phe
385 390 395 400

Gly Ser Leu Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His
405 410 415

Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys
420 425 430

Ala Leu Glu Phe Ile Pro Ser Asp Gln Gln Asn Glu Met Val Arg Glu
435 440 445

Leu Asp Gly His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His

450

455

460

Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe
 465 470 475 480

Ile Ile Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro
 485 490 495

Tyr Gly Cys Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro Asp
 500 505 510

Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln His Thr Glu Gln Leu
 515 520 525

Val Gln Asp Gln Tyr Gly Asn Tyr Val Ile Gln His Val Leu Glu His
 530 535 540

Gly Arg Pro Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly Asn
 545 550 555 560

Val Leu Val Leu Ser Gln His Lys Phe Ala Ser Asn Val Val Glu Lys
 565 570 575

Cys Val Thr His Ala Ser Arg Thr Glu Arg Ala Val Leu Ile Asp Glu
 580 585 590

Val Cys Thr Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met Met
 595 600 605

Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys Met Ile Asp Val Ala
 610 615 620

Glu Pro Gly Gln Arg Lys Ile Val Met His Lys Ile Arg Pro His Ile
 625 630 635 640

Ala Thr Leu Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys Leu
 645 650 655

Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
 660 665

<210> 317
<211> 2001
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 317
gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 60
cagccttatc aaggctcgcg tgatcaaccg tatcaaggta gaggggacca accatatcag 120
ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 180
caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 240
ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 300
cagccatacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa 360
ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcat 420
caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag 480
gggcgcgggg accagccata tcaaggaaga ggtgaccaac cttatcaggg tagaggcgat 540
cagccttatc aaggctcgcg tgatcaaccg tatcaaggta gaggggacca accatatcag 600
ggaaggggag atcaacctta ccaaggtcgg ggagatcagc cctaccaagg cagaggggat 660
caaccgtacc aggggagggg tgatcaacca taccagggtc gaggcgacca accctatcag 720
ggccgaggtg atcagccgta ccaagggcgt ggcgaccagc cctatcaagg acgtggggat 780
cagccatacc aaggacgcgg agatcaacca tatcaaggga gaggtgatca accctatcaa 840
ggtaggggtg accaaccgta tcagggtcgt ggagatcagc cttaccaggg caggggcat 900
caaccctacc agggacgtgg tgatcaacct tatcaaggcc gtggtgacca gccttatcag 960
cgcagtcgtt tattagagga tttccgtaac aaccgttacc ctaatttgca actgcgtgag 1020
attgctggcc acattatgga attttcacaa gaccagcacg gatcgcgttt cattcaactt 1080
aaattagaac gcgctacgcc agccgaacgc cagttagttt tcaacgaaat ttacaagcg 1140
gcataccaac tgatggtgga cgtttttggg aattatgtta tccagaagtt cttcgagttt 1200
ggaagcctgg agcagaaaact tgccctggcg gaacgcattc gtggtcacgt cttagtttg 1260
gcactgcaga tgtatgggtg ccgtgttatc caaaaagctc ttgagtttat cccatctgat 1320

cagcagaacg aaatggtacg cgagctggac ggccatgttc ttaaatacgt aaaggaccag	1380
aacggtaatc atgttggtaca gaaatgcacg gaatgcgtcc agccacagtc tctgcagttc	1440
atcattgatg ctttcaaagg ccaagttttt gcccttagca cgcatcccta cgggtgtcgt	1500
gtcatccaac gcattcttga gcattgctta ccagatcaaa ccttgccaat cctggaggaa	1560
ttgcaccaac aactgaaca gctggtacaa gatcaatatg gtaactatgt aattcagcac	1620
gttctggaac atggacgccc tgaggacaag tctaaaattg tcgcggaaat ccgtggaaac	1680
gtattggtgt tgtccaaca caaatgtgcc agtaatgtcg tggagaaatg cgtaacccat	1740
gctagccgta ccgaacgcgc agtcttaatc gacgaagttt gcacaatgaa tgacggcccg	1800
cattcggctt tatatacaat gatgaaggac cagtacgcta attatgtcgt gcagaaaatg	1860
attgatgtag cggagcctgg tcagcgcaag attgtgatgc acaagatccg cccgcacatt	1920
gcgacattgc gtaagtatac gtacggcaaa cacatcttgg cgaaacttga aaagtactac	1980
atgaaaaatg gcgtggacct t	2001